










The handle http://hdl.handle.net/1887/22622 holds various files of this Leiden University 
dissertation 
 
Author: Plas, Anton Adriaan van der 
Title: Complex regional pain syndrome related dystonia : exploratory metabolomics and 
therapeutic studies 
Issue Date: 2013-12-03 
Complex Regional Pain Syndrome Related Dystonia
Exploratory Metabolomics and Therapeutic Studies
Anton Adriaan van der Plas
2
Anton A. van der Plas
Complex regional pain syndrome related dystonia: exploratory metabolomics and 
therapeutic studies
PhD thesis, Leiden University Medical Center, Leiden 2013
ISBN: 978-90-9027902-2
2013 Anton Adriaan van der Plas
Copyright of the individual chapters lies with the publisher of the journal listed at the 
beginning of each respective chapter
Printed by: Pasmans Drukkerij BV, Den Haag
3
Complex Regional Pain Syndrome Related Dystonia
Exploratory Metabolomics and Therapeutic Studies
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van de Rector Magnificus Prof…
volgens besluit van het College voor Promoties
te verdedigen op dinsdag 19 november 2013
klokke 15.00 uur
door










Prof. dr. R.A.C. Roos 
Prof. dr. A. Dahan
Prof. dr. F.J.P.M. Huygen (Erasmus Medisch Centrum Rotterdam)
This PhD project was performed within TREND (Trauma RElated Neuronal Dysfunction), 
a Dutch consortium that integrated research on epidemiology, assessment technology, 
pharmacotherapeutics, biomarkers and genetics on Complex Regional Pain Syndrome. 
The consortium aimed to develop concepts on disease mechanisms that occur in 
response to tissue injury, its assessment and treatment.
TREND was supported by a government grant (BSIK03016).
Financial support for this thesis has 





Η περιέργεια είναι η αρχή της σοφίας
(Σωκράτης)






Chapter 1    9
General introduction 
PART I. INTRATHECAL BACLOFEN TREATMENT IN CRPS
Chapter 2   31
The efficacy of intrathecal baclofen on different pain qualities in complex
regional pain syndrome (A.A. van der Plas, M.A. van Rijn, J. Marinus, 
H. Putter, J.J. van Hilten – Anesthesia & Analgesia; 2013 Jan; 116(1): 
211-215)
Chapter 3   45
The lack of efficacy of different infusion rates of intrathecal baclofen in
complex regional pain syndrome: a randomized, double-blind, crossover
study (A.A. van der Plas, J. Marinus, S. Eldabe, E. Buchser, J.J. van Hilten –
Pain Medicine; 2011 Mar; 12(3): 459-65)
Chapter 4   61
Baclofen-induced chorea in complex regional pain syndrome-related 
dystonia (A.A. van der Plas, M.A. van Rijn, J.J. van Hilten – Movement 
Disorders 2010 May 15; 25(7): 959-960)
PART II. INTRATHECAL GLYCINE TREATMENT IN CRPS
Chapter 5    71
Intrathecal glycine for pain and dystonia in complex regional pain syndrome
(A.G. Munts, A.A. van der Plas, J.H. Voormolen, J. Marinus, I.M. Teepe-Twiss,
P. Onkenhout, J.M. van Gerven, J.J. van Hilten – Pain 2009 Nov; 146(1-2): 
199-204)
8
PART III. EXPLORATORY STUDIES USING MASS SPECTROMETRY
Chapter 6   91
Explorative analysis of urine by capillary electrophoresis-mass spectrometry
in chronic patients with complex regional pain syndrome (A.A. van der Plas, 
R. Ramautar, E. Nevedomskaya, R.J.E. Derks, G.W. Somsen, G.J. de Jong, J.J. 
van Hilten, A.M. Deelder, O.A. Mayboroda – Journal of Proteome Reseach 
2009 Dec; 8(12): 5559-67)
Chapter 7 117
1H-NMR metabolic profiling of cerebrospinal fluid in patients with complex
regional pain syndrome (A.A. van der Plas, A. Meissner, S. Göraler, N.T. van
Dasselaar, André M. Deelder, J.J. van Hilten, O.A. Mayboroda – Pain; accepted 
for publication)
PART IV. INTRAMUSCULAR MAGNESIUM SULPHATE TREATMENT IN CRPS
Chapter 8 145
An explanatory study evaluating the muscle relaxant effects of intramuscular
magnesium sulphate for dystonia in complex regional pain syndrome (A.A. 
van der Plas, J.C.M. Schilder, J. Marinus, J.J. van Hilten – Journal of Pain; 2013 













1.1 FROM PAST TO PRESENT 
Causalgia
It is 1864. The American Civil War takes its toll. At the end of the war more than 
1,000,000 casualties and losses are counted. Silas Weir Mitchell, a US Army physician at 
the Turners Alne Hospital for Nervous Diseases in Philadelphia, is a close witness of the 
many casualties on the Union side. In his book “Gunshot Wounds and Other Injuries of 
Nerves”, Mitchell describes the symptoms and signs of peripheral nerve injuries as he 
observed them in Unionist soldiers.1 In a small number of men he perceives “pain which 
they described as ‘burning’ or as ‘mustard red-hot’ or as a ‘red-hot file rasping the skin’
... The part itself is not alone subject to a deep burning sensation, but becomes 
exquisitely hyperesthetic, so that a touch or tap of the finger causes pain”. Mitchell uses
the term causalgia (from the Greek terms "kausis" or burning and "algos" or pain) to 
summarize the characteristics of this condition. Next to pain and other sensory 
abnormalities, he also describes features suggestive of:
(1) vasomotor changes: “The burning comes first, the visible skin-change afterwards”, 
(2) trophic changes: “When the acute stage has departed, the tissues become hard…”, 
(3) edema: “… a painful swelling of the joints…may attack any or all articulations of a 
member”.
The term causalgia was maintained for many years to come, although only for patients 
who developed symptoms after major nerve injury.
Reflex sympathetic dystrophy
The discovery of X-rays at the end of the 19th century opened up new avenues in the 
understanding of underlying mechanisms of diseases. In 1900 Paul Hermann Martin 
Sudeck, a surgeon from Hamburg, applied this new diagnostic tool to examine patients 
suffering from causalgia and documented a “patchy osteoporosis of the small bones of 
the hand or feet and the distal metaphysis of forearm or tibial bones” in these patients.2
The term “Sudeck’s atrophy” was introduced, which was changed to “limb dystrophy” in 
1936 by Reider, a student of Sudeck. 
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In the first half of the 20th century, different hypotheses were proposed about the 
underlying mechanism of the disorder. Sudeck suggested an “exaggerated inflammatory 
response after injury or operation of an extremity” as a cause of the disease.3 Rene 
Leriche, a military surgeon during WW1, related the symptoms and signs with 
sympathetic disorders and documented “… I asked myself whether, by acting upon the 
perivascular sympathetic, I might be able to succeed in modifying the causalgia.”4 In one 
patient he exposed the brachial artery of the affected limb and removed its adventitia 
over a distance of 12 cm. The next day, the patient reported clear improvement of pain
which supported his theory of a sympathetic disturbance underlying the disorder. Based 
on this experience he advocated “novicain infiltrations of the paravertebral sympathetic 
chain” as an effective treatment.5 The chronicity of the symptoms was thought to result 
from “a reflex travelling through the nervous system”. To capture these various 
pathophysiological hypotheses the nomenclature “reflex sympathetic dystrophy or RSD” 
was formulated.6 The term RSD was maintained for decades to come and exclusively 
used to describe symptoms of causalgia, but without evident causative nerve damage.
Complex regional pain syndrome
Based on doubts about the pathophysiological role of the sympathetic nervous system 
and the inherent inadequacy of the terms RSD and causalgia, a special consensus 
workshop of the International Association for the Study of Pain (IASP) was held in 1993 
in Orlando to provide the new nomenclature “complex regional pain syndrome or 
CRPS”.7 Two types of CRPS were recognized: type I without nerve injury (replacing the 
term “RSD”) and type II associated with major nerve injury (replacing the term 
“causalgia”). This committee formulated diagnostic criteria for CRPS type I (table 1.1).8
Of note, the presence of an initiating noxious event, or a cause of immobilization was
not considered mandatory to establish the diagnosis.  The diagnostic Orlando criteria for
CRPS were modified following an international consensus meeting in 2003 in Budapest 
(table 1.2).9 Compared to the Orlando criteria, the Budapest-criteria have higher 
specificity and also include disease-related trophic changes and motor dysfunction. The
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Table 1.1. The diagnostic Orlando criteria for CRPS type 1
1 The presence of an initiating noxious event, or a cause of immobilization
2 Continuing pain, allodynia, of hyperalgesia with which the pain is disproportionate to any inciting 
event
3 Evidence at some time of edema, changes in skin blood flow, or abnormal sudomotor activity in the 
region of the pain
4 Absence of a condition that would otherwise account for the degree of pain and dysfunction
Criteria 2-4 are obligatory for a diagnosis of CRPS
Budapest criteria have recently been adopted by the IASP as the new diagnostic 
standard following an international cohort study, which confirmed the validity of the 
criteria.9
1.2. EPIDEMIOLOGY OF CRPS
CRPS is considered a rare disease. The incidence of CRPS in population-based studies 
varies from 5.5/100,000 persons per year in the USA10 to 26/100,000 persons per year in 
the Netherlands.11 However, it should be noted that these incidence rates are based on 
the Orlando criteria and that the IASP has meanwhile formally accepted the Budapest 
criteria as the diagnostic standard. The latter are stricter, which indicates that if current 
diagnostic standards would have been applied, the incidence rate would have been 
considerably lower. CRPS can manifest at any age, but most patients are aged between 
40 and 70 years with women being more frequently affected than men (ratio of 3-4 to 
1).10,11 Patients with CRPS-related motor dysfunction are on average about 10 years 
younger.12 The female-to-male ratio in this subgroup of CRPS patients is approximately 
8-9 to 1.13,14 In about 60% of cases the upper extremity is affected and a fracture is the 
most common trigger (about 45%), followed by sprain (about 18%) and elective surgery 
(about 12%).11 Spontaneous onset of the disease has been described in 3-11% of 
cases.11,15-21
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Table 1.2. The diagnostic Budapest criteria for CRPS 
1 Persistent pain, which is disproportionate to any known inciting event 
2 The patient must report at least one symptom in three of the following categories to fulfill the 
clinical diagnostic criteria and at least one symptom in four of the following categories to fulfill the 
research diagnostic criteria (anamnestic hints):
- Sensory: reports of hyperesthesia and/or allodynia
- Vasomotor: reports of temperature asymmetry and/or skin color changes and/or skin color 
asymmetry
- Sudomotor/edema: reports of edema and/or sweating changes and/or sweating asymmetry
- Motor/trophic: reports of decreased range of motion and/or motor dysfunction (weakness, 
tremor, dystonia) and/or trophic changes (hair, nails, skin) 
3 The patient must display at least one sign in two or more of the following categories during the 
current physical examination:
- Sensory: evidence of hyperalgesia (to pinprick) and/or allodynia (to light touch and/or deep 
somatic pressure and/or joint movement)
- Vasomotor: evidence of temperature asymmetry and/or skin color changes and/or skin color 
asymmetry
- Sudomotor/edema: evidence of edema and/or sweating changes and/or sweating asymmetry
- Motor/trophic: evidence of decreased range of motion and/or motor dysfunction (weakness, 
tremor, dystonia) and/or trophic changes (hair, nails, skin) 
4 There is no other diagnosis that would otherwise account for the signs and symptoms and the 
degree of pain and dysfunction
1.3 PATHOPHYSIOLOGY OF CRPS
The clinical spectrum of CRPS is heterogeneous and includes sensory, autonomic, 
trophic, and motor changes of the affected limb (table 1.2). The different features 
reflect the involvement of multiple biological pathways, which most likely include 
exaggerated inflammation, vasomotor dysfunction, and maladaptive neuroplasticity.22
Aberrant inflammation
In the early stage of the disease the affected limb shows classical signs of local 
inflammation (calor, rubor, tumor, dolor, functio laesa) in the painful area.22 These
inflammatory changes in CRPS patients are likely mediated by the neuropeptide 
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substance P (SP; figure 1.1).23,24 In one studies the serum level of calcitonin-gene-related 
peptide (CGRP), another neuropeptide, was also found to be elevated in the acute stage 
of the disease, i.e. within 6 months after the onset of CRPS symptoms.23 However, in a 
recent meta-analysis the pooled effect estimate of CGRP was not significantly different 
in patients with acute CRPS compared to controls.25 Neuropeptides are released from 
peripheral terminals of sensory nerve fibers in skin, muscle and joints26 and promote the 
inflammatory processes of vasodilatation and protein extravasation in tissue.27 In 
addition, SP stimulates the production of other pro-inflammatory cytokines in 
keratinocytes (figure 1.1).28 The concentration of the pro-inflammatory cytokine TNF is 
elevated in skin tissue of the affected limb,29 which coincides with the identification of
Figure 1.1. Biochemical and neurophysiological changes in skin tissue and blood in the 
affected limb of CRPS patients in the acute phase of disease
   
TNF =   tumor necrosis factor 
SP        =  substance P
Symp  =  sympathetic
IL         =   interleukin
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polymorphisms in the TNF-encoding gene in genetic studies in CRPS patients (figure 
1.1).30 In the acute phase of disease pro-inflammatory changes can also be found in 
serum including increased concentrations of soluble TNF receptors and interleukin-825
and decreased concentrations of the anti-inflammatory cytokines interleukin-4 and
interleukin-10 (figure 1.1).31 These findings indicate an increased Th1-to-Th2 ratio in the 
early stage of CRPS.
The serum profile of cytokines and other inflammatory peptides changes as CRPS 
symptoms continue for more than 6 months. Concentrations of TNF and bradykinin
are particularly increased, whereas serum levels of SP, sE-selectin, sL-selectin and sP-
selectin are clearly decreased (figure 1.2).25 During the first 6 years after onset of
Figure 1.2. Biochemical and neurophysiological changes in skin tissue and blood in the 
affected limb of CRPS patients in the chronic phase of disease
   
   
TNF  =  tumor necrosis factor 
SP        =  substance P
Symp  =  sympathetic
ET-1    =  endothelin 1
NO      =  nitric oxide
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symptoms, concentrations of TNF and interleukin-6, which are not correlated to 
duration or severity of disease, only gradually decrease.32  In the later stage of disease
pro-inflammatory cellular changes with a raised percentage of the CD14+CD16+ 
monocyt/macrophage subgroup become manifest in blood.33 However, the exaggerated 
inflammatory response in CRPS patients is probably not caused by a cellular mediated 
immune response. In a subgroup of CRPS patients serum auto-antibodies are found, 
which bind to an inducible autonomic neuronal surface autoantigen.34 The relevance of 
this autoimmune process for the pathophysiology of CRPS remains to be elucidated. It is 
unclear if changes in pro- and anti-inflammatory cytokines in tissue and serum are 
already present prior to the onset of CRPS symptoms. 
Vasomotor dysfunction
In the early stage of the disease the skin temperature of the affected extremity usually 
rises as a result of excessive vasodilatation.35 A subgroup of CRPS patients with an 
elevated skin temperature displays unilateral inhibition of sympathetic vasoconstrictor
neurons, probably due to functional changes in the CNS (figure 1.1).35,36 As a result, the 
concentration of norepinephrine in venous blood declines in the affected limb proximal 
to the painful area.35 In the majority of CRPS patients the affected limb turns cold in the 
course of the following months.36 The excessive lowering in skin temperature is a 
reflection of disturbed thermoregulatory skin perfusion (figure 1.2). In approximately 
20% of patients the conversion from a warm to a cold skin temperature already occurs 
in the acute stage of disease.37
Remarkably, in some CRPS patients who display a cold skin temperature in the affected 
limb, the concentration of norepinephrine is decreased in the venous blood flowing 
proximal to the painful area,36 which suggests an increased density or affinity of -
adrenergic receptors in the skin of these patients.38,39
Lowering of the skin temperature in CRPS patients may also be caused by a decreased
endothelial release of nitric oxide and increased production of endothelin 1, resulting in
persistent vasoconstriction in the affected limb (figure 1.2).40,41  
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Maladaptive neuroplasticity
Disproportionate persistent pain and sensory changes in the affected limb are key 
features of CRPS and reflect both structural and functional changes in the CNS, a process 
also known as central sensitisation.42 Loss of inhibitory activity of normal cutaneous 
sensations on central sensory processing causes increased excitation of thalamocortical 
nociceptive networks.43,44 The activation and upregulation of glutamate receptors within 
the nociceptive circuit between spinal cord and cerebral cortex probably also play a 
major role in the process of central sensitization.45 On the other hand there are 
indications of downregulation of the inhibitory influence of corticospinal descending 
pathways to spinal nociceptive neurons.46,47 As a result, spinal nociceptive neurons turn 
more responsive to peripheral input and may even depolarize spontaneously. 
Inflammatory cytokines in CSF, especially interleukin-1 and interleukin-6, may also in 
part be responsible for the sensitization of spinal nociceptive neurons, although two 
studies produced contradictory results.13,48
Peripheral sensitization of primary afferent nociceptors may also contribute to CRPS 
related pain and in turn may induce central neuroplasticity.49,50 In some CRPS patients 
sympathetic dysfunction may increase the sensitivity of nociceptors or activate primary 
afferent neurons causing “sympathetically maintained pain”.51
Many CRPS patients experience a distorted shape or size of the affected limb which 
probably originates from cortical reorganization of somatotopic maps within the
primary somatosensory cortex representing the affected limb.52-54 Cortical 
reorganization is also found in the primary motor cortex and supplementary motor area, 
both ipsilateral and contralateral to the affected limb.55,56
In conclusion, there is compelling evidence that a combination of central and peripheral 
mechanisms is responsible for the variety of CRPS-related symptoms. Although the role 
of these different mechanisms in the development and persistence of CRPS has been 
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clarified to a great extent, the interaction between these mechanisms remains to be 
elucidated.   
1.4 DYSTONIA IN CRPS
In his extensive documentation of wounded soldiers suffering from causalgia, Silas Weir 
Mitchell also noted “When the acute stage has departed, the tissues become hard and 
partial ankylosis results”.1 It is unclear if he described an abnormal posturing of the 
affected limb which we now define as a fixed or tonic dystonia, or a contracture 
resulting from trophic changes in soft tissues. In 1984 Marsden et al comprehensively 
described 4 CRPS patients with muscle spasms and rhythmical jerking of the affected 
limb.57 The authors stated: “In the absence of pathological information the mechanism 
of the abnormal movements in our patients is open to speculation. Hopefully, however, 
this description will allow others to recognize the syndrome of muscle spasms 
associated with Sudeck's atrophy after trauma as a relevant disabling entity”. The 
authors’ wish was fulfilled in the following decades as CRPS related motor symptoms 
gained increasing interest both in the field of pain and movement disorders.58 During a 
consensus meeting in Budapest in 2003 it was decided to include decreased range of 
motion and motor dysfunction as an additional criterion into a new set of diagnostic 
criteria for CRPS.9
Although the term ‘dystonia’ - i.e., not related to CRPS - was already in use for many 
years, a proper classification and description of dystonia was only established in the 
1980’s.59 To date, dystonia is defined as an involuntary movement disorder with muscle 
contractions causing twisting and repetitive movements or abnormal postures.59
Dystonia can be classified according to the distribution of symptoms, age of onset and 
etiology (hereditary or acquired).60 Although different networks may be involved in the 
development of various types of dystonia, they likely share the involvement of 
sensorimotor circuits that are associated with motor learning and memory, which 
manifest as dystonic movements and postures.61 The term dystonia for abnormal 
posturing of a limb in CRPS patients, which typically present as a fixed flexion deformity 
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of the hand, fingers and toes and a fixed inversion deformity of the foot, therefore 
suggests a central underlying mechanism for this type of dystonia. This assumption is 
supported by (1) the spontaneous spread of dystonia to other limbs in a subgroup of 
CRPS patients,12 (2) neurophysiological research indicating central disinhibition in 
patients with CRPS-related dystonia64 and (3) improvement of dystonia in a large 
proportion of CRPS patients receiving intrathecal baclofen (ITB).62,63
CRPS-related dystonia may very rapidly lead to a fixed abnormal posture14,65 and in 
approximately half of the patients the lower limb is the site of dystonia onset.12 These 
features are atypical for other types of adult-onset dystonia, which are not 
symptomatic.60 Hence some experts in the field of movement disorders consider CRPS-
related dystonia a psychogenic movement disorder.66 However, most other 
characteristics of psychogenic dystonia are not applicable to dystonia in CRPS.67
Additionally, if psychological factors are expected to play an important role in the onset 
of the condition, one would assume that certain psychological traits or a particular 
unique psychological profile would be present either before or around the period of 
disease onset, but such associations with CRPS-related dystonia have not been found
thus far.68,69 As Marsden et al stated in their case-report on CRPS-related dystonia: “In 
the absence of pathological information the mechanism of the abnormal movements in 
our patients is open to speculation.”57
1.5 MANAGEMENT OF CRPS
The growing understanding of the role of different mechanisms underlying CRPS, 
especially in the past 10 years, stimulated the development of target-specific 
interventions. Indeed, different treatment strategies are now available to counteract 
processes of aberrant inflammation, disturbed vasomotor regulation and maladaptive 
neuroplasticity.70 Particularly in the field of pain management important progress has 
been made. In two placebo-controlled, double-blind trials intravenous S(+)-ketamine, an 
N-methyl-D-aspartate receptor antagonist, was administered for 4 and 10 days in 
chronic CRPS patients.71,72 Both studies revealed significant pain relief, not only at the 
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time of administration but also during the following months. These findings support the 
hypothesis that central sensitization is the origin of CRPS-related pain. 
Only a few studies were set up to evaluate the efficacy of an intervention in dystonia 
related to CRPS.62,63 In one study intrathecal administration of boluses of baclofen, a 
pre- and postsynaptic gamma-aminobutyric acid B receptor agonist, clearly improved 
dystonia in some chronic CRPS patients.63 The efficacy of ITB was also observed in the 
screening phase of a larger study, which supports the hypothesis of central maladaptive 
plasticity underlying CRPS-related dystonia.62 In the same study, patients who reported 
significant improvement during ITB administration in the screening phase received an 
implantable pump for intrathecal delivery of baclofen. Remarkably, after one year of ITB 
administration, 30% of these patients failed to reach the same level of improvement as 
noted during the screening procedure. Systematic reviews have revealed a lack of 
evidence of other centrally acting drugs in CRPS-related dystonia.70 Apart from central 
mechanisms involved in the development of dystonia and spasticity, pathological 
changes in muscle tissue, which contribute to stiffness around a joint, may occur in 
these conditions.73,74
1.6 AIMS OF THIS THESIS
The first aim was to study the efficacy and safety of ITB (Part I) and intrathecal glycine 
(Part II) in patients with CRPS-related dystonia and evaluate the role of central GABA-B 
receptor modulation in the pathobiology of pain and dystonia related to CRPS. Chapter 2 
describes the efficacy of ITB on 10 different pain qualities related to CRPS. In Chapter 3
the influence of different infusion rates of ITB in CRPS-related dystonia is discussed. 
Chapter 4 reports on the development of chorea after baclofen in 4 CRPS patients and 
addresses the potential role of supraspinal GABA-B receptor modulation in the 
development of CRPS-related dystonia.
Chapter 5 describes the efficacy and safety of intrathecal glycine in patients with CRPS.
The second aim of this thesis was to unravel pathobiological processes involved in the
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development and maintenance of CRPS (Part III) using mass spectrometry. Chapter 6
describes the explorative analysis of urine by capillary electrophoresis-mass 
spectrometry in CRPS patients. The results of 1H-NMR based metabolic profiling of CSF
in patients with CRPS-related dystonia are described and discussed in chapter 7.
The third aim (Part IV) was to find evidence of efficacy for a treatment modality with a 
good safety profile. In chapter 8 the results of an explanatory study evaluating the 
muscle relaxant effects of intramuscular magnesium sulphate for dystonia in CRPS are 
discussed.
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ABSTRACT
Background. Complex regional pain syndrome (CRPS) is characterized by severe 
debilitating chronic pain. Patients with CRPS may experience various pain sensations, 
which likely embody different pathophysiological mechanisms. In this study, we
evaluated the differential effects of central γ-aminobutyric acid (B) receptor stimulation 
on the different pain qualities in CRPS patients with dystonia.
Methods. The 10 pain qualities of the neuropathic pain scale, dystonia severity, and 
changes in use of antinociceptive drugs were evaluated every 3 months for a period of 1
year in 42 CRPS patients with dystonia receiving titrated doses of intrathecal baclofen 
(ITB) treatment in an open design. 
Results. Using a linear mixed model analysis and controlling for global dystonia severity 
and the use of supplemental analgesics, we found a significant improvement in global 
intense pain, sharp pain, dull pain and deep pain during the first 6 months. After this 
period, the scores leveled off despite further improvement of dystonia and continued 
ITB dose escalation. 
Conclusions. γ-Aminobutyric acid (B) receptor stimulation by ITB exerts differential 
antinociceptive effects on specific pain qualities in CRPS patients with dystonia.  
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INTRODUCTION
Complex Regional Pain Syndrome (CRPS) is a multifactorial disorder that is associated 
with an aberrant host response to tissue injury of a limb.1 The clinical spectrum of CRPS 
is heterogeneous and includes sensory, autonomic, trophic, and motor changes of the 
affected limb, which reflects the involvement of biological pathways that underlie 
exaggerated inflammation, vasomotor dysfunction, and maladaptive neuroplasticity.1
The key symptom of CRPS is spontaneous continuous pain, which is disproportionate to 
the inciting event.2 However, patients with CRPS exhibit various qualities of pain3
depending on the presence of allodynia, hyperalgesia, vascular involvement and fixed 
dystonia.4-8 Analgesics are often used in the management of pain in CRPS, but evidence 
supporting these treatments is limited.9 Different qualities of pain may have different 
underlying mechanisms. Studying the modifying effects of drugs with a known action on 
the different pain qualities in homogeneous groups of patients may contribute to the 
development of future pain management strategies.4 γ-Aminobutyric acid (GABA)ergic 
circuits play a major role in the processing of different types of pain, especially at the 
spinal level.10-12 In a previous study, we found that continuous delivery of intrathecal 
baclofen (ITB), a presynaptic and postsynaptic GABA(B) agonist, significantly improved 
the global severity of pain in patients with CRPS and dystonia.13 It is interesting to note 
that this improvement of pain was only partly explained by a decrease of dystonia, 
suggesting a direct antinociceptive effect of baclofen. This study therefore explored 
whether GABA(B) receptor stimulation by ITB exerted a differential effect on pain 
qualities in CRPS patients with dystonia.  
METHODS
Patients
Patients with a diagnosis of CRPS-I and dystonia in at least one extremity who were 
participating in a trial of ITB administration were included in this study.13 Written 
informed consent was obtained from patients in accordance with the Declaration of 
Helsinki and the local ethics committee approved the study. The trial was registered in 
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the Dutch Trial Register (NTR403) on September 12, 2005 with van Hilten serving as the 
principal investigator. Patients were assessed for eligibility between January 2002 and 
January 2007. Inclusion criteria were as follows: CRPS-I according to the diagnostic criteria 
of the International Association for the Study of Pain (IASP)2 and symptoms for at least 1 
year. The IASP criteria include a combination of the following: (1) the presence of an 
initiating noxious event or a cause of immobilization; (2) continuing pain, allodynia, or 
hyperalgesia disproportionate to the inciting event; (3) evidence at some time of edema, 
changes in skin blood flow, or abnormal sudomotor activity in the area of pain; and (4) 
the absence of a condition that would otherwise account for the degree of pain and 
dysfunction. Criteria 2 to 4 are required for the diagnosis of CRPS. In contrast to the 
previously reported study, this study also included patients who developed CRPS 
spontaneously because recent evidence emerged showing that the clinical presentation 
of these patients does not differ from those in whom the syndrome developed after a 
trauma.14 All patients were subjected to the same study design, including a single-blind
placebo run-in, dose escalation screening procedure, followed by open-label continuous 
ITB administration for 12 months for patients who met the responder criteria.13 The 
procedure for implantation of a pump (SynchroMed Infusion system; Medtronic Inc., 
Minneapolis, MN) and the verification of pump-catheter system integrity as well as the 
ITB dose escalation scheme were identical to those used in the previous study.13 The 
administration of ITB was started at a rate of 150 μg/day and  increased in 10 to 20% 
steps until patients experienced a satisfactory improvement of dystonia (the patient’s 
experience of dystonia relief) or dose-limiting side effects occurred.15,16 Changes of 
supplemental analgesics were allowed and monitored throughout the study. 
Measures
In this open label study, we performed a post hoc analysis of data from a study that was 
designed (1) to investigate the effectiveness of ITB in a dose escalation study in a large 
group of patients with CRPS-related dystonia and (2) to evaluate whether ITB is effective 
and safe in this population over a 12-month period.13
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This study was performed in an outpatient setting. Patients were evaluated at the start 
of continuous ITB administration and every 3 months for the following year. 
To study the effect of ITB on the different pain qualities we used the neuropathic pain 
scale (NPS), which includes 2 global ratings (intensity and unpleasantness) and 8 specific 
ratings (sharp, hot, dull, cold, sensitive, itchy, deep and surface).4 This scale uses a 
numeric rating scale (NRS) ranging from 0 (absent) to 10 (most severe) to rate each pain 
quality item. Preceding each 3-month visit, patients rated their global dystonia severity 
(GDS) at hourly intervals for 5 consecutive days using the same NRS.13 A mean NRS score 
was calculated from all ratings in these 5 consecutive days.13 A medication 
quantification scale (MQS) was used to quantify the use of analgesics based on the 
number of medications used, the pharmacological class of the drug, and the dosage 
level.17 The MQS score was calculated by multiplying the dosage level and a detriment 
weight, which was assigned for 8 classes of medication. The MQS scores of all drugs of 
each patient were summed to obtain a total MQS score per patient. 
Statistical analysis
We used a longitudinal linear mixed effects model with a heterogeneous first-order 
autoregressive covariance structure to test the hypothesis of change in NPS over time 
for each of the NPS qualities including time as a categorical variable. We analyzed the 
effect at each time point (3, 6, 9 and 12 months) compared with baseline and were not 
interested in a linear or quadratic change.
In this model, patients are treated as random effects, so the analysis can be adjusted to 
the pain level of each single subject. Furthermore, it adjusts for correlation between 
repeated measures from the same patient (assuming stronger correlations between 
scores that are closer in time), and allows missing data and analysis of repeated data 
with a variable number of measurements per subject. Because we used a linear mixed 
model, we examined the distribution of the residuals for all components of the NPS. An 
inspection of the normal probability plots showed that the distribution of the residuals 
was normal for all pain qualities. The analysis was controlled for the potential 
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confounding effect of other analgesic medication (MQS), GDS, and the absence or 
presence of an inciting event triggering CRPS. All statistical tests were 2-sided, with α =
0.05. The Cronbach α for internal consistency in our study was 0.93, and interitem 
correlations ranged from 0.27 to 0.90 with an average of 0.57. Because items are clearly 
not uncorrelated, we believe that correcting for multiple comparisons may not be
necessary. The results are expressed as mean (standard deviation [SD]). Given that the 
present study concerns a post hoc analysis of a study that was primarily aimed at 
reducing dystonia,13 no sample size calculations with respect to pain relief were 
performed. Analyses were performed using SPSS software (version 17.0; SPSS Inc., 
Chicago, IL).
RESULTS
Forty-two patients with a mean (SD) age of 37.3 (12.4) years and a mean (SD) disease 
duration of 8.8 (6.4) years were found eligible and participated in this study (figure 2.1). 
Forty patients (95%) were female and in 31 patients (74%) the onset of CRPS was 
triggered by a noxious stimulus. The number of affected extremities was 2 (24%) in 10 
patients, 3 (17%) in 7 patients, and 4 (60%) in 25 patients. Four patients failed to 
complete the 1-year follow-up period (figure 2.1) but were included in the linear mixed 
model analysis. A complete list of adverse events is illustrated in table 2.1.
After correction for the use of supplemental analgesics and GDS, a significant time effect 
was found for global intense pain (p=0.009), sharp pain (p<0.0001), dull pain (p=0.003),
and deep pain (p<0.0001) (table 2.2). This effect was characterized by a decline of scores 
over the first 6 months, after which the scores leveled off. We compared the course of 
the scores between each pair of these 4 pain qualities for the first 6 months within 
persons and considered the course to be similar if both pain qualities improved, 
worsened, or remained the same, and dissimilar if otherwise. Following this definition, a 
similar course of pain was found in 71% of cases for the combination of global intense 
and sharp pain, in 67% of cases for the combination of global intense and dull pain, in 
74% of cases for the combination of global intense and deep pain, in 68% of cases for
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Figure 2.1.  Enrollment of patients
a.  ITB = intrathecal baclofen
the combination of sharp and dull pain, in 66% of cases for the combination of sharp 
and deep pain and in 63% of cases for the combination of deep and dull pain. The time 
effect for GDS was also significant (p=0.003) with a continuous decline all through the 1-
year follow-up (table 2.2). The mean daily dose of ITB increased every 3 months during 
the year (table 2.2). The absence or presence of an inciting event triggering CRPS did not 
significantly influence the time effect for any pain quality, GDS, MQS, or daily dose of 
ITB.
DISCUSSION 
CRPS is associated with severe debilitating pain, which may involve different pain 
qualities across patients.4,6 These various pain qualities may result from different pain




38 completed the study
1 discontinued:
   pump explantation due to nausea
   and vomiting
1 discontinued:
   pump explantation due to pain in
   the pump region
2 discontinued:
   1 pump explantation due to
       pregnancy
   1 ITBa stopped due to headache







Table 2.1. Adverse events
Adverse events Type of event N


















Device-related, catheter (n = 49) Post-dural puncture headache
Dislodgement
Subcutaneous fluid collection/CSF leak
Occlusion/kink






Device-related, pump (n = 10) Pump pocket infection
Pain at pump site
Migration of pump





Other (n = 22) Worsening = CRPS symptoms
Psychiatricc
Excessive weight loss
Gastrointestinal problems (unrelated to ITB)








a. Psychosis: n = 2, depression and anxiety disorders: n= 1.
b. Diplopia, dizziness, anorgasmia.
c. Confusional state: n = 2, reactive depression: n = 1, reactive psychosis: n = 1.
d. Anemia, elevated liver enzymes, electrolyte changes.
mechanisms.4 This study focused on patients with CRPS characterized by dystonia. 
Homogeneous groups enhance the clinical, pathophysiological, and genetic coherence, 
which in turn may benefit research aiming to study or influence specific biological 
pathways. Patients in this study received baclofen, a presynaptic and postsynaptic 
GABA(B) agonist, which possesses analgesic properties.18-20 The intrathecal delivery of 
baclofen is used to overcome the obstacle of the blood-brain barrier and thus results in 
greater therapeutic effectiveness concentrated at the spinal site of action.13,21  
Table 2.2. Scores of the Neuropathic Pain Scale for different pain qualities, global dystonia severity, use of supplemental analgesics 
and daily dose of intrathecal baclofen over a 1-year follow-up
Baseline 3 months 6 months 9 months 12 months F value P value
NPS-item
   Global  7.6 (1.5) 6.3 (2.2) 5.7 (3.1) 5.9 (2.9) 5.6 (2.9) (4, 64.08) = 3.70 0.009
   Sharp 7.0 (2.3) 6.0 (2.5) 5.0 (3.6) 5.3 (3.4) 4.6 (3.4) (4, 56.28) = 7.18 <0.0001
   Hot 5.0 (3.0) 4.3 (3.3) 4.5 (3.5) 4.5 (3.5) 4.0 (3.3) (4, 59.83) = 0.33 0.858
   Dull 6.6 (2.4) 6.5 (2.7) 5.3 (2.8) 5.5 (3.0) 5.2 (3.1) (4, 55.98) = 4.67 0.003
   Cold 5.9 (3.4) 4.3 (3.3) 4.1 (3.6) 4.9 (3.5) 4.5 (3.8) (4, 40.68) = 1.50 0.221
   Sensitive 6.6 (3.2) 5.2 (3.7) 5.3 (3.7) 5.2 (3.5) 5.3 (3.5) (4, 55.78) = 2.40 0.061
   Itchy 2.6 (3.0) 1.5 (2.4) 1.4 (2.4) 2.2 (2.7) 1.8 (2.7) (4, 39.65) = 0.20 0.940
   Unpleasant 7.6 (1.5) 6.4 (2.2) 6.2 (2.9) 6.1 (2.9) 5.9 (2.7) (4, 71.61) = 1.65 0.170
   Deep 8.1 (1.4) 7.0 (2.2) 6.0 (3.1) 6.3 (3.0) 5.9 (3.0) (4, 55.85) = 8.96 <0.0001
   Surface 6.1 (3.2) 4.7 (3.4) 4.8 (3.5) 5.0 (3.2) 4.7 (3.3) (4, 66.89) = 0.24 0.917
GDS 7.1 (1.7) 5.2 (2.5) 4.9 (2.8) 4.5 (2.6) 4.2 (2.4) (4, 57.07) = 4.64 0.003
MQS 19.4 (11.6) 14.0 (12.1) 13.6 (13.4) 13.8 (12.0) 13.7 (11.8)     (4, 163.06) = 7.53 <0.0001
ITB (μg/day) 0 (0) 489 (248) 588 (295) 664 (332) 725 (344) (4, 77.46) = 153.20 <0.0001
NPS = neuropathic pain scale; GDS = global dystonia severity; MQS = medication quantification scale; ITB = intrathecal baclofen; values are presented as mean 
(standard deviation)
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In this study, we found a significant time effect with a reduction of pain scores during
the first 6 months of follow-up for global intense, sharp, dull and deep pain. These 
reductions can be interpreted as clinically significant (reduction in NRS scores ≥2) for 
global intense, sharp and deep pain and to a lesser extent for dull pain.22 Notably, the 
time effect was independent of the course of GDS and the use of supplemental 
analgesics, supporting the notion of baclofen’s antinociceptive effect on these pain 
qualities in these patients. This assumption is further supported by the significant 
decrease of supplemental analgesic consumption during the first 3 months. Oral 
administration of baclofen proved to be effective in the management of neuropathic
pain in both peripheral neuropathy and central pain syndromes.18-20 Notably, the add-on 
of ITB to spinal cord stimulation improved neuropathic pain over a prolonged period of 
time in patients who experienced insufficient benefit from spinal cord stimulation 
alone.23 However, this improvement was based on a reduction of the global pain ratings. 
Findings of our study show that a targeted stimulation of the central GABA(B) receptor 
may have differential effects on various pain qualities, which to our knowledge has not 
been described previously. The scores for the different pain qualities leveled off after 6 
months whereas GDS continued a declining course, and the dose of ITB was further 
escalated. The differential effects of these variables over time further support an 
independent role of GABAergic mechanisms on global intense, sharp, dull and deep pain 
qualities. Furthermore, patients were informed that the purpose of ITB was to improve 
dystonia severity. The continued decrease of GDS with further ITB dose escalations 
when improvement of different pain qualities had stabilized additionally highlights the 
differential roles of GABA(B) receptors in mechanisms underlying pain and dystonia in 
CRPS. 
The onset of CRPS is generally thought to result from a noxious stimulus, although this is 
not an obligatory criterion for the diagnosis following the IASP criteria.2 A previous study 
showed no significant difference in clinical characteristics between patients who 
developed CRPS spontaneously or after an inciting event.14 Also in this study, we found 
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no differences in outcomes between CRPS patients with and without an initiating 
trauma.  
Although most studies on CRPS report a female-to-male ratio of 3-4, the high 
percentage of female patients in this study (95%) is in line with other studies on CRPS 
patients with dystonia.7, 24, 25
One limitation of our study is the open-label design, which hampers the identification of 
a potential placebo effect, due to the absence of a control group. Ideally, a placebo-
controlled, randomized design would have been performed. Because this would involve 
the follow-up of patients with an implanted pump without medication for 1 year, this 
was considered unethical. However, we believe that the somewhat differential effect of 
ITB on particular pain qualities over time as compared with dystonia time makes a 
substantial role of a placebo effect on the outcomes of this study less likely. We cannot, 
however, exclude a placebo effect or natural progression of the disease affecting the 
pattern of the different pain qualities over time. 
Another limitation of the study could be the lack of homogeneity in dose escalation of 
ITB. However, this was inevitable because the occurrence of side effects limited dose 
escalation in some patients and the daily dose was maintained once a satisfactory result 
was achieved. Nonetheless, we noticed a trend of continuous increase of the daily dose 
of ITB throughout the whole 1-year follow-up period. 
In conclusion ITB proved beneficial in reducing global intense, sharp, dull and deep pain 
and highlights the differential antinociceptive effects of central GABA(B) receptor 
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ABSTRACT
Objective. Intrathecal baclofen (ITB) is effective in the treatment of dystonia related to 
complex regional pain syndrome (CRPS). In a previous study, we noted that the 
responsiveness to ITB declined in 30% of patients once drug delivery was switched from 
an external to an implanted device associated with a reduction of the infusion rate (IR). 
Design. In a double-blind study, we investigated the effect of varying the IR at a fixed 
daily dose on the efficacy and safety of ITB in patients with CRPS-related dystonia. 
Patients were randomized to either slower infusion rate delivery (SIRD) or four-times 
faster infusion rate delivery (FIRD) for 2 weeks and were crossed over after a 1-week 
washout period. 
Patients. Patients were eligible if they experienced no beneficial response to ITB on 
dystonia despite a minimum dose of 600 μg/day or because side effects limited dose
escalation. 
Outcome Measures. Primary outcome measures were changes in global dystonia and 
pain severity. 
Results. There were no significant differences between the FIRD and the SIRD groups for 
the median change of numeric rating scale dystonia (-0.3 [interquartile range {IQR} -1.1 
– 0.5]), pain (0.1 [IQR -0.8 – 1.3]), and secondary outcomes, except for the frequency of 
adverse events which was significantly higher during FIRD (12 vs 2). FIRD was preferred 
only by patients who were included because side effects to ITB prevented dose 
escalation. 
Conclusions. Increasing the IR at a fixed daily dose is not associated with improvement 
of dystonia or pain but warrants further investigation in patients in whom side effects 
prevent further dose escalation. 
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INTRODUCTION
Complex regional pain syndrome type I (CRPS I) is commonly preceded by injury, usually to 
a limb, and is characterized by pain, disturbed blood flow, temperature regulation, and 
motor control of the affected area.1-3 Approximately 20% of patients with CRPS develop 
dystonia, which is characterized by fixed flexion postures.1,4-7 Because dystonia in CRPS 
tends to spread to other limbs, the syndrome may evolve into a disabling disorder with a 
marked impact on quality of life.4,6,8 Impaired inhibitory control of sensorimotor circuits is a 
key pathophysiological finding in dystonia of CRPS.9 Baclofen stimulates pre- and 
postsynaptic γ-aminobutyric acid B receptors, which enhances central inhibitory 
activity.10,11 However, dystonia in CRPS is rarely controlled by oral baclofen, probably 
because of the drug’s poor ability to pass the blood-brain barrier;12,13 although in some 
patients, beneficial effects are reported with dosages as high as 90-120 mg per day.4
Epidural administration of baclofen was shown to be beneficial in intractable spasticity 
likely because the drug is lipid soluble and may cross the dura to act on the spinal canal.14
Intrathecal delivery of baclofen overcomes the obstacle of the blood-brain barrier and 
results in greater therapeutic efficacy concentrated at the spinal site of action.15,16
However, not all patients may respond to this mode of drug delivery, which is expensive 
and requires an invasive implantation procedure. Hence, a screening procedure with an 
external pump is frequently used to evaluate the responsiveness to intrathecal baclofen 
(ITB) to help select those patients that are most suitable for continuous ITB delivery 
through an implanted pump. Against this background, we screened patients using a 2-day 
placebo run-in dose escalation (200-800 µg ITB) design.16 The responder criterion for pump 
implantation was set at a ≥25% improvement of global dystonia severity on two 
consecutive baclofen days as compared to placebo. However, after pump implantation, 
30% of patients on ITB surprisingly failed to meet the responder criterion of the screening 
despite the use of a minimum daily dose of 600 µg or because side effects limited dose 
escalation. In an attempt to find an explanation for this finding, we reviewed the 
procedures of our study.16 We found that the infusion rates (IRs) applied during the 
screening and postimplantation period differed because of the use of different baclofen 
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concentrations (0.5 mg/mL vs 3 mg/mL) (table 3.1). The IRs decreased once patients were 
switched to 3 mg/mL concentration in the postimplantation period. Two different 
concentrations were used because of the utilization of two pumps with different 
requirements for effective drug delivery. Could the lack of response to ITB in some 
patients, after the switch to the higher baclofen concentration, be explained by the use of 
lower IRs? In an animal model, higher IRs of baclofen and bupivacaine increased the drug’s 
cerebrospinal fluid distribution; although experiments were performed in a 
nonphysiological setting17 and pain severity was reduced by increasing the IR of 
intrathecally delivered bupivacaine in patients with intractable pain.18 To our knowledge, 
the influence of the IR on the clinical efficacy of ITB, independent of the daily dose, has not 
been described to date. In this study, we compared the efficacy and safety of two ITB IRs at 
a fixed daily dose in patients with CRPS-related dystonia and hypothesized that the clinical 
efficacy may improve by increasing the IR without affecting safety as the daily dose was 
fixed.
Table 3.1. Drug delivery characteristics during screening procedure and post- pump 
implantation16
Screening procedure Postimplantation
Median (IQR) daily dose ITB (μg) 375 (275–500) 695 (393–838) 
Concentration baclofen (mg/mL) 0.5 3
Median (IQR) infusion rate ITB (mL/day) 0.74 (0.54–0.98) 0.24 (0.13–0.28) 
IQR = interquartile range; ITB = intrathecal baclofen
METHODS
Patients
The study was conducted in an ambulatory setting between April and December 2008. 
Patient consent was obtained in accordance with the declaration of Helsinki, and the 
study was approved by the local Ethics Committee. The trial was registered in The 
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Netherlands National Trial Register (NTR 1269). All patients were followed in our 
outpatient clinic and had CRPS-related dystonia in at least one extremity for which 
continuous ITB was administered. The patients fulfilled the CRPS criteria of the 
International Association for the Study of Pain (IASP) including continuing pain; allodynia 
or hyperalgesia disproportionate to any inciting event; evidence at some time of edema; 
changes in skin blood flow or abnormal sudomotor activity in the area of pain; and the 
absence of any condition that would otherwise account for the degree of pain and 
dysfunction.2 Patients had received an internal programmable Synchromed EL or II®
pump (Medtronic, Minneapolis, MN, USA) for continuous infusion of ITB after oral 
baclofen up to a minimal daily dose of 60 mg failed to provide beneficial response or 
side effects limited escalation of the daily dose.16 Patients were eligible for the IR study 
if they experienced no beneficial response to ITB on dystonia at a minimum daily dose of 
600 μg, or dose-limiting side effects prohibited dose escalation of ITB. Furthermore,
patients had to rate their global dystonia severity as at least 5 on a numeric rating scale 
(NRS) ranging from 0 (absent) to 10 (most severe) in order to be eligible for the study. 
Exclusion criteria were identical to those used in a previous study examining the efficacy 
of ITB in CRPS-related dystonia.16 In 11 patients, a screening procedure was performed 
using an external microinfusion pump before pump implantation.16 The remaining three 
patients participated in a trial with intrathecal glycine, after which they were switched 
to ITB without a screening procedure.19 These three patients were included in this study 
because they failed to improve >25% in dystonia severity as a result of dose-limiting side 
effects to ITB. Pump-catheter system integrity was verified in all patients prior to the 
study, and other conditions potentially influencing dystonia severity were ruled out. At 
baseline, the administered daily dose varied between patients, and all patients used a 
baclofen solution of 3 mg/mL.  
Design
In a double-blind, randomized, two-period, crossover design, solutions of 3 and 0.75 
mg/mL baclofen were administered in a randomized sequence. A computer method was 
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used to randomly allocate patients to one of the two sequences of different IRs. Prior to 
the start of the study, all patients received ITB at a simple continuous rate with a 3 
mg/mL concentration. To obtain two IRs at a 4:1 ratio with a fixed daily dose, 
concentrations of 3 mg/Ml (slower infusion rate delivery) [SIRD]) and 0.75 mg/mL (faster 
infusion rate delivery [FIRD]) were used. A physician who was not involved in the 
assessments of the patients carried out the switch procedure at the start of each 
sequence, filling the pump reservoir with baclofen concentrations of 0.75 or 3 mg/mL. 
Notably, reservoir fillings were always changed, regardless of the assigned new 
concentration to guarantee maintenance of blinding. When the baclofen concentration 
is changed, a bridge bolus can be used to empty the internal pump tubing and external 
catheter with the old baclofen concentration with the original IR. With a fixed daily 
administered dose, the replacement of the 3 mg/mL concentration will result in a 
substantial delay before the new concentration reaches the tip of the catheter. As this 
concentration-dependent delay may potentially contribute to deblinding, we used the 
side port to carry out a procedure that included aspiration of the content of the external 
catheter followed by multiple boluses to replace the removed volume. As a result of this 
approach, the new concentration would always reach the tip of the catheter within an 
hour regardless of the old concentration. During the first 2 weeks of the study, the first 
assigned IR was used. This was followed by a 1-week open administration of the 3 
mg/mL concentration of baclofen to minimize potential consequences of any carryover 
effect. Subsequently, over the following 2 weeks, patients received the other IR. 
Outcome Measures
Patients were asked to rate the global severity of pain and dystonia using an NRS 
ranging from 0 (absent) to 10 (most severe) once every day starting 1 week before the 
first switch procedure until the end of the second treatment period. At the start and end 
of each treatment period prior to changing the IR, a blinded clinical assessor rated the 
dystonia severity using the Burke-Fahn-Marsden (BFM) scale, which is the sum of the 
scores of the individual body regions.20 The same rater assessed the change of CRPS 
51
signs and symptoms from baseline on a global impression scale (GIS) at the end of each 
treatment, ranging from -3 (much worse) to +3 (much better) with 0 for ”no change”. At 
the end of the study, patients were asked to compare both treatment periods using a 
patient preference questionnaire (PPQ). The PPQ consists of a 10-cm horizontal line 
ranging from -5 to +5. A score of 0 reflects no preference, whereas -5 or +5 expresses 
maximal preference for the first or second treatment period, respectively. In addition, 
patients were asked to indicate the reasons for their preference. At the end of each 
study the clinical assessor was asked to guess treatment assignment to evaluate the 
integrity of blinding. The primary outcome measure was the difference in change in 
global severity of pain and dystonia between baseline and end of each IR period. The 
secondary outcome measures were defined as the difference in change in BFM score 
between baseline and end of each IR period, the difference in GIS between both 
treatment periods, the PPQ score, and the frequency and severity of adverse events 
assessed at the end of each IR period. 
Statistical Analysis
The results are expressed as median (interquartile range [IQR]). For all variables, a 
Wilcoxon signed rank test or Mann-Whitney U test was used to examine differences 
within and between patients, respectively. A chi-square test was conducted to compare 
the amount of adverse events between the FIRD and the SIRD groups. Significance was 
assumed at the 0.05 level. Assuming an alpha of 0.05, beta of 0.2, a standard deviation 
of the NRS of 2, and a correlation between measures of 0.6, we calculated that 14 
patients would be required to detect a statistically significant difference of ≥25% in the 
reduction of NRS scores between both IRs. 
RESULTS
Demographic and Baseline Characteristics
Fourteen CRPS patients (13 women) aged 45.5 years (IQR 37.3–56.0) with a median 
disease duration of 12.5 years (IQR 8.0–16.3) were found eligible and participated in the 
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study (table 3.2). The median daily dose of ITB was 695 g (IQR 393–838), with the 
median thoracic level of the catheter tip at T7 (range T2–T11). Seven patients (six 
women) were allocated to the FIRD-SIRD sequence; seven patients (all women) were 
allocated to the SIRD-FIRD sequence. All patients completed the study. A Wilcoxon 
signed rank test indicated there were no significant differences between baseline 
measures (NRS for dystonia and pain and BFM) of the first and second treatment period 
for each sequence, indicating a successful washout (table 3.3). Additionally, a Mann-
Whitney U test indicated that there were no significant differences between these 
baseline measures of patients assigned to each treatment sequence (FIRD-SIRD or SIRD-
FIRD). 
Table 3.2. Demographic and clinical characteristics
Characteristics Value
Median (IQR) age (years) 45.5 (37.3–56.0)
Sex
      Male
      Female
1      
13     
Median (IQR) dystonia NRS 7.2 (5.9–8.0)
Median (IQR) pain NRS 6.4 (5.5–7.8)
Median (IQR) duration of CRPS (years) 12.5 (8.0–16.3)
Median (IQR) duration of dystonia (years) 12.5 (7.8–16.3)
Median (IQR) duration of ITB (years) 3.9 (2.6–5.1)
Number of affected extremities (%)
        1
        2
        3
        4
0 (0)
    1 (7)
2 (14)
11 (79)
Number of dystonic extremities (%)
        1
        2
        3
        4
0 (0)
   1 (7)
3 (21)
10 (72)
Median (IQR) Burke-Fahn-Marsden score 47 (33-62)
IQR = interquartile range; NRS = numeric rating scale; CRPS = complex regional pain syndrome; ITB = 
intrathecal baclofen.
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Table 3.3. Baseline scores for primary and secondary outcome measures
NS = not significant; FIRD = faster infusion rate delivery; SIRD = slower infusion rate delivery; NRS = 
numeric rating scale.
Results on Outcome Measures
There were no significant differences between the FIRD and the SIRD group in median 
change of NRS score for dystonia (-0.3 [IQR -1.1–0.5]) and pain (0.1 [IQR -0.8–1.3]) and 
BFM score (2 (IQR -4–13)) (table 3.4). Six patients preferred FIRD with a median PPQ 
score of 3.0 (IQR 1.6–4.3), and seven patients favored the SIRD with a median PPQ score 
of 3.0 (IQR 1.0–3.0). One patient had no preference for any of the IRs. The difference 
between both groups in PPQ score was not significant. After FIRD, six patients showed 
an improvement on the GIS (+1 in four and +2 in two patients), three patients 
deteriorated (-1 in two and -2 in one patient), and five patients showed no change. After 
Table 3.4. Difference in change for primary and secondary outcome measures
Measure FIRD,         
median (IQR)






    NRS for dystonia -0.6 (-1.3–0.2) 0.0 (-1.3–0.8) -0.3 (-1.1–0.5) NS
    NRS for pain -0.4 (-0.8–0.4) 0.0 (-1.8–0.2) 0.1 (-0.8–1.3) NS
Secondary outcome measure
     Burke-Fahn-Marsden scale 0 (0–7) -2 (-6–0) 2 (-4–13) NS
Negative values represent improvement in outcome measures. P values were derived from a Wilcoxon 
signed rank test. NS = not significant; FIRD = faster infusion rate delivery; SIRD = slower infusion rate 
delivery; IQR = interquartile range; NRS = numeric rating scale.
Measure FIRD, median (IQR) SIRD, median (IQR) P value
Primary outcome measures
    NRS for dystonia 7.4 (5.9–8.3) 7.4 (6.4–8.1) NS
  NRS for pain 6.7 (5.5–7.5) 7.0 (5.9–7.8) NS
Secondary outcome measure
    Burke-Fahn-Marsden scale 50 (33–60) 48 (32–65) NS
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SIRD, four patients showed an improvement on the GIS (+1 in three and +3 in one 
patient), three patients deteriorated (-1 in one and -2 in two patients) and seven 
patients showed no change. There was no significant difference in change found on the 
GIS score between both IRs (z = -1.66). There was no significant effect of IR sequence on 
any of the outcome measures. Twelve adverse events (five moderate, seven mild) were 
reported in eight patients on FIRD (Table 3.5). Headache was the most frequently 
reported adverse event (N = 5), which in three patients was typical of intracranial 
hypotension headache and likely resulted from aspiration of catheter content during the 
switch procedure. Two patients reported one adverse event (both mild) while on SIRD 
including one patient with intracranial hypotension headache. There were significantly 
more adverse events on FIRD compared with SIRD (2 = 6.78, df = 1, P = 0.01), even after 
the removal of events due to intracranial hypotension (2 = 6.97, df = 1, P = 0.01). 
Table 3.5. Adverse events reported after each infusion rate treatment
Adverse event SIRD FIRD
Headache 1 (7) 5 (36)
Chorea 0 1 (7)
Nausea 1 (7) 1 (7)
Hallucinations 0 1 (7)
Short-term amnesia 0   2 (14)
Light-headedness 0 1 (7)
Drowsiness 0 1 (7)
Numbers represent N (%).
SIRD = slower infusion rate delivery; FIRD = faster infusion rate delivery.
Post Hoc Subgroup Analysis
None of the demographics or clinical characteristics predicted any outcome measures 
except for the reason of inclusion in the study, which was related to the preference of a 
particular IR (Figure 3.1). 
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Figure 3.1. Box plot illustrating patient’s preference for patients with a poor response 
with and without dose-limiting side effects.
Six out of eight patients, who entered the study because side effects prohibited dose 
escalation of ITB, reported preference for FIRD because dystonia and pain improved 
(median PPQ score 2.5 [IQR -1.4–3.8]). All six patients, who entered the study because 
they did not respond to a minimum daily dose of 600 μg ITB without baclofen-related 
side effects, preferred SIRD, except one patient who reported no preference for any of 
the IRs (median PPQ score 2.0 [IQR 0.8–3.5]). Mann-Whitney U test revealed a 
significant difference in patient’s preference (P = 0.03) between groups, stratified 
according to “reason of participation”. No significant difference was found for any of the 
other primary and secondary outcomes as well as the rate or severity of adverse events 
between both groups (P > 0.05). The clinical assessor’s guess of which IR was 
administered was correct in 57%.
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DISCUSSION
Intrathecal drug delivery has opened new avenues for the administration of drugs like 
baclofen that have difficulty passing the blood-brain barrier. However, once the drug is 
in the intrathecal space, many aspects may influence its profile of efficacy and safety.21
One of these aspects is the IR of a drug, which surprisingly has barely been explored.17,18
In a recent study on long-term effects of ITB in CRPS-related dystonia, we noted that a 
substantial percentage of patients, who responded to ITB during a screening procedure 
using an external pump, subsequently failed to respond to continuous ITB with an 
implanted pump.16 These poor responders included patients who failed to improve 
>25% in global dystonia severity in spite of repeated dose escalations (up to 600 g/24 
hours) and patients in whom dose escalation was limited because of the occurrence of 
side effects. Interestingly, the intrathecal IR applied during the screening period 
exceeded the IR of the postimplantation period as much as seven times because a lower 
concentration (0.5 mg/mL) was used. Additionally, the daily dose at the time patients 
qualified for the responder criterion of the screening procedure was lower in the 
majority of patients compared with the daily dose administered during the 
postimplantation period (table 3.1). Triggered by these findings, we evaluated if 
different IRs at a fixed daily dose influence the efficacy and safety of ITB in patients with 
CRPS-related dystonia. In addition to dystonia, we evaluated the influence of ITB on pain 
because baclofen may exert an analgesic effect.22 Prior to the start of this study none of 
the patients experienced a beneficial response in pain to ITB. Both for the total group as 
well as the subgroups defined by reason of inclusion, we found no differences between 
FIRD and SIRD on any of the primary outcome measures. Blinding was adequately 
maintained, as the sequence of IRs was correctly guessed in approximately half of the 
cases. Our findings may indicate that IR differences up to a factor four do not account 
for the lack of response to ITB in implanted patients. Although we cannot exclude that 
the difference between the two IRs was too small to detect a clinically relevant 
difference, the use of a four-times higher IR seemed appropriate. The use of a 
concentration below 0.75 mg/mL would have implied an extra refilling of the pump 
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during the FIRD period in some patients, which may have caused deblinding. The 
majority of patients displayed dystonia in all extremities reflecting the referral of more 
severely affected patients to our tertiary center. One could argue the severity of 
dystonia may account for the lack of response to ITB. However, only patients who had 
demonstrated responsiveness to ITB at an earlier stage were included in this study. 
Another limitation of this study could be the large variability in the daily administered 
dose of ITB across the patients, which reflects individual differences with respect to the 
dose of ITB at which patients perceived some albeit insufficient benefit (<25%) or the 
highest tolerated dose that did not cause unacceptable side effects. Consequently, it 
was not possible to equalize the daily administered dose of ITB. On the other hand, 
using a crossover design, patients served as their own controls with the daily dose fixed 
for each patient. Contrary to the primary outcomes, patient’s preferences indicated 
significant differences with respect to the preferred IR. Except for one case, all patients 
who were included because they failed to respond to sequential dose escalations of ITB 
(without baclofen-related side effects) favored SIRD. Surprisingly, the majority of 
patients, who were included in the study because side effects restricted further dose 
escalation of ITB, reported a preference for FIRD. In a written statement delineating 
their preference, all but one patient in both subgroups revealed that their preference 
was based on the influence of the IR on dystonia and pain, which apparently 
outweighed the severity of adverse events.
Of note is that patients’ preferences were paralleled neither by changes in primary and 
secondary outcome measures of dystonia nor by the clinical impression of change, 
which may question the responsiveness of the applied assessment scales to subtle 
changes. Possibly, increasing the IR under a fixed daily dose reduces the severity of side 
effects as compared with increasing the IR by raising the daily dose. In 11 patients, a 
screening procedure was performed prior to pump implantation. Interestingly, patients 
who participated in the study because ITB-related side effects limited dose escalation 
had a significantly larger difference between the IRs of the screening and 
postimplantation, compared with patients with a poor response without side effects 
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(table 3.6). All patients of the first category favored FIRD, except for one patient, who 
suffered from severe intracranial hypotension headache during FIRD and consequently 
preferred SIRD. However, it deserves emphasis that the aforementioned findings are the 
result of post hoc subgroup analyses and hence warrant further investigation in future 
studies. During the FIRD, patients reported significantly more adverse events of a 
supraspinal origin. As the daily dose of ITB was fixed for both IRs, this finding likely 
suggests a more extended intrathecal distribution of baclofen with higher IRs. 
Table 3.6. Ratios of drug delivery characteristics for screening vs postimplantation 
period 
Poor response  with no 
side effects 
Poor response with dose-
limiting side effects
z Value P value
Median (IQR) daily 
dose ratio 
0.4 (0.3–0.6) 1.0 (0.6–1.2) -2.19 0.03
Median (IQR) infusion 
rate ratio
2.6 (2.0–3.4) 5.6 (3.6–7.0) -2.19 0.03
The screening to postimplantation period ratio for infusion rate and daily dose for patients with a poor 
response with and without side effects to ITB [16]. P values were derived from a Mann-Whitney U test.
IQR = interquartile range.
Conclusions
In conclusion under a fixed daily dose, a four-times higher IR enhances the intrathecal 
distribution of baclofen as evident from the significantly higher number of adverse 
events. However, in CRPS a fourfold higher IR is not associated with clinically overt 
improvement of dystonia or pain. Patients in whom side effects restricted further dose 
escalations of ITB favored FIRD because of subjective improvement of dystonia and pain. 
In these patients, FIRD did not cause more side effects than in patients who failed to 
respond to ITB after subsequent dose escalations but who had not experienced side 
effects. Consequently, in the subgroup of patients in whom side effects prevent ITB dose 
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ABSTRACT
Dystonia in complex regional pain syndrome (CRPS) is often treated with baclofen, a γ-
aminobutyric acid B agonist. The authors report four CRPS-patients who developed 
baclofen-induced chorea, which coincided to a large extent with body regions that were 
initially affected by dystonia. Treatment with tiapride resolved the chorea, suggesting 
that striatal dopaminergic hyperactivity underlies baclofen-induced chorea. 
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INTRODUCTION
Complex regional pain syndrome (CRPS) is a chronic disorder characterized by persistent 
pain, vasomotor and trophic features, which usually is preceded by tissue injury.1
Approximately 20% of patients with CRPS also develop fixed dystonia.2 Baclofen, a γ-
aminobutyric acid B (GABA-B) receptor agonist is commonly used in the management of 
spasticity of various causes, but is occasionally used in primary and secondary dystonia. 
To overcome baclofen’s poor ability to pass the blood-brain barrier, intrathecal
administration of baclofen (ITB) can be used, requiring only small doses to produce 
satisfactory clinical improvement. In the course of our research on ITB in CRPS patients 
with dystonia we encountered several cases with baclofen-induced chorea (BIC). The 
aim of this study is to characterize these patients and discuss potential mechanisms.
METHODS
Since 1996 approximately 300 patients have been evaluated in our clinic for CRPS-
related dystonia. Patients were eligible for ITB, if they fulfilled the CRPS I diagnostic 
criteria of the International Association for the Study of Pain, 1 had fixed dystonia in one 
or more extremities, and showed an insufficient response to oral baclofen up to a 
minimal daily dose of 60 mg or had side effects which limited dose-escalation. Seventy-
four patients who fulfilled the criteria were implanted with a programmable pump and 
received continuous ITB for a mean (range) duration of 48 (2 – 147) months at a median 
(range) daily dose of 650 (150 – 1500) µg. The clinical characteristics of patients, in- and 
excluded for pump implantation, were similar.
Four patients were identified who developed chorea while on baclofen treatment (three 
on ITB). All patients were Caucasian and female with a mean (range) age of 52 (48 - 56) 
years and a mean (range) disease duration of 12 (8 - 17) years. The interval between the 
onset of CRPS and dystonia was less than a year in all cases. All patients showed a 
gradual spread of dystonia to other body parts (three multifocal dystonia and one 
hemidystonia; figure 4.1). None of the patients had a family history of dystonia and 
other causes of dystonia, including birth injury, head trauma, neuroleptic treatments
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Figure 4.1. Distribution patterns of dystonia (left figure) and chorea (right figure) of four 
patients with CRPS. Case 1 also exhibited both dystonia and chorea in the 
oromandibular region. Case 1 to 3 received ITB. Case 4 received oral baclofen only.
        Case 1           Case 2   Case 3        Case 4
CRPS = complex regional pain syndrome; ITB = intrathecal baclofen
were not reported or identified in the medical history or correspondence. Laboratory
tests, including serum copper and ceruloplasmin as well as computed tomography or 
magnetic resonance imaging of the brain were normal. 
The patients on ITB developed chorea at 3, 4 and 38 months after initiation of ITB at a 
mean (range) daily dose of 490 (315 – 650) µg with the catheter tip positioned at level L1, 
T7 en T10, which was comparable to patients without chorea. One patient developed 
chorea on oral baclofen two months after the start of this treatment at a daily dose of 70 
mg. One of the patients on ITB used an oral contraceptive at the time chorea developed. 
However, a relation with chorea seemed unlikely since the oral contraceptive was initiated 
29 years prior to the onset of chorea and its withdrawal did not improve chorea. The other 
three patients did not use medication with the potential to induce chorea. In all cases there 
were no symptoms or signs indicative of baclofen intoxication at the time chorea 
developed. Laboratory screening, including hematocrit and thyroid hormone tests, 
antinuclear factor, anti-DNA, antiphospholipid antibodies, antistreptolysin titer, 
acanthocytes, serum copper and ceruloplasmin and CAG repeat expansion mutation
analysis for Huntington disease (performed in two patients) ruled out other causes of 
chorea.
In all cases chorea developed gradually, was continuous while awake, not distractible and 
simultaneously presented in the proximal and distal part of an extremity. None of the 
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patients experienced a sensory component related to the movement disorder. The 
distribution pattern of chorea varied between patients, but largely matched the 
distribution of dystonia within each patient, except for the occurrence of chorea on the 
contralateral non-dystonic side in patient 1 (figure 1). Patient 2 suffered from dystonia 
in both legs and the right hand, but developed chorea only in the lower limbs (figure 1). 
In all cases, dose-escalation of baclofen improved dystonia, but worsened chorea, and a 
reduction of baclofen dosage was associated with improvement of chorea and worsening 
of dystonia. In all four patients tiapride was administered, up to 300 mg in three divided 
doses, which successfully resolved chorea in all cases.
DISCUSSION
We present four patients who developed chorea while using baclofen (three on ITB). 
Dose-escalation of ITB always improved dystonia but worsened chorea and vice versa. 
Medical and medication history as well as laboratory tests ruled out other causes of
chorea. Phenotypically, akathisia can appear as chorea. Akathisia is characterized by 
whole body, predominantly axial rocking movements and is associated with a sense of a 
need to move. In our patients the distribution pattern of movements coincided to a 
large extent with body regions that were initially affected by dystonia and the 
movements were not associated with a sensory component. A psychogenic origin was 
also considered unlikely since there was no acute onset or fast progression, and the 
movements were not distractible. Our findings thus suggest that these patients 
developed BIC. Hitherto, BIC has only been reported in three patients on oral treatment 
who suffered from various disorders.3-5 ITB is predominantly used in patients with 
spasticity but surprisingly no cases with BIC have been reported using this treatment. 
Although a referral bias to our tertiary centre likely inflated the findings, the apparent 
lack of reports on patients with BIC on ITB may highlight an increased susceptibility to 
develop BIC in patients with CRPS.  The relative variability of the daily dose and long 
interval between the start of baclofen and the onset of chorea in our patients may 
question their relation. However, this is not an uncommon finding in other drug-induced 
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movement disorders and most likely reflects individual differences in susceptibility to 
drug-induced side-effects. CRPS is associated with a hyperactive state of the spinal cord 
(central sensitization) which is characterized by enhanced signal transmission in the pain 
circuitry to the cortex.6 In CRPS patients with dystonia, different studies have found 
evidence of impaired central inhibition along the neuraxis but  it remains unclear if 
these findings genuinely reflect a pathophysiological marker of dystonia.2 When 
baclofen is infused around the spinal cord it inhibits afferent input by stimulation of pre-
and postsynaptic GABA-B receptors. Dystonia in CRPS responds to ITB which may suggest 
that this type of dystonia is associated with loss of GABAergic inhibition in the spinal 
cord.2
In CRPS, significant changes have been found in the cerebral circuitry involved in motor 
processing.7 These changes, which involve the basal ganglia and (pre)supplementary 
motor area have been suggested to play a role in the motor impairments encountered 
in patients with CRPS.7 Hence, in CRPS, spinal sensitization may bring about changes in
supraspinal circuitry, finally leading to chorea.  
Although several mechanisms may underlie chorea, enhanced activity of striatal 
dopamine has been proposed as a major mechanism for the development of chorea 
induced by drugs including levodopa, dopamine agonists and antagonists, and lithium.8
Interestingly, baclofen is known to exert anti-dopaminergic activity9 and the drug has 
also been used to treat chorea in Huntington’s disease and tardive dyskinesias. Tiapride 
is a selective D2/D3 dopamine receptor antagonist in limbic areas, the striatum, and 
nucleas accumbens without any affinity for other neurotransmitter receptors of the 
brain.10 Treatment with tiapride resolved the chorea, indicating that striatal 
dopaminergic hyperactivity underlies BIC in our patients. Collectively, our observations 
may suggest that alterations in synaptic processes mediated by GABA-B receptors 
underlie BIC in a subset of CRPS-patients.
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ABSTRACT
Since glycinergic neurotransmission plays an important inhibitory role in the processing 
of sensory and motor information, intrathecal glycine (ITG) administration may be a 
potential therapy for both pain and movement disorders in patients with complex 
regional pain syndrome (CRPS). Aims of the current study, which is the first report on 
ITG in humans, were to evaluate its safety and efficacy. ITG treatment during 4 weeks 
was studied in CRPS patients with dystonia in the period before they received 
intrathecal baclofen treatment. Twenty patients were assessed and after exclusion of 
one patient, the remaining 19 patients were randomized in a double-blind placebo-
controlled crossover study. Safety was assessed by clinical evaluation, blood 
examinations and electrocardiograms. Efficacy measures involved pain (numeric rating 
scale, McGill pain questionnaire), movement disorders (Burke–Fahn–Marsden dystonia
rating scale, unified myoclonus rating scale, tremor research group rating scale), activity 
(Radboud skills questionnaire, walking ability questionnaire), and a clinical global 
impression (CGI) and patient’s global impression score (PGI). Treatment-emergent 
adverse events were generally mild to moderate and not different from placebo 
treatment. During ITG treatment growth hormone levels were slightly increased.
Although there was a trend to worsening on the CGI and PGI during ITG treatment, 
there were no significant differences between ITG and placebo treatment in any of the 
outcomes. ITG given over 4 weeks was ineffective for pain or dystonia in CRPS. Although 




Complex regional pain syndrome type I (CRPS) which is more common in women and 
often preceded by a trauma, is characterized by spontaneous pain, edema, changes in 
skin temperature and color, hyperhidrosis, and motor disturbances.1,2 The latter mainly 
include fixed dystonia of the distal extremities.3,4 The pathophysiology of CRPS is still 
unclear but over the last decade there is increasing evidence showing that different 
mechanisms may contribute to its broad clinical spectrum.1,5,6
The initial symptoms of CRPS have been attributed to a perturbed regulation of 
inflammation in which both C and Aδ sensory nerve fibers (neurogenic inflammation) 
and the immune system of the skin are involved.7-10 Peripheral inflammation or injury 
may in turn lead to profound changes in the processing of sensory input at the spinal 
level, a process known as central sensitization.11,12 As a result, pain may become chronic 
and allodynia and hyperalgesia may develop. Additionally, these central changes may 
corrupt the normal control of motor circuits.13,14
Compelling evidence from neurophysiological studies that focused at the spinal or 
cortical level in patients show that disinhibition is a key characteristic in the involvement 
of the central nervous system in CRPS patients with and without dystonia.15-18
Cutaneous C and Aδ afferents are linked to spinal interneuronal circuits that mediate 
nociceptive withdrawal reflexes (NWRs).19 Interestingly, both sensitized NWRs in animal 
models and pain and dystonia in CRPS patients respond to the intrathecal administration 
of the GABAB agonist baclofen (ITB), which enhances spinal GABAergic inhibition.20-22
In addition to GABAergic circuits, glycinergic circuits may also be involved in central 
sensitization. In rats, peripheral inflammation-induced central sensitization has been 
associated with loss of glycinergic inhibition.23 Following peripheral inflammation or 
spinal PGE2 injection, mice with a glycine receptor deficiency show a reduced pain 
sensitization.24,25 In animal models of neuropathic pain, intrathecal glycine (ITG) 
reduced26,27 or prevented28 hyperalgesia. Besides involvement in afferent processing, 
glycine may play a prominent role in the control of motor functions. Strychnine is a 
glycine receptor antagonist, and poisoning with this drug results in overwhelming 
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muscle spasms, rigidity and tremor.29 Glycine receptor mutations in both humans and 
animals result in spasms, tremor and myoclonia,30,31 motor features that bear a 
remarkable similarity to those reported in CRPS.
In view of the important role of disinhibition in chronic CRPS and the potential role of 
glycinergic mechanisms in pain and motor processing, drugs such as glycine that 
enhance glycinergic inhibition may provide a new mode of treatment in CRPS. Because 
glycine is abundantly present in food, it would seem plausible that this potentially 
dangerous inhibitory neurotransmitter has limited access to the CNS. Indeed, two 
animal studies have reported a poor blood-brain barrier (BBB) passage of glycine.32,33 As 
a consequence, glycine requires intrathecal administration (ITG) to explore its role in the 
management of pain and dystonia in CRPS.
Aims of the current study were to evaluate the safety and efficacy of ITG in patients with 
CRPS. We here report the results of a double-blind randomized placebo-controlled 
crossover trial evaluating 4 weeks of ITG treatment in 20 chronic CRPS patients.
METHODS
Subjects were male or female out-patients, at least 18 years of age, with a clinical 
diagnosis of CRPS with dystonia who were referred to the movement disorders 
outpatient clinic of the Department of Neurology and were candidates for ITB 
treatment. Patients who qualified for ITB treatment were requested to participate in the 
current study, which was performed in the period before ITB treatment started. Patients 
were referred by physicians throughout the Netherlands. Inclusion criteria were CRPS-I
according to the diagnostic criteria of the International Association for the Study of Pain,34
clinically significant fixed dystonia in one or more extremities, and symptoms for at least 1 
year. Exclusion criteria were satisfactory relief of symptoms with conventional treatments 
including oral baclofen, pregnancy, breastfeeding, childbearing potential without using 
effective contraception, clinically significant psychiatric illness, suspicion of poor 
compliance, or involvement in legal proceedings concerning compensation for CRPS. All 
patients were evaluated by a psychiatrist to exclude psychiatric comorbidity. In all subjects 
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a programmable SynchroMed pump (Medtronic, Minneapolis, MN) for continuous IT 
administration was implanted. The catheter was introduced in the subarachnoid space 
(L2-L3) under X-ray guidance with the distal tip of the catheter placed in the midthoracic 
region. The catheter was then tunneled subcutaneously and connected to the pump. 
Pump-catheter system integrity was verified post-operatively. We aimed to recruit 20 
patients, which was considered a reasonable sample size for a first safety study. Patient 
consent was obtained according to the Declaration of Helsinki and the study was approved 
by the Ethics Committee of the Leiden University Medical Center.
N = 1 experience
To date no published studies on ITG in humans are available. The dose schedule of ITG in 
the current study was based on our experiences in one CRPS patient who progressed to 
generalized dystonia and did not respond to ITB. After consent was obtained from both 
the local Ethics Committee and the patient, a last resort therapy with ITG was started. 
We noted a sustained and prominent decrease in pain with moderate effects on 
dystonia at a dose of 30 mg/24 h. ITG was administered for 1 year and no side-effects 
occurred.
Study design
We used a double-blind randomized placebo-controlled crossover design. 
Randomization was done by a computer-generated list and took place at the Department 
of Pharmacy. Treatment allocation remained concealed from patients and investigators 
(including those who performed the assessments) throughout the study. Every subject 
received two intrathecal treatments: 21 mg/mL glycine solution during 4 weeks, and 
sodium chloride 0.9% (w/v) during 4 weeks (placebo), with a tapering and wash-out 
period in-between both treatments: tapering in 1 week (3 equal dose reductions with an 
interval of 48 h), followed by a wash-out period of 1 week. The carry-over between 
treatments was considered minimal because the plasma half-life of IV glycine ranges from 
30 to 60 min35 (the half-life of ITG is unknown). Placebo and ITG have the same watery 
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appearance, which made unblinding by inspection of the administered substances 
impossible. Treatment was started at 8 mg/24 h  and was increased weekly with 8 mg/24 
h. Unless side-effects occurred, glycine administration reached a daily dose of 32 mg/24 h 
in the last week of the glycine period. Higher dose administrations were not studied 
because of the associated short filling interval (< 1 month) of the pump, which was 
considered not feasible in clinical practice.
An independent data safety board monitored the study. The committee monitored the 
safety of the patients by evaluating the treatment-emergent adverse events (AEs). The 
study is registered with the Netherlands Trial Register, number NTR499.
Outcome measures
Safety assessments included history taking, physical examination and routine blood 
assessments (every other week) and electrocardiograms (every other week). Pain was 
evaluated with a numeric rating scale (NRS) for pain, and the McGill pain 
questionnaire.36 A TSA-II thermal sensory analyzer (Medoc Ltd., Ramat Yishai, Israel), 
using a thermode placed on both hands (thenar eminences), was used to assess detection 
thresholds of temperature change (method of limits).37 Efficacy on movement disorders 
was studied with the Burke-Fahn-Marsden (BFM) Dystonia Rating Scale38, unified 
myoclonus rating scale (Sections 2-4)39 and tremor research group rating scale (Items 1-
8).40 Assessment of activity level included the Radboud skills questionnaire41 (if arms 
were involved) and the walking ability questionnaire42 (if legs were involved). Change of 
CRPS signs and symptoms was rated on a global impression scale: both the investigator 
(clinical global impression, CGI) and the patient (patient’s global impression, PGI) assessed 
the change during treatment on a scale ranging from -3 (very poorly) to +3 (very well).
Success of the blinding was investigated by asking both the patient and investigator to 
guess which treatment was administered.
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Plasma glycine and growth hormone analysis
Blood samples for glycine measurement were taken at the last day of treatment (before 
tapering). Blood was collected in EDTA (ethylene diamine tetraacetic acid) tubes and 
directly cooled with melting ice. Plasma was isolated after centrifugation at 20C for 7 
min at 1500g and stored at -20C until analysis. Glycine was determined on a Biochrom 
30 automated amino acid analyzer (Biochrom, Cambridge, UK) as previously described;43
however 250 µM L-methionine sulfone (Sigma, St Louis, MO) was used as the internal 
standard and a short buffer program of 50 min was used.
Because in a previous study in children, IV glycine increased growth hormone (GH) 
levels,44 blood levels of GH were monitored at baseline and at the last day of each of the 
interventions.
Statistical analysis
To study differences between 4 weeks of ITG treatment and 4 weeks of placebo treatment, 
the paired t test (if data were normally distributed) or Wilcoxon test (if not) were used. 
Significance was assumed at the 0.05 level. For all tests, the SPSS software package version 
14.0 (SPSS Inc., Chicago, IL) was used.
RESULTS
No patients refused to participate in the study in the period before their ITB treatment 
started. Patients were aged 26-58 years (19 women, 1 man). One patient withdrew her 
consent after implantation. The remaining 19 patients entered the study (table 5.1). In 
one patient, the study was ended prematurely because participation was experienced as 
too burdensome (she received ITG during 21 days, and no placebo).
Safety
Treatment-emergent AEs were found in 15 patients. The most frequently reported AEs 
were drowsiness, headache, dysesthesia and nausea and vomiting (table 5.2). 
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Table 5.1. Baseline characteristics - before pump implantation (n = 19)
Characteristic Value
Median age, years (IQR) 41 (34-51)
Sex
     Male 1
     Female 18
Median duration of CRPS, years (IQR) 9 (5-17)
Number of dystonic extremities (%)
      1 0
      2 6 (31)
      3 3 (16)
      4 10 (53)
Modified Rankin scale (%)45
      No significant disability 0
      Slight disability 7 (37)
      Moderate disability 5 (26)
      Moderately severe disability 7 (37)
      Severe disability 0
CRPS = complex regional pain syndrome type I; IQR = interquartile range.
The proportion of patients with one or more AEs was similar during ITG (12/19 = 63%; 
18 AEs) and placebo treatment (9/18 = 50%; 13 AEs; χ2 = 0.23, df = 1, p = 0.63).
Serious AEs did not occur. Other AEs during ITG treatment were categorized as mild to 
moderate. In one patient, a mild but persistent exacerbation of pain and dystonia 
occurred, which began at the first day of ITG treatment. 
Plasma glycine and GH measurements
Mean serum glycine concentrations were not different between ITG treatment (242 μM, 
range 106-461) and placebo treatment (241 μM, range 105-499) at 28 days of treatment 
(p = 0.75, paired t test).
At baseline, four patients had GH values (8.8, 9.8, 25.9 and 70.6 mU/l) above the normal 
range (0.0-5.0 mU/l). GH was significantly increased at day 29 of ITG treatment (median 
2.1, interquartile range [IQR] 0.7-5.3, maximum 30.7 mU/l) compared to day 29 of 
placebo (median 0.9, IQR 0.5-4.2, maximum 13.4 mU/l; p = 0.031, Wilcoxon test). There 
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Table 5.2. Treatment-emergent adverse events






Restless legs 1 -
Nervousness 1 -
Emotional liability 2 -
Nausea or vomiting 1 3
Palpitations - 1
Polyuria 1 -
Unpleasant feelings 1 2
Myalgia 2 -
Fever (1 day) 1 -
CRPS exacerbation 2 -
Total 19 14
CRPS = complex regional pain syndrome type I; ITG = intrathecal glycine.
were no significant abnormalities in other clinical laboratory tests or 
electrocardiograms.
Efficacy
There were no significant differences in any of the outcome measures, between ITG and 
placebo treatment (table 5.3). During ITG treatment, one patient reported improvement 
(PGI +2), and nine reported worsening (PGI -3 in one patient, -2 in four, and -1 in four). 
The CGI score showed improvement in one patient during ITG treatment (+2), and 
worsening in five (-3 in one, and -1 in four). During placebo treatment, two patients 
reported improvement (PGI +2), and four reported worsening (-2 in three, and -1 in
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Table 5.3. Summary of secondary outcome events (medians (IQR) are presented) 
Outcome event Range scalea Intrathecal glycine
Baseline                       4 weeks
Placebo
Baseline                       4 weeks 
P valueb
Pain (numeric rating scale) 0 - 10 6 (4 - 8) 6 (5 - 8) 7 (5 - 8) 7 (5 - 7) 1.0
McGill pain questionnaire 
    Number of words chosen
    Pain rating index
0 - 20
0 - 63
12 (7 - 13)
21 (11 - 28)
13 (8 - 14)
20 (13 - 32) 
12 (8 - 14) 
22 (14 - 28)
12 (8 - 14)
19 (13 - 31)  
0.20
0.49
Thermal sensory analyser (C)
    Cold detection threshold (T)
    Heat detection threshold (T)
0.1 - 17.0  
0.1 - 18.5
1.3 (0.3 - 4.7)
1.4 (0.5 - 5.1)
1.0 (0.3 - 3.8)
1.8 (0.9 - 4.3)
1.0 (0.4 - 5.6)
2.3 (1.2 - 6.1)
1.0 (0.4 - 4.2)
2.0 (0.8 - 4.0)
0.70
0.23
Burke-Fahn-Marsden dystonia rating scale 0 - 120 32 (14 - 44) 35 (12 - 48) 27 (12 - 41) 31 (16 - 48) 0.60
Unified myoclonus rating scale
    Myoclonus at rest
    Stimulus sensitivity
    Myoclonus with action
0 - 128 
0 - 17
0 - 160
0 (0 - 8)
0 (0 - 1)  
10 (0 - 20)
0 (0 - 5) 
0 (0 - 0)  
0 (0 - 16)
0 (0 - 1) 
0 (0 - 1)  
3 (0 - 20)
0 (0 - 1)  
0 (0 - 1)  




Tremor research group rating scale (item 1-8) 0 - 76 2 (0 - 6) 2 (0 - 6) 1 (0 - 6) 2 (0 - 6) 0.96
Radboud skills questionnaire (total) 1 - 5 4 (3 - 5) 4 (3 - 4) 4 (3 - 4) 4 (3 - 4) 0.18
Walking stairs questionnaire 
    Walking in the house
    Walking outside
0 - 10
0 - 10
9 (8 - 10)
10 (7 - 10)
9 (6 - 10) 
10 (7 - 10)
9 (6 - 10)
10 (9 - 10)
9 (7 - 10)







0 (-1 to 0)
0 (-2 to 0)
0 (0 - 0)
0 (0 - 0)
0.32
0.74
a. Best score is underlined
b. ITG at 4 weeks versus placebo at 4 weeks (Wilcoxon signed rank test)
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one), the CGI showed improvement in none, and worsening in one (-1). The effect of 
placebo was 0% for the pain NRS and -15% for the BFM Dystonia Rating Scale.
Patient’s and investigator’s guesses of which treatment was administered were
incorrect in 57% and 59%, respectively. There was no significant effect of sequence (ITG-
placebo or placebo-ITG) on the pain NRS and BFM dystonia rating scale baseline scores.
DISCUSSION
Central disinhibition plays an important role in CRPS and enhancing the GABAergic 
inhibitory status through intrathecal administration of baclofen has proven beneficial in 
the treatment of dystonia and to a lesser extent on pain.21,22,46 Against this background, 
we were interested if similar results could be obtained by enhancing glycinergic 
inhibition in CRPS patients. Because no information is available on the tolerability of this 
mode of glycine administration in humans, this study firstly focussed on the safety of 
ITG and secondly evaluated its efficacy in doses up to 32 mg/24 h. No major AEs 
occurred in 19 CRPS patients treated with ITG over 4 weeks. The proportion of most 
frequently reported AEs (drowsiness, headache, dysesthesia and nausea and vomiting) 
were similar for ITG and placebo treatment. Compared to placebo, median GH values 
increased during ITG treatment (0.9 versus 2.1 mU/l). GH levels still remained in the 
normal range of 0-5.0 mU/l, and were smaller than the increases that are observed with 
intravenous GH. Notably, the absence of functional disturbances in our patients is at 
best only a surrogate marker for the absence of neurotoxicity of ITG.47 Evolving deficits 
may not be revealed by functional indices for an extended period of time, whereas 
histological examination demonstrates a continuing event.48 Consequently, our findings 
are insufficient to assume that ITG is not associated with neurotoxicity and further 
studies are required to address this issue.
Over the dose-escalation period of 4 weeks with doses up to 32 mg/24 h we did not find 
evidence of efficacy of ITG. Several explanations for this lack of efficacy of ITG are 
possible. First, it is possible that not glycinergic but GABAergic mechanisms play a key 
role in central disinhibition of CRPS. Second, ITG may have been administered in an 
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insufficient dose, although GH-increases indicate that the doses were pharmacologically 
active. Third, effective synaptic concentrations of glycine are regulated by glycine 
transporters which mediate its uptake into nerve terminals and adjacent glial cells.49
Hence, the lack of efficacy of ITG could result from a compensatory ITG-mediated 
increased activity of glycine reuptake transporter mechanisms. In this case, selective 
inhibitors of glycine transporter could be more efficacious. Finally, however, our patient 
and clinician-based impression scores may hint at another explanation. Although the 
primary outcomes showed no difference, there was a trend on the patient and clinician-
based impression scores to show deterioration during ITG. Nine patients worsened 
during ITG, versus four during placebo treatment according to the patient-based PGI 
score. In line with this, the investigator-based CGI indicated that five patients got worse
during ITG, versus one patient during placebo treatment. Although, the PGI and CGI 
were not significantly different from zero, the trend towards a deterioration of signs and 
symptoms with ITG suggests that glycine may play a pathophysiological rather than a 
therapeutic role in CRPS. This could be caused by the dual action of glycine, which 
serves both as an obligatory coactivator of the spinal excitatory NMDA receptor, and as 
a neurotransmitter at the inhibitory strychnine-sensitive glycine receptor.50,51 It is 
possible that the excitatory effects prevailed in the applied dose range. In CRPS, chronic 
pain, allodynia, and hyperalgesia, are assumed to result from central sensitization, a 
state reflecting enhanced synaptic transmission efficiency of neurons in the dorsal horn 
of the spinal cord.11 In central sensitisation, the NMDA receptor is upregulated, and 
open studies using NMDA antagonists memantine and ketamine have reported 
beneficial effects on pain in CRPS.52-54 Hence, ITGs efficacy could depend on the state of 
the NMDA receptor and stimulation of the excitatory glycine receptor of the 
upregulated NMDA receptor may potentially worsen symptoms such as pain, explaining 
the trend of poorer ratings of patients and physicians when patients were using ITG.55-57
Interestingly, intrathecal administration of 2-amino-5-phosphonopentanoate, an NMDA 
receptor antagonist, unmasked the analgesic action of glycine in rats.58 Hence, future 
studies could analyze whether or not NMDA inhibition, administered prior to or 
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simultaneously with ITG may enhance its therapeutic potential under circumstances of 
central sensitisation. Because intrathecal administration of NMDA inhibitors is 
neurotoxic,59 this hypothesis can only be tested with orally or intravenously 
administered agents.
We studied a population of severely affected CRPS patients with long disease duration. 
Consequently, this patient sample involved a selection of treatment refractory patients, 
who are not representative for all CRPS patients. However, it would be unethical to 
evaluate ITG in acute stage patients, in whom symptoms might resolve spontaneously or 
following less invasive treatment options. 
There is no data on the magnitude of the placebo responses in trials evaluating chronic 
treatment in CRPS patients with dystonia until now. In our previous study, placebo 
responses to two intrathecal saline injections were 4% and 8 %, respectively.21
Interestingly, there was no detectable placebo response in the current study during 4
weeks of intrathecal treatment. This finding might be useful for designing future trials 
on this subject.
In conclusion, ITG in doses up to 32 mg/24 h during 4 weeks was not associated with
serious adverse events, but further studies are required to rule out potential
neurotoxicity of ITG. Although results from animal studies were promising, this study did 
not find efficacy on pain or dystonia in patients with chronic CRPS. Several potential 
explanations for this finding could be addressed in future studies.
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ABSTRACT
Complex Regional Pain Syndrome (CRPS) is characterized by various combinations of
sensory, autonomic and motor disturbances. Pain disproportionate to the severity and 
duration of the inciting event is the most devastating symptom. Diagnosis of CRPS is 
difficult as the underlying mechanisms remain unclear. To try to derive metabolic 
indicators potentially characteristic for CRPS, we applied capillary electrophoresis time-
of-flight mass spectrometry (CE-ToF-MS) to the explorative analysis of urine. The CE-
ToF-MS method provided fast and stable metabolic profiles of urine samples. The mean 
intraday and interday CVs were <2% and <9% for migration times and peak areas, 
respectively, demonstrating robustness of the method. With the use of multivariate 
chemometric analysis, discrimination between urine samples from CRPS patients and 
controls was obtained, emphasizing differences in metabolic signatures between CRPS-
diseased patients and controls. Several compounds, such as 3-methylhistidine, were 
responsible for discriminating the samples. The biological relevance of these compounds 
with regard to CRPS is discussed. Thus, CE-ToF-MS-based metabolic profiling of urine 
from CRPS patients and controls revealed metabolites that differentiate between 
diseased and control, illustrating the usefulness of this approach to get more insight into 
the pathology underlying CRPS.
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INTRODUCTION
Complex Regional Pain Syndrome (CRPS) is a chronic pain condition characterized by a
combination of sensory, vasomotor, and trophic changes. About 25% of the patients 
with CRPS develop movement disorders, like tremor, myoclonia and dystonia.1,2 The 
syndrome is more common in women and usually is preceded by tissue injury like a 
fracture or surgery. Following tissue injury, the body may respond with a series of 
specific reactions aiming to repair the damage, promote wound healing and recruit host 
defence mechanisms. Indeed, there is some evidence to suggest that multiple biological 
mechanisms responsible for inflammation, vasomotor dysfunction and pain may 
become involved in CRPS.3-10 Collectively, these facts indicate that in the acute phase of 
CRPS the body response to trauma may turn aberrant. Still, in a substantial number of 
patients the disease course becomes chronic. In the majority of the patients, CRPS 
remains restricted to one extremity; however the syndrome may spread to other 
extremities without a new trauma.11-13 These more affected chronic phenotypes have a 
much younger age at onset, which might suggest a genetic predisposition.13
Mechanisms that play a role in this phase of the syndrome are largely unknown, and 
even if such mechanisms are suggested, they are seldom based on solid biochemical 
data. Consequently, explorative “omics” based approaches, such as metabolomics, 
could be a good starting point for further delineation of mechanisms underlying CRPS.
At first glance, metabolic profiling is quite similar to other “omics” approaches, but 
unlike genomics and proteomics which often only indicate a potential for physiological 
(pathophysiological) effects, metabolomics data provide insight into the end points of 
biochemical activities of the organism.14-16 The output of a metabolomic experiment 
could either be treated as “a metabolic signature” or “phenotype” and used for building 
up diagnostic routine, or extrapolated to other “omics” data in order to reveal systemic 
mechanisms of pathology. Metabolic profiling of body fluids has a broad analytical basis: 
nuclear magnetic resonance spectroscopy (NMR), gas chromatography-mass 
spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS) and capillary 
electrophoresis-mass spectrometry (CE-MS).17 This diversity of analytical methods, in a 
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way, reflects the diversity of chemico-physical properties of compounds composing the 
human metabolome. At the end, the final selection of a method depends entirely on the 
type of sample and the “target” group of metabolites. For example, to access the 
inflammatory axis of CRPS, one might consider urine as a sample of choice. The urinary 
metabolome consists mainly of polar and ionic compounds;18 and therefore, CE is a very 
attractive separation technique as it provides a high-resolution separation for highly 
polar and ionic compounds.19,20
Recently, we have demonstrated the analytical quality and feasibility of a CE-MS 
method for the profiling of amino acids and related compounds in urine from patients 
with urinary tract infection.21 In the present study, we show that this CE-MS method can 
be used for metabolic profiling of human urine and we have applied this method for the 
first time to the explorative analysis of urine samples to investigate changes in 
metabolite patterns between patients with CRPS and control subjects.
MATERIALS AND METHODS
Chemicals
PB (hexadimethrine bromide) and a 25% (m/v) aqueous solution of poly(vinyl sulfonate) 
(PVS) sodium salt were from Sigma-Aldrich (Steinheim, Germany). A 10% (m/v) PB 
solution was prepared by diluting PB with Milli-Q water. A 5% PVS solution was made by 
diluting the purchased PVS solution with Milli-Q water. The polymer solutions were 
passed through a 0.22 μm filter and stored at 4C. Formic acid was from Riedel de Haën 
(Seelze, Germany). Ammonium hydroxide 25% was from Merck (Darmstadt, Germany). 
All L-Amino acids with a concentration of 1 mM of each in 0.1 M hydrochloric acid were 
purchased from Sigma-Aldrich. HPLC-grade methanol was supplied by Biosolve BV 
(Valkenswaard, the Netherlands). Hippuric acid, 3-methylhistidine, xanthine, guanosine, 
L-carnitine, phenylalanine-glycine, N-methylnicotinamide were purchased from Sigma-
Aldrich. Standard solutions were prepared with water taken from a Milli-Q water 
purification system or with background electrolyte (BGE) (Millipore, Bedford, MA, USA). 
BGE solution was prepared by dissolving formic acid in Milli-Q water (1 M, pH 1.8).
95
Patients and urine samples: subjects and CRPS diagnosis
Thirty-four consecutive patients (table 6.1) from the department of Neurology of the 
Leiden University Medical Center fulfilled the CRPS criteria of the International 
Association for the Study of Pain (IASP). Thirty-one patients also had developed fixed 
dystonia of one or more extremities. Other causes of dystonia had been excluded using
appropriate blood and imaging studies (computed tomography or magnetic resonance 
imaging) of the brain. All patients were also evaluated concerning the interval that had
Table 6.1. Demographic, CRPS characteristics and treatment (n=36).
Demographic and injury CRPS characteristics Previous treatment Current treatment
Age, median (range)
   41 (17 – 60)a
Genderb
   Male                              6
   Female                        30
Affected limb
   Upper                          30
   Lower                          26
Type of injury
   Contusion                   15
   Fracture                        8
   Surgery                         7
   Other                            6
Symptoms duration,
   median (range):
   72 (1 – 340)c
Spontaneous pain        
Mechanical allodynia  
Color changes              
Edema                           
Hyperhidrosis              
Temperature changes
Motor changesd          





NRS pain, e    
   median (range)













































































a. Median (range) age of controls = 27 (21 – 41) years            f. Non-steroidal anti-inflammatory drugs
b. Gender of all controls was female             g. Physiotherapy (P.T) and Occupational 
c. Duration in months                 therapy (O.T)
d. Dystonia was present in 31 patients (86%)             h. Transcutaneous electrical nerve stimulation
e. Numeric rating scale for pain             i.  Spinal cord stimulation
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elapsed between onset of CRPS symptoms and time of sampling, medication used at the 
time of sampling, and previous therapy. The pain intensity was evaluated using a 
numeric rating scale. Patients with renal or bladder pathology were ruled out in order to 
limit confounding conditions. All patients were examined at our outpatient clinic for 
movement disorders. None of the patients had a family history of dystonia and other 
causes of dystonia, including birth injury, head trauma, neuroleptic treatments were not 
reported or identified in the medical history or correspondence. Laboratory tests, 
including serum copper and ceruloplasmin and computed tomography or magnetic 
resonance imaging of the brain were normal. Control subjects were recruited from 
volunteers working in our hospital and selected to match the overall age and sex 
distribution of the patients, and had no history of disease. Only females, who reported 
no significant medical history and used no medication, were included to optimize the 
homogeneity of the group. This comprised the number of control subjects, who were 
eligible for participating in the study.
Patients and urine samples: urine collection and analysis
All samples were collected early in the morning between 4.00 and 7.00 a.m. to minimize
potential confounding influences of circadian rhythms of constituents excreted in the 
urine. Patients used standard 50 mL non-sterile containers to store urine temporarily. 
The same day patients visited the hospital and within 10 h after micturition (act of 
urinating), samples were transferred to nonsterile polypropylene micro tubes of 0.5 mL 
and then stored at -80C. A total of 100 μL of each urine sample from controls and 
patients were pooled and used as quality control (QC) samples. Prior to CE-MS analysis, 
the urine samples were thawed to room temperature, mixed with BGE (1:1 v/v) and 
centrifuged (13200 rpm) for 5 min. The sample sequence started with five QC samples 
spiked with amino acids at different concentration levels for the measurement of a 
calibration plot, which was followed by a nonspiked urine sample. Next, urine samples 
from 18 control subjects and 36 patients were analyzed in an alternating way. This 
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sample sequence was randomized with QC samples to evaluate the performance of the 
CE-MS method during the analysis of the sequence.
Instrumentation and procedures
The CE experiments were carried out on a Beckman Coulter PA 800 instrument 
(Beckman Coulter, Fullerton, CA). Fused-silica capillaries were from Composite Metal 
Services (The Chase, Hallow, UK) with a total length of 130 cm and an internal diameter 
of 50 μm. Capillaries were noncovalently coated with a bilayer of Polybrene (PB) and
poly(vinyl sulfonate) (PVS). Formic acid (1 M, pH 1.8) was used as BGE. Sample injections 
were performed hydrodynamically for 90 s at 90 mbar (1.3 psi). Prior to sample 
injection, a small plug (50 mbar, 9 s) of 12.5% ammonium hydroxide was injected for 
pH-mediated stacking. Electrophoretic separation was performed at +30 kV and the 
capillary temperature was set at 25 °C. For more experimental details we refer to ref 21.
MS was performed using a micrOTOF orthogonal-accelerated time-of-flight (TOF) mass
spectrometer (Bruker Daltonics, Bremen, Germany). Spectra were collected with a time
resolution of 1 s. Postrun internal mass calibration was performed using sodium formate
cluster ions Na+(HCOONa)1-9 ranging from 90.9766 to 430.9137 m/z. CE-MS coupling 
was realized by a coaxial sheath liquid interface (Agilent Technologies, Waldbronn, 
Germany) with methanol-water-formic acid (50:50:0.1, v/v/v) as sheath liquid. The 
following spray conditions were used: ESI voltage was -4.5 kV; sheath liquid flow, 4 
μL/min; dry gas temperature, 180°C; nitrogen flow, 4 L/min; nebulizer pressure, 0.5 bar.
Micellar electrokinetic chromatography (MEKC) combined with UV detection was used 
for the determination of 3-methylhistidine in urine samples. The employed 
experimental procedure has been described in detail elsewhere.22
Analytical validation
The procedures for the determination of linearity of response for amino acids in BGE 
and in QC samples were described in a previous paper.21 The limit of detection (LOD) for 
amino acids in BGE and QC samples was calculated as the concentration yielding a S/N 
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of 3 via extrapolation of the S/N-ratio produced by the lowest concentration used for 
the construction of calibration plots of amino acids in BGE and QC samples, respectively.
Intra- and interday variation of migration time and peak area were determined for 12
endogenous urinary metabolites (L-arginine, L-valine, L-glutamic acid, L-phenylalanine, 
L-histidine, hippuric acid, N-methylnicotinamide, creatine, xanthine, L-carnitine,
guanosine and phenylalanine-glycine) with different physicochemical properties. The 
intraday variation for migration time and peak area was determined by analyzing ten 
replicates of a pooled urine QC sample. The interday variation was determined by 
analyzing a QC sample on 5 different days. Recovery was evaluated in a previous 
study.21
Data analysis
The raw data files were converted to netCDF format. For nonlinear alignment of the 
data and feature detection of the data, we used an open source XCMS software.23 CE-
MS data were processed using default settings (see documentation for XCMS, 
http://metlin.scripps.edu/download/) except for parameters: “steps” of xcmsSet 
method set to 3, and “bw” of group method set to 20. The normalization of the data 
was performed using nonparametric algorithm.24 The table of ion features and 
normalized intensities was imported into SIMCA-P+ (version 12.0; Umetrics) software 
for further multivariate analysis. Principal component analysis (PCA) and partial least-
squares - discriminant analysis (PLS-DA) were performed both on original data and on 
data after orthogonal signal correction (OSC). PLS-DA models were constructed after 
removal of extreme outliers and validated using permutation test with 100 
permutations. To identify metabolites of interest, rational chemical formulas were 
generated based on internally calibrated monoisotopic masses within 10 mDa mass 
error, using the SmartFormula tool within the DataAnalysis (DA) software package 
(Bruker Daltonics). The chemically-reasonable formulas were submitted to metabolome 
databases: Kyoto Encyclopedia of Genes and Genomes (KEGG) ligand database,25 the 
Human Metabolome Database (HMDB),26 and the METLIN database.27 The isotopic 
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distribution patterns of the matched metabolite candidates were simulated with the 
Simulate Pattern tool of DA and compared with observed mass spectra to reduce 
further the number of potential elemental compositions.28,29
RESULTS
Evaluation of CE-ToF-MS method for metabolic profiling
Recently, we have developed a CE-ToF-MS method for the analysis of amino acids in 
human urine using capillaries noncovalently coated with a bilayer of Polybrene (PB) and 
poly(vinyl sulfonate) (PVS).20,21 The PB-PVS coating proved to be very reproducible 
yielding stable CE-MS patterns of amino acids in human urine with favorable migration 
time repeatability (RSDs <2%). The CE-ToF-MS method showed linear responses 
between 0.5 and 250 M for most amino acids (R2 >0.99), indicating a good dynamic 
range. Here, we demonstrate that our method can be used for the profiling of ionogenic 
compounds with electrophoretic properties similar to amino acids (e.g. amines, small 
peptides and related metabolites). In CE, all cationic compounds migrate toward the 
cathode (in our set-up towards the MS). Therefore, in principle all cationic compounds 
can be analyzed using the PB-PVS CE-MS configuration. To analyze all cations 
simultaneously, a very low pH electrolyte, 1 M formic acid (pH 1.8), was used to confer a 
positive charge on all cationic metabolites, making them amenable to MS analysis. 
Figure 6.1 shows a typical total ion electropherogram of a urinary profile from a control 
subject obtained by CE-ToF-MS analysis. A metabolic profile of positively charged 
compounds in the m/z region from 50 to 450 was obtained in less than 18 min. 
Approximately 300 compounds were detected within a total separation time of 24 min.
(using an injection volume of ca. 100 nL). The legend below figure 6.1 shows the type of 
compounds detected in the given migration time intervals (indicated by a different 
colour). At the low pH conditions used for separation, all compounds with a basic 
functionality are positively charged, allowing their migration toward the MS detector. 
Compounds with a higher number of amine groups in their structure, such as lysine or 
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Figure 6.1. Total ion electropherogram of a urine sample from a control subject 
obtained by CE-ToF-MS analysis. The legend below the electropherogram shows the 
type of compounds migrating in the specified colored time regions.
arginine, migrated first (10-11 min). Next a group of metabolites comprising amino acids 
(e.g., valine, leucine, threonine, proline), vitamins (e.g. carnitine) and amines (e.g.,
creatine and N-methylnicotinamide) migrated together with small peptides like 
phenylalanine-glycine (12-14 min). Subsequently, the slower migrating amino acids 
comprising phenyl moieties (such as phenylalanine and tyrosine) migrated and then 
nucleosides like guanosine (14-17 min). Acidic metabolites, such as hippuric acid, are
slightly anionic at pH 1.8 and, therefore, migrate just after the EOF. Hence, the CE-ToF-
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MS method is capable of separating different classes of metabolites simultaneously in 
human urine, as required for metabolic profiling. 
The analytical quality of the data derived from the CE-ToF-MS analysis of QC samples 
was evaluated. The intra- and interday variation of migration time and peak area were 
determined for a number of endogenous urinary metabolites with different 
physicochemical properties (supplemental table 6.1) and are stated in table 6.2. The 
intraday and interday CVs were <2% and <9% for migration times and peak areas, 
respectively, demonstrating robustness of the method. Analytical recovery was 
determined in a previous study.21 In brief, five QC samples before and after addition of 
known metabolite concentrations (5, 25 and 100 M) were analyzed. Recoveries ranged 
from 75% to 99% and the CVs were 7%-11% for all metabolites. The LODs for amino 
acids in human urine varied from 85 to 280 nM (S/N = 3). 
We also evaluated the performance of the MS detector with respect to mass accuracy.
For this, the m/z value of histidine was determined in 10 urine samples of control
Table 6.2. Precision data (CV, %) for migration time and peak area of endogenous 
compounds in human urine analyzed by CE-ToF-MS.
Classification Compound name Intraday (n=10)
Migration time    Peak area
Interday (n=5)
Migration time Peak area

























Organic acid Hippuric acid 1.1 6.5 1.3 6.9
Amine Creatine 0.9 8.6 1.1 7.8
Pyridine base N-Methylnicotinamide 1.1 5.5 1.0 7.0
Purine Xanthine 1.2 7.0 1.2 7.6
Vitamin L-Carnitine 1.2 7.7 1.2 7.8
Nucleoside Guanosine 1.3 6.4 1.2 7.3
Small peptide Phe-Gly 1.4 7.6 1.5 7.5
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subjects. The observed mass deviation from the theoretical m/z value of histidine was 
less than 2 mDa (supplemental figure 6.1), indicating a stable performance of the ToF-
MS instrument.
Metabolic profiling and multivariate statistics
We have used the CE-ToF-MS method for the metabolic profiling of urine samples from 
36 patients with CRPS and from 18 control subjects (for the analytical workflow, see
supplemental figure 6.2). Data sets were subjected to a preprocessing routine –
migration time alignment and normalization – and then, to an explorative analysis using 
a set of chemometrical methods. The PCA scores plot revealed only weak tendency for 
grouping of control samples and patient samples. At the same time, there were no 
indications of grouping based on acquisition time, sampling time or gender of subjects 
(supplemental figure 6.3). To enhance class separating variance and at the same time to 
get an overview of metabolites contributing to it, we used a supervised data analysis 
method: PLS-DA. As data were acquired in two large acquisition blocks over 2 days, we 
split our data in two parts: data acquired on day one (18 patients and 9 controls) was 
used as a training set (to build a model) and data acquired on day two (18 patients and 9 
controls) was used as a prediction set (to test the model). The PLS–DA score plot 
demonstrates an obvious visual clustering based on a two-class model (figure 6.2). The 
quality of the PLS-DA model was verified by a correlation coefficient R2 (goodness to fit) 
and a cross-validated correlation coefficient Q2 (goodness of prediction), respectively. A 
good prediction model is achieved when Q2 > 0.5. The PLS-DA model showed a R2 of 
0.96 and a Q2 of 0.855 indicating a good fitting and prediction ability. Then, we used 
data acquired on the second day (second acquisition block) to test the predictive power 
of our two-class model. Figure 6.3 shows that a majority of the samples were predicted 
correctly. Thus, the CE-ToF-MS method is capable of dissecting the metabolic signatures 
discriminating cases and controls. The strongest identified loadings from our model are 
listed in table 6.3. The identification of compounds was based on accurate mass 
measurements,   analysis   of  isotopic  profile   and   migration  time information. The 
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Figure 6.2. Partial least squares-discriminant analysis (PLS-DA) model based on CE-ToF-
MS data of urine from control subjects and patients with CRPS. (A), PLS-DA model based 
on CE-ToF-MS data of urine samples measured on day 1; R2 of 0.96 and a Q2 of 0.55. (B), 
Validation of the model using 100 permutations.
         B)
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Figure 6.3. Predictive ability of PLS-DA model based on urine samples measured on day 
1. (A), PLS-DA scatter plot showing the prediction of urine samples from control subjects 
and patients with CRPS measured on day 2; (B), Column plot displaying the predicted 
response value for all responses from the last component.
                   
   A)   
  
                
    B)
Plot colored according to the model (brown) and 
prediction set (Controls, green; CRPS, red)
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molecular formula obtained was subsequently introduced in, for example, The Human 
Metabolome Database and METLIN database to obtain the identification of the 
metabolites.
Table 6.3. Summary of metabolites identified that showed most significant differences 
between the two sample sets.
Name Molecular 
formula
m/z observed    m/z calculated    Error (mDa)        Increased/
decreaseda
3-Methylhistidine              C7H11N3O2 170.09185 170.09240 0.6                           ↑
2-Aminobenzoic acid         C7H7NO2 138.05429 138.05495            0.7 ↑
3-Amino-octanoic acid      C8H17NO2            160.13341 160.13321           -0.2 ↑
Hippuric acid                      C9H9NO3 180.06658 180.06552           -1.1                                  ↓
Histidine C6H9N3O2 156.07529 156.07675             1.5                                  ↓
Proline betaine C7H13NO2 144.10248 144.10191           -0.6                                  ↓
Creatine C4H9N3O2 132.07590 132.07675            0.9 ↓
a. Concentration increased or decreased compared to controls
DISCUSSION
Hitherto, the diagnosis of CRPS is fully based on clinical symptoms and signs and 
potential mechanisms of disease have only partly been elucidated. This situation reflects 
most likely the complex origin of CRPS and the fact that, so far, hypothesis-driven 
strategies have provided a limited contribution to our understanding of the syndrome. 
Here, we present an attempt to use an alternative approach, namely, explorative 
analysis of the metabolome of urine, a body fluid which so far never has been analyzed 
systematically in CRPS. The urinary metabolome consists mainly of polar and ionic 
compounds and the choice of CE as a separation technique is, therefore, a logical one as 
in CE compounds are separated on the basis of their charge-to-size ratio. CE is especially 
suited for the high-resolution separation of highly polar and charged compounds. Other 
important advantages of CE are cost efficiency (fused-silica capillaries instead of 
expensive LC columns and low consumption of chemicals) and little or no need for 
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sample preparation. The only drawback of CE is its limited concentration sensitivity due 
to the nanoliter-scale sample volume loaded into the capillary. The sensitivity, however, 
can be improved by the use of in-capillary pre-concentration techniques, such as pH-
mediated stacking. The preconcentration technique used here is based on the injection 
of a short plug of alkaline solution prior to a long hydrodynamic injection of an acidified 
urine sample. With this approach, basic and zwitter-ionic compounds such as amino 
acids were preconcentrated within the capillary resulting in detection limits at the low 
nanomolar range. This approach also exemplifies the compatibility of pH-mediated 
stacking for the direct analysis of complex samples while minimizing off-line sample 
handling. 
Advantages of using a mass spectrometer as a detector, and especially the favorable 
characteristics of a ToF mass analyzer have been discussed in literature before.30
Moreover, we have recently shown the applicability of our CE-ToF-MS method for urine 
analysis. In our previous publication,21 we have put main emphasis on the analysis of 
amino acids. Here, we show that our method covers a range of classes of metabolites: 
amino acids, small peptides, nucleosides and even organic acids (figure 6.1, 
supplemental table 6.1). Some organic acids, such as hippuric acid, for example, can be
(partly) negatively charged at pH 1.8, and although behaving as an anion during the CE 
separation, they can be detected as protonated molecules in positive ion mode MS. To 
sum up, all small compounds carrying a positive charge at pH 1.8 can be analyzed within 
17.5 min (before electro-osmotic flow) with this method. Although the CE-ToF-MS 
method is able to simultaneously analyze charged, low–molecular weight compounds 
comprising various metabolite classes, it is not effective for the separation of neutral 
compounds and large biomolecules such as fatty acids, sugars and steroids and larger 
peptides. Therefore, the analysis of urine samples of CRPS patients and controls by 
UPLC-ToF-MS and GC-ToF-MS methods has the potential to greatly expand the coverage 
of the urinary metabolome, thereby increasing the chance of finding more metabolic 
indicators potentially related to CRPS.
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The CE-ToF-MS method has been used for metabolic profiling of urine, and so far, such 
an approach has not been carried out in CRPS. We have shown that metabolic profiles of 
urine of CRPS diseased-patients show a composition which is substantially different 
(table 6.3). Considering the relatively small group size and the potential heterogeneity 
among subjects, it is not surprising that differences between patients and controls are 
not reflected in the main axis of a variance represented by PCA plot. Hence, a 
supervised method of analysis is more obvious choice. Indeed, the PLS-DA model not 
only revealed class dependent variance, but predicted almost correctly an external hold-
out set. Another important output of PLS-DA is the possibility to estimate and rank the 
influence of individual features on our model with VIP (variable influence on the 
projection). In theory all features above threshold (α ≥ 1) are considered to be 
significant for the given model, but in practice, the threshold depends on the size of the 
data set. A limited number of samples may result in overfitting of the model, and 
therefore, only molecules with α ≥ 3 and standard deviation significantly lower than the 
ranking factor were selected for molecule assignment and identification. Structural 
assignment of molecules, based on mass position, isotopic pattern, migration time and 
extensive use of open source metabolome databases (METLIN, KEGG, HMDB), provided 
a realistic chemical identity of all candidates. However, if for compounds like histidine, 
hippuric acid and creatine this assignment hardly could be questioned, for n-amino-
octanoic acid and proline betaine it remains the best guess possible of the available 
data. Methylhistidine also belongs to a special case. Although the calculated elementary 
composition and migration time both point unequivocally to a methylated form of 
histidine, it is impossible to distinguish between 1- or 3-methylhisitidine. As correct 
assignment of methylhistidine isomer was essential for later data interpretation (see 
below), we used a MEKC method to confirm that the isomer was indeed 3-
methylhistidine (supplemental figure 6.4).
The power of metabolomics lies not in the ability to build allusive pathways starting 
from one or few detected metabolites, but in its multiplex characterization.27 This is 
underscored in this study – each single metabolite by itself failed to show a significant 
108
difference between both groups, whereas taken together, a distinct multivariate 
metabolic signature of CRPS emerged. Although our approach revealed a rather solid 
model, the interpretation of its biological significance remains a challenging task. The 
patient group, as presented in table 6.1, shows a great heterogeneity. Nevertheless, no 
abundant drug metabolites have appeared as a significant classifier in our models. All 
metabolites that contributed significantly to a class separation in our model belong to 
the category of so-called “usual suspects”, in other words reflect metabolites which are 
frequently reported as discriminators in clinical and toxicological studies.31 Thus, at the 
current stage, we have not made an attempt to allocate them into pathways and to 
build around those pathways a mechanistic hypothesis. For example, it is impossible to 
explain whether a positive correlation of aminobenzoic acid results from changes in the 
tryptophan metabolism or whether it reflects a change of gut microflora. The same is 
true for the interpretation of changes of hippuric acid and proline betaine 
concentration. However, our analysis did reveal a conspicuous increased urine clearance 
of 3-methylhistidine in CRPS patients. 3-Methylhistidine is formed as a result of post-
translational methylation of actin and myosin. This amino acid is not reused in protein 
synthesis; thus, its elevated clearance in urine is a rather specific indication of 
catabolism of muscle tissue, a finding which has been associated with conditions like 
chronic physical stress, starvation, injury of muscle tissue, primary muscle diseases and 
malignancy.32 Since many of the latter causes of muscle catabolism have been excluded, 
this finding may indicate that in chronic CRPS factors like physical stress and dietary 
intake need to be further explored. The shift in the muscle tissue homeostasis may also
be triggered by pro-inflammatory cytokines, which are assumed to play a role in the 
pathogenesis of CRPS.33 However, further research is necessary to clarify the 
contribution of muscle protein catabolism and influence of inflammatory processes.
Conclusion
In this work, it is shown that CE-ToF-MS is a very attractive method for metabolic 
profiling of human urine, especially applicable in the case of high risk explorative 
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studies, which have to be performed with minimal costs and consumption of patient 
material. With this method, we identified a urinary metabolomic signature of chronic 
CRPS patients. Although our findings have to be validated in a further study with larger 
numbers of patients and age- and sex-matched controls, the results of this study 
unexpectedly highlight a conspicuous increased muscle catabolism. Since this condition 
may further compromise the physical health state of patients, this explorative study 
identified a potentially important issue for future research in CRPS.
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SUPPLEMENTAL TABLE AND FIGURES
Supplemental table 6.1. Names and physico-chemical properties of the test mixture 
metabolites.
Classification Compound name MW1 pKa2  acid pKa2  base Log P3

























Organic acid Hippuric acid 179.05824 3.60 -   0.24
Amine Creatine 131.06947 2.67 11.02 -1.58
N-Methylnicotinamide 136.06366 3.50 - -0.21
Purine Xanthine 150.01778 0.80 7.44 -1.04
Vitamin L-Carnitine 161.10519 3.80 - -3.90
Nucleoside Guanosine 283.09167 1.60 9.21 -2.06
Small peptide Phe-Gly 222.1005 2.34 9.09   0.03
1. Monoisotopic mass
2. Data taken from CRC Handbook of Chemistry & Physics 89th Edition
3. Predicted by ALOGPS software
Supplemental figure 6.1. Instrument performance with respect to mass accuracy. The 
observed mass deviation from the theoretical m/z value of histidine less than 2 mDa 
over 10 consecutive runs of urine samples.
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Supplemental figure 6.2. Analytical work flow used for metabolic profiling of urine samples.
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Supplemental figure 6.3. PCA score plot colored according to observation ID; Unsupervised model shows no strong clustering of 
patients and controls for the first two principal components. Total variance covered by the PC1 and PC2 is about 10% and 9% 
respectively.
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Supplemental figure 6.4. MEKC-UV electropherograms of 3-methylhistidine (3-MT). 
Four overlaid electropherograms are shown: (1) 3-MT dissolved in water (standard), (2) 




1H-NMR Metabolic Profiling of Cerebrospinal Fluid in Patients
with Complex Regional Pain Syndrome
Anton A. van der Plas*,1
Axel Meissner*,2
Nick T. van Dasselaar3
André M. Deelder2
Jacobus J. van Hilten1
Oleg A. Mayboroda2
1. Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands
2. Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands
3. Department of Anesthesiology, Reinier de Graaf Gasthuis, Delft, The Netherlands





Background. In Complex Regional Pain Syndrome (CRPS) related dystonia, compelling 
evidence points at involvement of the central nervous system, but the underpinning 
pathobiology is still unclear. Thus, to enable a hypothesis free, unbiased view of the
problem and to get new insight into the pathobiology of dystonia in CRPS we have 
applied an exploratory metabolomics analysis of cerebrospinal fluid (CSF) of patients 
with CRPS related dystonia. 
Methods and Findings. 1H-NMR spectroscopy in combination with multivariate modeling 
were employed to investigate metabolic profiles of a total of 105 CSF samples collected 
from patients with CRPS related dystonia and controls.  We found a significantly 
different metabolic profile of CSF in CRPS patients as compared to controls. The 
differences are reflected already in the first two principle components of the PCA model 
which is an indication that the variance associated with CPRS is stronger than variance 
caused by such classical confounders as gender, age or individual differences. A 
supervised analysis generated a strong model pinpointing the most important 
metabolites that contributed to the metabolic signature of patients with CRPS related 
dystonia.  From the set of identified discriminators, the most relevant metabolites were 
2-keto-isovalerate, glucose, glutamine, lactate, which all showed increased 
concentrations and urea which showed a decreased concentration in CRPS subjects. 
Conclusion. Our findings point at a catabolic state in chronic CRPS patients with dystonia 
which likely is associated with inflammation.
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INTRODUCTION
Complex Regional Pain Syndrome (CRPS) is a multifactorial disorder which is associated 
with an aberrant host response to tissue injury of a limb and predominantly affects 
women.28 The clinical spectrum is heterogeneous and includes chronic pain, autonomic 
and trophic changes of the affected limb which reflect the perturbed regulation of 
biological pathways that underlie aberrant inflammation, vasomotor dysfunction, and 
maladaptive neuroplasticity.28 Approximately 25% of the patients with CRPS develop 
dystonia which is characterized by sustained contractions of distal flexor muscles 
resulting in an abnormal posture.46 Dystonia in CRPS may spread to other limbs and has 
a poor prognosis.17,50 Although compelling evidence suggests that abnormal motor 
function in CRPS is associated with changes within the central nervous system,27,31,49 the 
pathobiology underlying dystonia in CRPS is still unclear. Given its location in the body, 
cerebral spinal fluid (CSF) is by definition the body fluid that should best reflect the 
functional status of the central nervous system (CNS) and as such may provide an 
excellent medium for the search of the markers related to the pathobiology of dystonia 
in CRPS. Three previous hypothesis driven studies in CRPS patients with dystonia 
explored the role of CSF cytokines but found inconsistent results.3,4,34 Consequently, 
exploratory, hypothesis generating approaches, such as metabolomics, could be a good 
alternative for further delineation of biological pathways involved in dystonia in patients 
with CRPS. Metabolomics refers to a study of the metabolome: the “complete” set of 
the metabolites (the end products and intermediates of the metabolism) to be found 
within a biological sample.36,37,39 As the metabolome provides the most direct reflection 
of a physiological status of an organism, metabolomics is increasingly integrated in 
clinical studies as an essential functional readout. 1H-NMR spectroscopy is the
commonly accepted “golden standard” of the modern metabolomics.26 Being one of the 
most standardized screening technologies in modern biomedical sciences, 1H-NMR 
spectroscopy is the method of choice for screening of a large number of clinical samples.   
Additionally, the nondestructive processing of samples by 1H-NMR spectroscopy leaves 
the option open for consecutive sample analysis on an additional analytical platform. 
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In this study we used 1H-NMR spectroscopy on CSF in search for metabolites reflecting 
common pathobiology underlying dystonia in CRPS.
METHODS
Patients and controls
CSF samples were obtained from patients with a diagnosis of CRPS-1 and dystonia in at 
least one extremity who qualified for participation in one of three trials on intrathecal 
administration of baclofen, glycine or methylprednisolone.32,33,51 Patients were referred 
by physicians throughout the Netherlands. Inclusion criteria were: CRPS-1 according to 
the diagnostic criteria of the International Association for the Study of Pain (IASP)1 and 
symptoms of CRPS for at least 1 year. Other causes of dystonia were excluded using 
appropriate blood tests, nerve conduction studies and imaging (computed tomography, 
magnetic resonance imaging) of the spinal cord and brain. Exclusion criteria for 
participating in the above mentioned trials were: satisfactory relief of symptoms with 
conventional treatments including oral baclofen, pregnancy, breastfeeding, childbearing 
potential without using effective contraception, clinically significant psychiatric illness, 
suspicion of a poor compliance, or involvement in legal proceedings concerning 
compensation for CRPS.
Controls were selected from subjects who underwent a lumbar puncture for spinal 
anesthesia because of a surgical intervention, including urologic (e.g. transurethral 
resection of a urinary bladder tumour), orthopaedic (e.g. total knee prosthesis), vascular 
(femoropopliteal bypass), gynaecologic (vulvectomy) and general (e.g. lipoma excision) 
surgery. Otherwise, controls did not suffer from neuropathic pain or neurological 
diseases. Patient consent was obtained according to the Declaration of Helsinki and the 
study was approved by the Ethics Committee of the Leiden University Medical Center.
CSF acquisition and sample processing
CSF samples (5 mL) of 57 patients were collected prior to the administration of 
intrathecal trial medication. In 41 of these patients CSF was obtained from a lumbar 
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puncture with a 15-gauge Tuohy introducer needle preceding the positioning of a 
percutaneous catheter that was introduced into the subarachnoid space (L3-4) and 
advanced to the lower thoracic region to administer trial medication in case of 
participation in the baclofen or glycine trial. CSF was collected in 16 patients who 
participated in the methylprednisolone trial, by means of a lumbar puncture with a 20-
gauge spinal needle prior to the administration of trial medication.
In 61 controls CSF (5 mL) was obtained from a lumbar puncture with a 20-gauge spinal 
needle prior to spinal anesthesia for a surgical intervention. Neither patients nor 
controls had any ongoing or recent infection at the time of the sample collection.
After CSF was obtained, a small amount was used for leucocyte and erythrocyte count. 
Subsequently, CSF was centrifuged at 1790g for 5 minutes and supernatant was 
collected. Thereafter, supernatants were frozen and stored at -80° C. In all subjects, the 
complete procedure was performed within 2 hours and the concentration of 
erythrocytes in CSF was less than 1000 per l. All subjects gave written informed 
consent prior to inclusion, and the study was approved by the hospital ethics 
committee.
Preparation of CSF samples for 1H NMR spectroscopy 
After thawing, 500 l of individual CSF samples were mixed with 300 μL of 0.9 % saline 
solution each (vortex). Samples were then placed on cooled sample racks (6°C) after 
transfer into 96 deep-well plates. For sample preparation 60 l of 50 mM phosphate 
buffer (pH 7.0) in D2O containing 1.2 mM sodium 3-trimethylsilyltetradeuterio-
propionate (TSP) and 0.1% (w/v) NaN3 were mixed with 540 l of CSF/Saline in a 96 deep 
well plate using a Gilson 215 liquid handler controlled by a Bruker Sample Track LIMS 
system. 
NMR data acquisition and processing 
1H-NMR data was obtained using a Bruker 600 MHz AVANCE II spectrometer (Metabolic 
ProfilerTM) equipped with a 5mm TCI cryo probe and a z-gradient system; a Bruker 
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Efficient Sample Transfer (BEST) system was used in combination with a 120 uL cryofit 
flow insert for direct infusion of the samples into the probe head. One-dimensional (1D) 
1H-NMR spectra were recorded at 300K using the first increment of a NOESY pulse 
sequence23 with presaturation (γB1 = 50Hz) during a relaxation delay of 4 sec and a 
mixing time of 10 msec for efficient water suppression.44 Thirty-two scans of 65536 
points covering 12336 Hz were recorded and zero filled to 65536 complex points prior to 
Fourier transformation, an exponential window function was applied with a line-
broadening factor of 1.0 Hz. The spectra were manually phase and baseline corrected 
and automatically referenced to the internal standard (TSP = 0.0 ppm). Phase offset 
artifacts of the residual water resonance were manually corrected using a polynomial of 
degree 5 least square fit filtering of the free induction decay (FID).7 In order to monitor 
proper filling of the NMR flow cell and for quality control one-dimensional gradient 
profiles52 along the z-axis were recorded for each sample prior and post data 
acquisition. Duration of 90 degree pulses were automatically calibrated for each 
individual sample using a homonuclear-gated nutation experiment58 on the locked and 
shimmed samples after automatic tuning and matching of the probe head.
Multivariate data analysis of NMR spectroscopic data 
A bucket table with a bucket size of 0.02 ppm was generated for the regions 10.0 – 5.2 
and 4.4 – 0.2 ppm, respectively, using the AMIX (version 3.9.11, Bruker Biospin, 
Germany)9 software package. Bucket table and meta data were merged using Open 
Office Calc (version 3.3.0, http://www.openoffice.org). Variables were centered, and 
pareto scaled21 prior to statistical analysis using the SIMCA-P+ (version 12.0, Umetrics, 
Sweden) software package. For initial analysis and outlier detection, principal 
component analysis (PCA) was performed using 7 components. 
For partial least squares-discriminant analysis (PLS-DA)38 and orthogonal projection to 
latent structure discriminant analysis (OPLS-DA)6 data was normalized according to the 
sum of the total intensity of three spectral regions, namely 3.67-3.56, 1.85-1.50 and 
1.10-0.70 ppm, respectively, and samples were categorized based on clinical data. The 
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low-field regions of citrate (2.71 to 2.65 ppm buckets) were excluded due to the 
presence of positional noise artifacts. Statistical models from supervised multivariate 
data analysis were validated by random permutation of the response variable and 
comparison of the goodness of fit (R2Y and Q2Y)25,54 as well as by analysis of variance of 
the cross-validated residuals (CV-ANOVA).12 Relative changes in metabolites were 
identified based on coefficient plots and variable importance in the projection (VIP).57
Identity of individual metabolites was confirmed based on NMR reference data from 
BioRefBase (Bruker Biospin, Germany). Metabolite concentrations were determined by 
deconvolution of representative signals using an in-house automation script applying 
Topspin mdcon line fitting algorithm (Bruker Biospin, Germany). Metabolite 
concentrations were obtained after normalization of absolute concentrations as 
determined from quantification according to internal standard TSP. Absolute 
concentrations were not corrected for differential attenuation of the signals caused by 
relaxation during the mixing time and rapid-pulsing saturation effects. For normalization 
the same normalization factors as for the bucket table were used. Individual metabolites 
were analyzed by independent t test with the Mann-Whitney U-test (R version 2.10.1, 
http://www.r-project.org/). To test the predictivity of the obtained OPLS-DA model for 
classification of CSF profiles, a misclassification table was calculated using a two-class 
response variable by assigning each observation to the nearest class. In addition 
predicted values of the response variable Y from the built OPLS-DA model were used to 
calculate a receiver operating characteristic (ROC) curve (R version 2.10.1, 
http://www.r-project.org/). 
RESULTS
Data overview; unsupervised modeling
Clinical characteristics of the study cohort are summarized in table 7.1. 1H-NMR spectra 
of CSF samples collected from 49 CRPS patients and 56 controls were included in the 
analysis. Initial principal component analysis (PCA) was used for outlier detection and 
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identification of associations with clinical parameters. After outlier removal, apparent 
clustering according to CRPS classification can be observed in the scores plot of the first 
two principal components of a PCA model (7 components explaining 91.2% of the 
variability), indicating a strong influence of CRPS on CSF metabolite profiles 
(supplemental figure 7.1). No further associations with gender or additional clinical 
parameters can be observed in the initial PCA analysis. In addition, a separate control 
based PCA model based on 9 components (explaining 92.1% of the variability) did not 
reveal associations according to gender or age (data not shown). Even though the CRPS 
and control clusters appear to be well separated in the scores plot of the initial PCA
analysis, some of the samples were apparently allocated to the wrong cluster.
Supervised modeling, first round
To explore the discrimination of CRPS samples from control samples, supervised
methods using CRPS classification as response variable were applied. This approach may
Table 7.1. Demographics and clinical characteristics of patients and controls
CRPS (n = 49) Controls (n = 56)
Age – mean (SD), years 43.3 (12.0) 60.6 (17.2)
Sex – male / female, no. 6 / 43 25 / 31 
Disease duration – mean (SD), years 8.7 (5.7) -
Extremities affected by CRPS – no. (%)
     1
     2
     3






Extremities affected by dystonia – no. (%)
     1
     2
     3






Content of CSF, mean (SD)
   White blood cell count






facilitate the process of finding the largest discrimination between the groups of 
interest, in contrast to unsupervised methods like PCA that only allows identifying the 
main sources of variability within a given data set. We built an initial PLS-DA two-class 
model using the class identity as response variable (Y). Cumulative explained variance 
(R2Y) of 0.62 and cross validated predictive fraction (Q2Y) of 0.53 were calculated for 
the model and the model validation plot showed intercepts of the R2Y and Q2Y 
regression lines with the vertical axis at 0.147 and -0.183, respectively, indicating a valid 
model. In the scores plot of the first two components the samples of CRPS patients and 
controls are clearly separated. However, two of the control samples and 9 of the CRPS 
samples are still located to the wrong cluster (supplemental figure 7.2).  
Data normalization and second round of the supervised modeling
Detailed analysis of the loadings and coefficients for this model did not result in a 
specific metabolic pattern as discriminator, but indicated a general dilution effect for 
the CRPS type 1 cluster. We therefore decided to normalize all data prior to further 
analysis in order to compensate for this effect. Since major components like glucose can 
introduce a bias resulting in normalization artifacts when using total area 
normalization, we decided to exclude spectral regions of high abundant metabolites 
when computing the normalization coefficients of the individual spectra. From initial 
analysis we identified three spectral regions (3.67-3.56, 1.85-1.50 and 1.10-0.70 ppm) 
suitable to serve as reference region for normalization.8,10 To further refine the 
statistical model for investigation of CRPS-related effects, a second PLS-DA model was 
built after normalization and removal of the low field citrate regions. The positional 
noise of the low-field citrate resonances are correlated with the dilution effect most 
likely reflecting the citrate/Ca2+ complexation equilibrium. As expected, the quality 
parameters of the new model did decrease in comparison to the initial model. A 
cumulative R2Y of 0.47 and Q2Y of 0.42 were observed with intercepts of the R2Y and 
Q2Y regression lines with the vertical axis at 0.12 and -0.11, respectively, in the model
validation plot. Since the dilution artifact has been removed in this model the observed
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Figure 7.1. Scores plot of first and orthogonal components from OPLS-DA model built 
using 1H-NMR data of CSF from CRPS type 1 patients () and control subjects (), 
respectively, after outlier removal. PC[1] resolves the two classes explaining 57.4% of 
the covariance between the spectra with a cross validated predictive ability of 35.4%. 
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discrimination between CRPS samples and controls can now be attributed to
physiological differences. The observed clusters are not completely separated, but show 
a very clear trend between the two groups (supplemental figure 7.3).
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Identification and statistical validation of the metabolites
For further investigation of metabolic signatures of CRPS in CSF and identification of the 
metabolites contributing to this signature an OPLS-DA two class model was built using 
CRPS classification as response variable (Y). A cumulative R2Y of 0.90 with a cross 
validated predictive ability Q2Y of 0.84 was achieved using 3 orthogonal components. 
The reliability of the model was tested by analysis of variance testing of cross-validated 
predictive residuals (CV-ANOVA)12 showing a fraction of total corrected SS of 76.0 with a 
p value of 6.81E-30, indicating a valid model. Samples from CRPS patients and controls 
are very well separated in the scores plot of the first and orthogonal component as 
shown in figure 7.1. Based on coefficients and loadings from this model the responsible 
metabolites for discrimination between the two groups were identified. In figure 7.2 the 
covariance plot colored by Y-relevant coefficients of the corresponding OPLS-DA model 
is shown. The coefficients with positive sign indicate spectral regions that show 
increased signal intensity in CRPS samples whereas coefficients with negative values
represent regions with decreased signal intensity in CRPS or in other words indicate 
regions with increased signal intensity in controls. Identified metabolites from regions 
relevant for discrimination between the two classes were then quantified by spectral
Figure 7.2. Covariance plot colored by Y-relevant coefficients of OPLS-DA model built 
using 1H-NMR data of CSF from CRPS type 1 patients and control subjects. Spectral 
regions with positive intensity are increased in CRPS type 1 as compared to control.
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deconvolution and subjected to non-parametric significance tests by independent t test 
with the Mann-Whitney U-test as summarized in table 7.2. 
Identification of the most relevant metabolites
From the set of identified discriminators, the most relevant metabolites were glucose, 
glutamine, 2-ketoisovalerate, and lactate which all showed increased concentrations 
and urea with a decreased concentration in CRPS subjects. However, typical ratios 
involving some of these metabolites like creatine/creatinine2 and lactate/pyruvate did 
not show any significant correlation with CRPS. In figure 7.3 the bean plot for these 
metabolites is shown illustrating the concentration distribution for these metabolites in 
the respective groups. In addition we tested the predictivity of our OPLS-DA model for 
potential classification of unknown samples. Classification based on prediction of the 
response variable Y as summarized in table 7.3 showed a correct prediction of over 90%. 
The AUC of the corresponding ROC curve for the predicted class was 0.951 (figure 
7.4) indicating excellent separation between the two groups within the underlying 
model.      
DISCUSSION
The clinical presentation of patients with CRPS is variable, reflecting the existence of 
several subtypes.  One of such subtypes is characterized by predominant dystonia which 
tends to spread to other limbs, leaving patients severely disabled.50 Though findings 
from different sources indicate involvement of the central nervous system in CRPS 
related dystonia,27,31,49 the pathobiology underlying this condition remains unclear. 
Thus, to enable a hypothesis free, unbiased approach to further enhance our 
understanding of the pathobiology of dystonia in CRPS we have applied exploratory 
metabolomics of CSF in these patients. We found a significantly different metabolic 
profile of CSF in CRPS patients as compared to controls. The differences are reflected 
already in the first two principle components of the PCA model which is an indication
that the variance associated with CPRS is stronger than variance caused by such
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Table 7.2. Changes of metabolite concentrations in CSF of CRPS type 1 patients 
compared to control
Metabolite  [ppm]a VIPb CRPSc Controlc Fold 
changed
P valuee
acetate 1.93 0.03 14.40±11.51 12.86±7.48 1.120 0.139
acetone 2.23 1.12 18.48±15.02 14.75±7.28 1.252 0.084
alanine 1.47, 1.49 0.02, 0.05 40.37±12.06 37.17±12.49 1.086 0.017
2-OH butyrate 0.89, 0.91, 0.23, 0.24 19.31±9.01 16.64±7.47 1.160 0.270
3-OH butyrate 1.19, 1.21 0.59,0.53 9.09±17.75 7.45±8.50 1.221 0.443
choline 3.21 0.47 1.11±0.46 1.01±0.45 1.092 0.195
citrate 2.53, 2.55 1.09, 1.53 210.43±54.09 213.81±43.83 0.984 0.928
creatine 3.05, 3.95 0.54, 0.49 48.41±12.98 45.69±11.04 1.059 0.152
creatinine 3.05, 4.07 0.54, 0.58 75.80±14.67 68.01±13.96 1.115 0.029





3940.21±713.42 3390.03±661.74 1.162 3.0e-5
glutamine 2.13, 2.45 1.90, 1.38 593.15±99.22 504.00±87.18 1.177 7.7e-4
myo-inositol 3.63, 4.07 0.52, 0.58 163.23±28.10 148.04±29.50 1.103 0.040
3-OH isovalerate 1.27 0.78 3.45±1.42 3.61±1.00 0.956 0.488
2-ketoisovalerate 1.13 0.44 6.24±2.20 4.83±1.84 1.293 5.6e-4




1713.44±326.56 1521.37±258.10 1.126 4.7e-4
pyruvate 2.37 0.41 60.04±16.83 54.52± 15.43 1.101 0.022
tyrosine 7.21 0.27 6.21±2.92 5.15±2.09 1.204 0.043
urea 5.77, 5.79 4.05, 4.02 254.15±96.53 348.60±102.45 0.729 2.1e-4
valine 0.99, 1.05 0.75, 0.69 10.78±3.63 10.26±2.92 1.050 0.412
unknown 
7.25 (d) / 6.91 (d)
6.91, 7.25 0.98, 0.44 6.60±14.14 9.54±13.15 0.692 0.121
creatine/creatinine - - 0.64±0.20 0.67±0.20 0.961 0.907
lactate/pyruvate - - 27.55±7.35 27.43±5.16 1.004 0.843
a.  Mean value of corresponding bucket. 
b.  Importance of contribution values of buckets. 
c.  Median of concentrations in relative units ± SD. 
d.  Fold change was calculated by dividing the median concentration for each metabolite from CRPS
     patients by the median concentration of the same metabolite from control subjects. 
e.  P value was analyzed by independent t test with the Mann-Whitney U-test.
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Figure 7.3. Bean plot for most significant (p<0.05) metabolites in CSF responsible for 
discrimination between CRPS and control group. Black and grey areas represent 
concentration distributions for metabolites in CRPS and control subjects, respectively. 
Black bars indicate median concentration for the respective group and metabolite.
classical confounders as gender, age or individual differences. A supervised analysis 
generated a strong model pinpointing the metabolites, which contributed most 
significantly to the metabolic signature of patients with CRPS related dystonia. As figure
7.4 shows, the predictive power of the entire model is high, though individual
metabolites contributing to this specific metabolic signature provide no simple 
explanation of potential mechanisms underpinning CRPS related dystonia.  
The very first question is whether this metabolic signature is a reflection of dystonia or 
CRPS. An overview of the available literature on dystonia hardly provides a ground for 
an unequivocal answer. Firstly, a range of the clinical conditions associated with 
dystonia is very broad going from neurodegenerative conditions to the diseases with a 
strong hereditary component such as dopa-responsive dystonia;5 as a consequence 
there is little consistency in the observations. Secondly, unlike our exploratory approach, 
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Table 7.3. Misclassification table for class prediction from OPLS-DA model built using 
1H-NMR data of CSF from 48 CRPS type 1 patients and 54 control subjects.
Members Correct predicted CRPS I Control No class (YPred < 0)
CRPS I 48 91.67% 44 4 0
Control 54 90.74% 5 49 0
No class 0 0 0 0
Total 102 91.18% 49 53 0
Fishers prob. 1.7e-018
practically all previous attempts to address metabolic changes in dystonia used so-called 
targeted approach, where one or several metabolites were measured  and selection of 
the metabolites was usually driven by the concepts existing in the field.24,42 Thus, we 
probably have to accept that at the current state of knowledge it is practically 
impossible to “distil” the pure metabolic effect of dystonia from CRPS one and 
description given in the title – “CRPS related dystonia” – appears as most logical one.
Another key question is to which extent this characteristic profile reflects involvement 
of the CNS in CRPS. It is often taken for granted that concentrations of CSF metabolites 
are largely dependent on their rate of production in the brain. However, MRI studies of 
the patients with a chronic pain published so far show that such assumption could be 
debatable:  the metabolic changes reported in such studies (e.g. decreased levels of N-
acetylaspartate, changes of GABA or glutamate concentratiosns) are highly 
compartmentalized and rather speak against such a simple generalization.13,14,29   
Besides, considering the chemical diversity of the CSF metabolites and complexity of the 
human metabolic network no simple generalization is possible. For example, there is 
experimental evidence showing a strong correlation between the rate of production of 
organic acids in CNS and their concentrations in CSF,15 but for such important 
constituent of CSF as glucose this correlation remains uncertain. We have shown that 
elevated levels of glucose are an important element of the CRPS-specific metabolic 
signature. Likewise, elevated levels of CSF glucose have been reported for drug naïve
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Figure 7.4. ROC curve (AUC = 0.951) for predicted class from OPLS-DA model built using 
1H-NMR data of CSF from 48 CRPS type 1 patients and 54 control subjects.
schizophrenia patients, where authors link this effect to the brain-specific alteration of 
glucoregulatory mechanisms.16 Their interpretation is supported by the fact that there is
little doubt about the central origin of schizophrenia. Earlier studies on CRPS, however, 
identified both central and peripheral mechanisms which may contribute to the clinical 
presentation of CRPS.28 Hence, our finding of elevated glucose concentration in the 
CRPS group does not automatically imply an alteration of an underlying central process. 
The increased concentration of glutamine is another characteristic feature of the profile. 
In view of the importance of the glutamate-glutamine turnover for the entire CNS 
metabolism it seems only logical to interpret elevated levels of glutamine in CSF as a 
consequence of disregulation in the brain glutamate-glutamine balance. However, 
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multiple observations showing that CSF glutamine levels are elevated in hepatic 
encephalopathy rule out such a simple interpretation, indicating the existence of 
peripheral factors which may affect the concentration of glutamine in CSF.53
Table 7.2 includes one compound, namely urea, which most likely cannot be a product 
of the metabolic activity of human brain and there is little doubt about the direct 
correlation of its concentration in CSF and the concentration in the systemic circulation.  
Urea is a small, polar, nonelectrolyte molecule, the end product of the protein 
catabolism; thus from a biochemical point of view urea is not more than a waste 
product. The bulk of urea in the systemic circulation is produced in the liver as a result 
of the deamination of amino acids. It has been shown that urea is absorbed into CNS 
from the circulation19,22 which explains it presence in CSF.56 Thus, the lower 
concentrations of urea in CSF of patients with CRPS most likely reflect a more systemic 
effect, which is associated with chronic disease, stress and disuse.20,40,48  All of these 
conditions apply to the patients investigated in this study. Moreover, the changes in 
energy metabolism encountered in these conditions are also associated with increased 
muscle protein degradation.11 The muscle wasting that occurs in catabolic states results 
primarily from accelerated breakdown of the long-living myofibrillar proteins, such as 
actin and myosin.  Unlike other proteins, actin and myosin contain a unique amino acid 
3-methylhistidine which is released during the breakdown of muscles.47 Interestingly, 
we recently found elevated levels of 3-methylhistidine in urine of chronic CRPS 
patients.45 Our CSF findings therefore do not seem to provide evidence for the 
involvement of major primary metabolic derangements of the nervous system but 
instead corroborate with previous findings and underscore the important role of the 
catabolic state in chronic CRPS patients. In conditions associated with a catabolic state, 
including sepsis, trauma, burns, and major surgery, activation of ubiquitin-proteosome 
system has been demonstrated as the major pathway underlying muscle wasting.30,34,55
Moreover, the catabolic state in chronic patients with CRPS may lead to an impaired
immune function35 which not only increases the susceptibility to local infections and 
sepsis but also raises an important question whether a catabolic state may play a role in 
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the maintenance of inflammation, thus delaying the recovery of CRPS.41 Thus, in line 
with the care suggested for other inflammatory conditions,18 our findings indicate that 
appropriate nutrition assessment, intervention, and monitoring should be considered in 
patients with CRPS. Nutrition support alone however, is insufficient to prevent muscle 
loss during active inflammation and other interventions aiming to blunt the undesirable 
aspects of inflammation should be considered in the management of CRPS patients as 
well.18
Finally, our interpretation provides no final solution for the pathobiology of CRPS and 
some issues associated with this study limit the generalizability of our findings to other 
phases and subtypes of CRPS. The most important one is that this study included only 
patients with chronic CRPS and dystonia. However, since aberrant inflammation plays 
also a key role in acute CRPS, our findings suggest that future studies should evaluate 
whether early implementation of anti-inflammatory approaches and measures to 
maintain an optimal nutrition state may improve recovery of CRPS.
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Supplemental figure 7.1. Scores plot of first two principal components from PCA model 
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Supplemental figure 7.2. Scores plot of first two principal components from PLS-DA 
two-class model built after outlier removal. Data points are colored according to control 
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Supplemental figure 7.3. Comparison of PLS-DA models before (left) and after (right) 
exclusion of apparently misclassified samples. In the plot on the right, the excluded 
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ABSTRACT 
The treatment of dystonia related to complex regional pain syndrome (CRPS) remains 
unsatisfactory, raising the need of alternative targets for intervention. In dystonia 
pathological muscle changes may occur, which contribute to stiffness. Since magnesium 
sulphate (MG) may act as a muscle relaxant through its actions on the neuromuscular 
junction and muscle, we performed an explanatory study of the muscle relaxant effect 
and safety of intramuscular MG (IMMG) in CRPS patients with dystonia. In a double-
blind randomized placebo-controlled crossover study 30 patients were assigned to 3-
week treatments of IMMG and placebo. Treatments were separated by a one-week 
washout period. The daily dose of IMMG was 1000 mg in week 1, 1500 mg in week 2 
and 2000 mg in week 3. The primary outcome measure was the difference in change in 
Burke-Fahn-Marsden (BFM) scores after 3 weeks of treatment between both 
interventions. Secondary outcomes involved severity of dystonia, myoclonus, tremor, 
pain and functional activity. Data of 22 patients available for the explanatory analysis 
revealed no significant differences between IMMG and placebo treatment in any of the 
outcomes. In conclusion, we found no indication of efficacy of IMMG in a daily dose of 
2000 mg as a muscle relaxant in CRPS-related dystonia.
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INTRODUCTION 
Complex regional pain syndrome (CRPS) is characterized by various combinations of 
sensory, autonomic and motor disturbances, and its onset is usually triggered by a 
trauma to a limb.22 Dystonic postures are one of the most prevalent motor disturbances 
in CRPS occurring in 20% of the patients.10,13,38,49,51 Since these postures are frequently 
associated with severe disability,3,49 several therapeutic efforts have been undertaken to 
correct or improve these postural abnormalities.26,47,48,50 Systematic reviews on these 
efforts, however, have revealed a lack of evidence of symptomatic benefit of splints, 
oral muscle relaxants and botulinum toxin A in CRPS-related dystonia.32 Supported by 
findings from neurophysiological studies, which have highlighted the role of central 
disinhibition in this type of dystonia,37,39,46 several studies have examined the efficacy of 
intrathecal baclofen.47,48,50 Though this treatment may substantially decrease dystonia 
severity, the adverse event profile of this approach in CRPS is poor and in 30% of cases 
no benefit was established.50 Given the current status of treatment options for dystonia 
in CRPS, alternative targets for intervention are needed. 
Apart from central mechanisms involved in dystonia and spasticity, pathological changes 
may occur in muscle tissue and this may contribute to stiffness such that the range of 
motion around a joint is limited.41 Consequently, drugs that effectively reduce the 
influence of this factor may contribute to the treatment of dystonia in CRPS. 
The regulation of muscle contraction is highly dependent on calcium fluxes in muscle 
tissue and at the neuromuscular junction.29,45 In turn, these calcium fluxes are controlled 
by magnesium,9,18,25,30,52-54 which is demonstrated by the relaxant property of 
parenterally administered magnesium sulphate (MG) in both smooth and striated 
muscle.21,33,36,44 Oral administration of magnesium salts, which are currently used in 
clinical practice, are not suitable for achieving efficient muscle relaxation as the systemic 
bioavailability of these salts is generally poor.8,34 Although most studies used 
intravenous regimens to evaluate the effect of MG, intramuscular injections of MG 
(IMMG) proved equally effective in studies on (pre)eclampsia and severe head injury 
using similar dose regimens.1,14,54 Additionally, in our experience, IM injections may be 
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preferred because CRPS patients are more susceptible to phlebitis during intravenous 
drug infusion.
This explanatory study was carried out to evaluate if there is supporting evidence of the 
muscle relaxant effects of IMMG in patients with CRPS-related dystonia, which would 
justify exploration of alternative modes of administration.
MATERIALS AND METHODS
Patients
Subjects were male or female out-patients, aged 18 years or older and diagnosed with 
CRPS-related dystonia. Patients had to fulfill the diagnostic criteria for CRPS I established 
at the Orlando consensus conference in 1993, which were the criteria formally endorsed 
by the International Association for the Study of Pain at the time this study started 24 and 
suffer from tonic or intermittent dystonia resulting in slight disability or worse in one or 
more extremities for at least 1 year. Patients were excluded in case of satisfactory relief of 
symptoms with conventional treatments or intrathecal baclofen. Other exclusion criteria 
were a history of alcohol or drug abuse within the past year, a clinically significant 
psychiatric illness, pregnancy, breastfeeding, childbearing potential without using 
effective contraception, a history of poor compliance to medical regimens or study 
requirements or the suspicion of poor compliance, insufficient command and 
understanding of the Dutch language, involvement in legal proceedings (claiming 
compensation for CRPS I), impaired coagulation or renal function (i.e. serum creatinine 
below 10 or exceeding 80 µmol/l), hypermagnesaemia (i.e. total serum Mg exceeding 
1.10 mmol/l) or requirement of diuretics. The study lasted from October 2009 to May 
2012. Patient consent was obtained according to the Declaration of Helsinki and the 
study was approved by the Ethics Committee of the Leiden University Medical Center.
Study design
This was a randomized placebo-controlled crossover study conducted at the movement
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disorders out-patients clinic of the Leiden University Medical Center. Patients, treating 
physicians and assessors were blinded for the sequence of treatments.
An independent pharmacist randomized patients over the two sequences of IMMG and 
placebo in blocks of 4 using a computer generated randomization list. Each subject 
received two intramuscular treatments of 3 weeks each: magnesium sulphate 100 
mg/ml solution and sodium chloride 0.9% (placebo). Both treatments were separated by 
a 1 week wash-out period, which was considered sufficient based on the 
pharmacokinetic data on magnesium sulphate.20 Patients self-administered 
intramuscular solutions twice per day during each treatment period. Treatment started 
at a daily volume of 5 ml twice a day and was increased in week 2 and 3 to twice daily 
volumes of 7.5 ml and 10 ml, respectively. Syringes with 0.4 mm diameter needles were 
used for infusion. Solutions were injected in the buttocks and the lateral upper margins 
of both thighs in alternating sequence. Intramuscular injections of MG can be painful 
and potentially contribute to unblinding. To alleviate the pain of intramuscular 
injections and reduce the risk of unblinding, 2.5 gram of lidocaine-prilocaine 5% cream 
(EMLA) was applied 120 minutes before injection at the site of puncture. After 
application of the cream the area was covered with a transparent film (Tegaderm) 
prior to needle insertion to facilitate penetration through the various layers of the skin. 
This regimen has proved effective in decreasing both the superficial pain of needle 
puncture as well as the deeper pain of infiltration.5,15,17,42 Prior to the first injection, 
patients were instructed how to prepare and perform the injections properly. If needed -
because of the occurrence of (probable) severe or serious adverse events or the 
development of hypermagnesaemia (i.e. total serum Mg level exceeding 1.10 mmol/l)-
IMMG was reduced to the previous dose or stopped. In case of (probable) severe or 
serious adverse events, concentrations of free-Mg were measured. An independent data 
monitoring committee reviewed unblinded data for patient safety. An investigator, not 
involved in the clinical assessment of patients, was exclusively informed on the presence of 
adverse events, the decision taken by the data monitoring committee and the 
development of hypermagnesaemia. Assessments were performed by another 
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investigator, who was blinded to these data and the allocated sequence of treatment. 
The study was registered in the Netherlands National Trial Register, number NTR 1873.
Outcome measures
Patients were assessed one week before the first treatment was initiated and during 
both treatment regimens at days 1, 8, 15 and 22 prior to dose adjustment. Assessments 
were performed 2 hours after the first of the 2 daily injections of study medication. The 
efficacy assessments of movement disorders included the Burke-Fahn-Marsden (BFM) 
dystonia rating scale,6 the Barry-Albright dystonia (BAD) rating scale,2 the unified 
myoclonus rating scale (UMRS)12 and the tremor research group rating scale (TRGRS).16
The primary outcome measure was the difference in change of the BFM-score over 3 
weeks between IMMG and placebo. On the same days safety measurements were 
performed, including medical history taking, physical and neurological examination, a 
12-lead electrocardiogram and serum sampling of ionized calcium and magnesium, 
creatine kinase, blood urea nitrogen, creatinine and parameters of coagulation. Self-
assessment of pain and dystonia was performed every day at 6 PM, starting 1 week 
before the first injection until the end of the study. Patients were asked to assess the 
severity of global pain not related to dystonia as well as the severity of dystonia 
separately on two different 11-point numeric rating scales. They used the McGill pain 
questionnaire to measure different aspects of pain.23 In addition, patients rated the 
difficulty in performing activities every week, using the Radboud skills questionnaire27 (if 
arms were involved) or the walking ability questionnaire31 (if legs were involved). At the 
end of each treatment the investigator assessed the change of dystonia from baseline on a 
clinical global impression (CGI) scale ranging from -3 (much worse) to +3 (much better). At
the end of the study patients were asked to compare both treatment periods and 
express their preference using a patient preference questionnaire (PPQ), which consists 
of a 10 cm horizontal line ranging form -5 to +5. A score of 0 reflects no preference, 
whereas -5 or +5 expresses maximal preference for treatment period 1 and 2 
respectively. Secondary outcome measures were the difference in change after 3 weeks 
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between interventions on measures other than the BFM scale. After the study, patients 
and investigator guessed which period IMMG was administered to assess the adequacy 
of the blinding procedures.
Statistical analysis
Normality of the data was checked with the Shapiro-Wilk test and non-normally 
distributed data were transformed according to the shape of the distribution, and again 
tested for normality. Paired-samples t-tests were used to examine differences in change 
between both treatments for the normally distributed transformed and non-
transformed data. For the remaining non-transformed data, Wilcoxon signed-rank tests 
were used to investigate the difference in effectiveness between IMMG and placebo 
treatment. Chi square tests were used to examine differences between the number of 
patients who improved and did not improve on the CGI scale, and between the number 
of patients who preferred and did not prefer IMMG treatment. The Chi square test was 
also used to examine the difference in the number of adverse events between IMMG 
and placebo treatment. For the NRS and McGill Pain Questionnaire the scores of 7 
consecutive days prior to the start of a treatment or dose adjustment were averaged. To 
evaluate the efficacy of IMMG treatment only data of patients who received 3 weeks of 
IMMG and 3 weeks of placebo treatment were analyzed. For the evaluation of safety of 
IMMG all patients who were enrolled in the study were included.
Significance was assumed at the 0.05 level. To find a statistically significant difference of 
>25% in the reduction of BFM-scores between both treatments, 34 patients were required, 
assuming an alpha of 0.05, beta of 0.2, standard deviation of 12.5, and a correlation 
between measures of 0.6. To compensate for a potential drop-out (estimated as 15%), we 
aimed to recruit 40 patients. For all statistical tests, the SPSS© software package (version 
17.0; SPSS Inc., Chicago, IL) was used. 
RESULTS
Between October 2009 and April 2012, a convenience sample of 33 patients with CRPS-
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related dystonia were evaluated for eligibility, of which 30 patients (28 women) 
participated in the study (figure 8.1). It was decided to stop the study prematurely, 
because of difficulty with recruitment and the high dropout rate (27%). Table 8.1 
illustrates the demographic and baseline characteristics of all 30 participants. Sixteen 
patients were randomized to receive IMMG in the first period, while 14 started with 
placebo. Five patients dropped out during the first treatment period due to adverse 
events, of which 3 had received IMMG. One patient who was randomized to receive
Figure 8.1. Trial profile
33 participants assessed for
eligibility
3 excluded because of severe
    comorbidity
30 met criteria of eligibility and 
were randomly assigned
16 allocated to and given
      magnesium sulphate
      3 discontinued after first week
          2 injection pain
          1 broadend QRS complex
      13 analyzed
14 allocated to and given placebo
      1 discontinued after first
          week due to headache
      1 discontinued after second 
          week due to severe
          dystonia
      12 analyzed
12 allocated to magnesium
      sulphate 
      1 discontinued after first 
          treatment period due to
          injection pain
      11 given magnesium sulphate 
            1 discontinued after first
                week due to injection
                pain
      10 analyzed
13 allocated to and given placebo 
      1 discontinued after second
          week due to exacerbation
          of CRPS  
      12 analyzed
First treatment period of 
3 weeks




placebo in the second period discontinued before this treatment was started. Two other 
patients, one in each tier, did not complete the second treatment period as a result of 
injection pain or exacerbation of CRPS. 
Given the proof-of-concept nature of this study aiming to evaluate the muscle relaxant 
effect of MG on dystonia in CRPS, the efficacy of IMMG was analyzed only for the 22 
patients who completed the study. There was no significant effect of sequence (IMMG-
placebo or placebo-IMMG) on the BFM measure baseline scores. Mann-Whitney U tests 
showed no significant differences in age, sex, inciting event, disease duration, dystonia
Table 8.1. Baseline characteristics of participants
Characteristics Patients completing
the study (n = 22)
Dropouts (n = 8)
Median (IQR) age (years) 40 (29 - 52) 42 (35 - 45)
Sex
      Male
      Female
   1
21
   1
   7
Inciting event (%)
        Fracture
        Surgery
        Soft tissue injury
        Spontaneous
   4 (18)
   3 (14)
10 (46)
   5 (23)
   1 (13)
   2 (25)
   5 (63)
   0 (0)
Median (IQR) duration of CRPS (years) 11.5 (6.0 - 16.0) 5.0 (2.5 - 8.5)
Median (IQR) dystonia severity
        Burke-Fahn-Marsden rating scale
        Barry-Albright dystonia rating scale
        Numeric rating scale
24 (15 - 35)
  8 (4 - 11)
  7 (6 - 8)
18 (12 - 34)
  6 (4 - 12)
  7 (6 - 8)
Number of affected extremities (%)
        1
        2
        3
        4
   4 (18)
   7 (32)
   5 (23)
   6 (27)
   2 (25)
   2 (25)
   2 (25)
   2 (25)
Number of dystonic extremities (%)
        1
        2
        3
        4
   7 (32)
   8 (36)
   5 (23)
   2 (9)
   3 (38)
   2 (25)
   1 (13)
   2 (25)
Median (IQR) heart rate (bpm) 72 (62 - 90) 68 (60 - 75)
CRPS = complex regional pain syndrome; IQR = interquartile range; bpm = beats per minute.
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severity, heart rate and number of affected and dystonic extremities between patients 
who completed the study and dropouts (table 8.1).
Efficacy
There was no significant difference between the change in dystonia severity over three 
weeks of treatment with IMMG and placebo (table 8.2). Concerning the secondary 
outcomes, only the NRS for pain and the functional section of the UMRS (table 8.2) 
showed a significant improvement after 3 weeks of IMMG treatment in comparison with 
placebo (p < 0.05). Reflect and logarithm transformation was applied to data of the 
number of word count in the McGill pain questionnaire and the ‘rising’ section of the 
walking ability questionnaire. Logarithmic transformed data were used for the 
functional and action section of the UMRS and items 9-12 of the TRGRS. The proportion 
of patients improving on the CGI scale was significantly larger during IMMG treatment 
(11/22 = 50%) compared to placebo treatment (3/22 = 14%; 2 = 5.13, df = 1, p = 0.02). 
Thirteen patients preferred IMMG with a median PPQ score of 4.0 (IQR 2.3 – 4.6), 6 
patients preferred placebo with a median PPQ score of 4.7 (IQR 2.9 – 5.0) and 3 patients 
had no preference (McNemar test: 2 (1) = 1.895; P=0.169). The preference for IMMG or 
placebo treatment, though not significant, was based on the improvement of dystonia in 
all cases. The guess of the investigator and patient of which treatment was administered 
in which period was correct in 50% and 63%, respectively. Post-hoc analysis revealed no 
distinctive features in patients who improved >25% in BFM-scores during IMMG 
treatment compared to patients who failed to reach this level of improvement. 
Safety
The mean (range) total magnesium concentration in blood remained within the normal 
range during both the IMMG (0.90 [0.67 – 1.10] mmol/L) and placebo (0.84 [0.66 – 1.05] 
mmol/L) treatment. Blood levels of total magnesium increased significantly during 
IMMG treatment (mean [SD] change of 0.11 [0.07]) compared with placebo treatment 
(mean [SD] change of 0.00 [0.06]; p<0.0001).
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Table 8.2. Summary of clinical outcome events 
Outcome event Range 
scalea
n Intramuscular magnesium sulphate
Baseline                 After 3 weeks
Placebo
Baseline                 After 3 weeks 
P valueb
Dystonia rating scales 
   Burke-Fahn-Marsden dystonia rating
   Barry-Albright dystonia rating
   Numeric rating







  7.9 (4.6)
  7.1 (1.7)
21.8 (15.4)
  6.8 (4.6)
  6.2 (2.1)
23.9 (14.1)
  7.6 (4.2)
  7.1 (1.3)
24.0 (15.9)
  7.6 (5.0)




Pain rating scales 
   Numeric rating
   McGill number of words chosen
   McGill pain rating index






  7.3 (1.6)
13.4 (3.5)
27.4 (10.4)
  6.7 (2.1)
12.0 (3.3)
23.3 (11.5)
      
  7.2 (1.5)
13.2 (3.1)
26.5 (9.1)
      






Unified myoclonus rating scale 
    Myoclonus at rest
    Myoclonus with action
    Functional effect of myoclonus






  0.5 (1.5)
  2.1 (3.7)
  6.5 (5.7)
  0.2 (0.9)
  1.7 (3.3)
  5.6 (5.9)
      
  0.2 (0.9)
  3.5 (4.2)
  6.5 (5.7)
      
  0.3 (0.9)
  2.8 (4.5)




Tremor research group rating scale 
    Item 1 - 8





      
  2.1 (2.3)
  1.9 (2.5)
  1.7 (2.0)
  1.1 (1.9)
  2.3 (2.7)
  2.3 (3.0)
  2.3 (3.0)




    Radboud skills questionnaire (total)
    Walking ability questionnaire - indoor
    Walking ability questionnaire - outdoor
    Walking ability questionnaire - rising








  3.6 (0.9)
  4.7 (3.0)
  5.7 (2.6)
  7.2 (3.1)
  3.5 (1.1)
  3.9 (3.2)
  4.8 (2.8)
  6.8 (3.2)
  3.6 (0.9)
  5.1 (2.4)
  6.1 (2.2)
  7.0 (2.8)
      
  3.6 (1.0)
  4.6 (2.9)
  6.2 (2.2)
7.3 (3.0)





a. Best score is underlined    e. Paired samples t-test of transformed data with reflect and logarithm transformation                    
b. Change over 3-weeks IMMG treatment versus                                for McGill number of words chosen and walking ability questionnaire on rising and
      change over 3-weeks placebo treatment                                          logarithm transformation for section action and functional of the unified myoclonus
c.   Paired samples t-test of non-transformed data                               rating scale and item 9-12 of the tremor research group rating scale; scores represent
d.  Wilcoxon signed rank test of non-transformed data                       non-transformed data   
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Electrocardiographic monitoring did not reveal any serious arrhythmias, except for one 
patient who manifested with a broadened QRS complex pattern after the first week of 
the first treatment period (IMMG) and discontinued after this finding (figure 8.1). A 
causative relation between this arrhythmia and IMMG treatment was deemed unlikely 
as the blood concentration of total and ionized magnesium was normal.
The changes in heart rate during a treatment period were not significantly different 
between IMMG (mean change [SD] of 2 [9]) and placebo (mean change [SD] of 0 [13]; p 
= 0.57).
Thirty-eight adverse events (two severe, six moderate and thirty mild) were reported 
during IMMG treatment (table 8.3). Twenty-two adverse events (one severe, four 
moderate and seventeen mild) occurred during placebo treatment, including one 
serious adverse event of severe headache suggestive of subarachnoid hemorrhage. 
After in-patient hospitalization subarachnoid hemorrhage was ruled out, as were other 
serious causes of headache. There were significantly more patients, who reported 
adverse events during treatment with IMMG compared to placebo (2 = 9.08, df = 1, p = 
0.003). Injection pain was the most frequently reported adverse event during both 
treatments, but was reported significantly more often during administration of IMMG 
compared with placebo (n = 19 versus n=9; 2 = 5.42, df = 1, p = 0.02).
DISCUSSION
The treatment of CRPS-related dystonia remains unsatisfactory, raising the need of 
alternative targets for intervention.26,32,47,50 In dystonia and spasticity, pathological 
muscle changes may occur, which contribute to stiffness. Since MG may act as a muscle 
relaxant through its actions on the neuromuscular junction and involvement in 
terminating muscular contraction,21,33,36,44 we performed an explanatory study of the 
muscle relaxant effect and safety of IMMG in CRPS patients with dystonia.
Over the dose-escalation period of 3 weeks with doses up to 1000 mg b.i.d. we did not 
find evidence of efficacy of IMMG on dystonia in CRPS in 22 patients, who completed 
both treatment periods. There are several factors, which may explain this lack of 
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Table 8.3. Treatment-emergent adverse events
Adverse Event IMMG (n = 27) Placebo (n = 15)
Injection pain 19    9
Subcutaneous hematoma   7    -
Mild allergy   3    2
Itchy sensation at the site of injection   1   -
Edema   1    -
Flushing   1    1
Headache   1    3
Nausea   1    2
Impaired cardiac conduction   1    -
Sleepiness   1    -
Return of injection fluid   1    -
Hyperhidrosis   1    -
Exacerbation CRPS   -    1
Gingivitis   -    1
Hyperexcitation   -    1
Lightheadedness   -    1
Painful breasts   -    1
Total 38 22
CRPS = complex regional pain syndrome type I; IMMG = intramuscular magnesium sulphate
efficacy. First, in spite of efforts to enhance patient enrolment, we failed to meet the
recruitment target after 2.5 years of patient inclusion. One explanation for this 
recruitment failure may be that only patients were used, who were refractory to 
conventional treatments or intrathecal baclofen. This selection bias hampers 
generalization of our results. However, since we took a worsening of CRPS symptoms as 
a result of repetitive IMMG injections into account, we considered it appropriate to 
restrict our selection to patients who had experienced no benefit of conventional 
treatments or intrathecal baclofen. Also, a relatively large number of patients dropped 
out because of adverse events.
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However, given the associated patient burden of daily intramuscular injections, the aim 
of this explanatory study was not to find support for long-term administration of IMMG 
in relieving dystonia severity, but to yield evidence of the efficacy of MG through a 
method of administration that ensures systemic delivery. If efficacy of MG would have 
been demonstrated, this would set a basis for the development of alternative modes of 
administration with larger patient acceptability. Second, the lack of efficacy of IMMG 
may be related to the maximum daily dose of 2000 mg. Intravenous MG proved to be 
effective in reducing smooth muscle spasm21,28,40,43 with daily doses as low as 1.2 
gram28,40 but to our knowledge, there are no studies, which evaluated the efficacy of 
IMMG on striated muscle with a similar dose regimen. In a previous study the efficacy of 
MG in relaxing striatal muscle contraction was established in patients with severe 
tetanus, which may suggest an underlying mechanism different from CRPS-related 
dystonia.44 However, in this study intravenous drug delivery was used, which together 
with continuous monitoring in a clinical setting allowed the administration of much 
higher daily doses of MG. In one of the aforementioned studies, the serum 
concentration of total magnesium was monitored during the first 24 hours after MG 
injection with concentrations exceeding 1.5 mmol/L in the first 20 minutes after 
injection.28 Considering the pharmacokinetic properties of IMMG, which include optimal 
bioavailability 1 to 3 hours after injection, all assessments and blood sampling were 
performed 2 hours after the first of the 2 daily injections of study medication. At this 
time of assessment, we expected the concentration of serum magnesium at its peak and 
consequently maximum efficacy of IMMG. Using this approach, we found a relatively 
small increase of Mg blood levels in our patients. Administration of larger volumes of 
IMMG solution would be needed to further raise the serum concentration of 
magnesium but this would have increased the amount of pain associated with the 
injections, which in turn would decrease patient acceptability and retention of patients 
in the study. Also, the short half-life time of parenterally administered MG necessitated 
repeated administration of IMMG.20 Continuous intravenous administration of MG 
would circumvent this problem. However, we preferred intramuscular administration, 
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as CRPS patients in our experience seem to be more susceptible to phlebitis during 
intravenous drug infusion at the site of injection. During IMMG treatment a statistically 
significant improvement was found in pain severity as measured by an 11-point NRS. 
Magnesium treatment proved to be beneficial in other neuropathic pain conditions,4,35
probably by blocking NMDA-receptors in the dorsal horn.19 However, we consider the 
magnitude of change (here: 0.6) in NRS scores for pain in our study of insufficient clinical 
relevance, since it is much smaller than the 1.5 change in NRS (or 20% reduction) that is 
generally regarded as a minimal clinically important change in pain.11 In a previous pilot 
study intravenous magnesium significantly reduced CRPS-related pain.7 The authors 
suggested that intravenous magnesium as a treatment in CRPS 1 should be further 
explored in a larger well-designed trial. The improvement of pain severity found in our 
patients supports this proposal.
In conclusion, this explanatory study revealed no evidence of a muscle relaxant effect of 
MG in CRPS-related dystonia. Although several limitations may impede the 
interpretation of our data, we feel there is insufficient support for new studies, 
evaluating the efficacy of other routes of MG administration in CRPS-related dystonia. 
Additional studies are needed to provide better insight into the structural and functional 
changes in muscle tissue that are associated with dystonia in CRPS which may contribute 
to the development of new management strategies of this disabling feature. 
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This thesis describes the results of studies on patients with CRPS which were conducted 
within the program of the national consortium “Trauma RElated Neuronal Dysfunction 
(TREND). The studies include trials on the intrathecal delivery of baclofen (Part I) and 
glycine (Part II), exploratory evaluations using mass spectrometry on urine and CSF (Part 
III) and an explanatory study, evaluating the muscle relaxant effect of magnesium 
sulphate in patients with CRPS-related dystonia (Part IV). 
Chapter 1
Chapter 1 provides an overview of the broad clinical spectrum of CRPS. An update is 
given on the presumed molecular and neurophysiological basis of CRPS, including 
aberrant inflammation, vasomotor dysfunction and maladaptive neuroplasticity. Next, 
the history of the term CRPS-related dystonia is reviewed in short and controversial 
hypotheses about the underlying mechanism are addressed.
  
Chapter 2
The first part of this thesis is a sequel to a study which evaluated the efficacy of ITB on 
CRPS-related dystonia.1 This study comprised a screening phase with a placebo-
controlled dose-escalation study, followed by a one-year open label study. During the 
open label phase patients with CRPS-related dystonia received ITB in an ascending dose 
through an implanted pump. The severity of dystonia and global pain was assessed at 
baseline and every 3 months for the following year. ITB significantly improved both 
dystonia and global pain severity during the course of the year, especially in the first 6 
months. Interestingly, this improvement of pain was only partly explained by a decrease 
of dystonia, suggesting a direct antinociceptive effect of baclofen. 
The aim of the study described in chapter 2 was therefore to analyze the differential 
effects of central gamma-aminobutyric acid B (GABA(B)) receptor stimulation on the ten 
pain qualities of the neuropathic pain scale (NPS). Forty-two CRPS patients with 
dystonia, receiving titrated doses of ITB treatment in an open design, were evaluated 
every three months over a period of one year. The efficacy of long-term ITB was 
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assessed on the ten different pain qualities of the NPS, global dystonia severity and 
changes in use of antinociceptive drugs. Using a linear mixed model analysis and 
controlling for global dystonia severity and the use of supplemental analgesics, we 
found a significant improvement in global intense pain, sharp pain, dull pain and deep 
pain over the first 6 months. After this period the scores levelled off despite further 
improvement of dystonia and continued ITB dose escalation. We conclude that GABA(B) 
receptor stimulation by ITB exerts differential antinociceptive effects on specific pain 
qualities in CRPS patients with dystonia.
Chapter 3
In a single-blind placebo-run-in dose-escalation study van Rijn et al used an external 
device for ITB delivery to select patients with CRPS-related dystonia for the implantation 
of a pump to deliver long-term continuous ITB.1 During this screening phase patients 
had to improve at least 25% in global dystonia severity on a 10-point numeric rating 
scale on 2 consecutive days of ITB compared to placebo, in order to proceed to the 
pump implantation phase. Interestingly, 30% of the patients who received a pump never 
reached this improvement after one year of continuous ITB delivery. We noted that this 
decline in responsiveness to ITB was associated with a reduction of the infusion rate (IR)
after the switch of drug delivery from the external to the implanted device. Chapter 3 
describes a double-blind crossover study in which we investigated the effect of varying 
the IR at a fixed daily dose on the efficacy and safety of ITB in patients with CRPS-related 
dystonia. Patients were eligible if they experienced no beneficial response to ITB on 
dystonia despite a minimum dose of 600 μg/day or because side effects limited dose-
escalation. Patients were randomized to either slow (SIRD) or four-times faster infusion 
rate delivery (FIRD) for two weeks and were crossed over after a one week washout 
period. Outcome measures included changes in global dystonia and pain severity. We 
found no significant differences between the FIRD and the SIRD-group for any of the 
outcome measures, except for the frequency of adverse events which was significantly 
higher during FIRD. These adverse events mainly included supraspinal symptoms. FIRD 
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was preferred only by those patients who were included because side effects to ITB 
prevented dose escalation. Since increasing the IR at a fixed daily dose was not 
associated with improvement of dystonia or pain in the whole group of patients, we feel 
that further investigation is warranted in patients in whom side-effects prevent further 
dose-escalation. 
Chapter 4
Chapter 4 describes the development of chorea after long-term administration of 
baclofen in 4 patients with CRPS-related dystonia. Worldwide, baclofen has been used 
for more than a century, initially in the treatment of epilepsy and since the 1960’s as a 
first-choice drug in the treatment of spasticity.2 To our knowledge baclofen-induced 
chorea (BIC) has only been described in 3 patients worldwide, which is a minimal 
fraction of all the subjects who used and still use baclofen.3-5 Remarkably, within a few 
years time we identified BIC in 4 CRPS patients, which is a relatively large number of 
people in a group of patients suffering from the same disease. Treatment with tiapride 
resolved BIC in these patients, suggesting that striatal dopaminergic hyperactivity 
underlies baclofen-induced chorea. Interestingly, BIC coincided to a large extent with 
body regions that were initially affected by dystonia, which supports, at least in part, the 
theory of central disinhibition underlying CRPS-related dystonia. 
Chapter 5
Glycinergic neurotransmission plays an important inhibitory role in the processing of 
sensory and motor information. The aims of the study, described in chapter 5, were to 
evaluate the efficacy and safety of intrathecal glycine (ITG) administration in patients 
with CRPS-related movement disorders and pain. Nineteen patients were found eligible 
and randomized in a double-blind placebo-controlled crossover study. Patients were 
assigned to 4-week treatments of ITG and placebo. Treatments were separated by a 
one-week washout period. Safety was assessed by clinical evaluation, blood 
examinations and electrocardiograms. Efficacy measures involved pain, movement 
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disorders, activity and a global impression of perceived effect as evaluated by patient 
and clinician. 
We found no significant differences between ITG and placebo treatment in any of the 
outcomes. We conclude that ITG is an ineffective treatment for pain or dystonia in CRPS, 
although the sample size was too small to draw definite conclusions regarding its 
efficacy.
Chapter 6
CRPS is characterized by various combinations of sensory, autonomic and motor 
disturbances, reflecting the involvement of multiple biological pathways that underlie 
exaggerated inflammation, vasomotor dysfunction, and maladaptive neuroplasticity. In 
time, the syndrome may spread to other extremities without a new trauma, especially in
younger patients, which may suggest genetic predisposition. Mechanisms that play a 
role in this phase of the syndrome are largely unknown and even if such mechanisms are 
suggested, they are seldom based on solid biochemical data. The metabolome of urine 
provides an excellent insight into the actual biochemical status of an organism. In 
chapter 6 we described the explorative analysis of urine, applying capillary 
electrophoresis time-of-flight mass spectrometry (CE-ToF-MS). This CE-ToF-MS method 
provides fast and stable metabolic profiles of urine samples. The mean intraday and 
interday CVs were <2% and <9% for migration times and peak areas, respectively, 
demonstrating robustness of the method. Using multivariate chemometric analysis, 
discrimination between urine samples from CRPS patients and controls was obtained, 
emphasizing differences in metabolic signatures between CRPS-diseased patients and 
controls. Several compounds, such as 3-methylhistidine, were responsible for 
discriminating the samples. 3-Methylhistidine is formed as a result of post-translational 
methylation of actin and myosin and considered a rather specific indication of 
catabolism of muscle tissue, a finding which has been associated with conditions like 
chronic physical stress, starvation, injury of muscle tissue, primary muscle diseases and 
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malignancy. We conclude that our results warrant further exploration of factors like 
physical stress and dietary intake in chronic CRPS patients.
Chapter 7
In contrast to urine, the metabolome of CSF primarily reflects the biochemical status of 
the central nervous system. Although, central inhibition is suggested to play a major role 
in the development of CRPS-related dystonia, the underpinning pathobiology is still 
unclear. Chapter 7 involves an exploratory-based study, using 1H-NMR spectroscopy,
which aimed to search for metabolites in CSF that reflect common pathobiology 
underlying CRPS-related dystonia. CSF samples from 49 patients with CRPS-related 
dystonia and 56 controls were analyzed and the metabolic profiles of these groups were 
compared. Principal component analysis and partial least square discriminant analysis 
revealed significant separation between patients and controls. From the set of identified 
discriminators, the most relevant metabolites were 2-keto-isovalerate, alanine, 
creatinine, glucose, glutamine, myo-inositol, lactate, pyruvate and tyrosine which were 
increased in CRPS patients compared to controls and urea which was lower in CRPS 
patients. We hypothesize that the findings primarily reflect a catabolic state which likely 
is associated with inflammation. Our CSF findings therefore do not seem to provide 
evidence for the involvement of major primary metabolic derangements of the nervous 
system but instead corroborate with previous findings described in chapter 6. 
Chapter 8
In previous chapters we described the results of studies which evaluated the efficacy of 
various centrally acting drugs in patients with CRPS-related dystonia. The unsatisfactory 
response of these agents raised the need of alternative targets for intervention. In 
dystonia pathological muscle changes may occur, which contribute to joint and muscle 
stiffness. Magnesium sulphate (MG) may act as a muscle relaxant through its actions on 
the neuromuscular junction and muscle. Chapter 8 describes the results of an 
explanatory study in which we evaluated the muscle relaxant effect and safety of 
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intramuscular MG (IMMG) in CRPS patients with dystonia. In a double-blind randomized 
placebo-controlled crossover study 30 patients were assigned to 3-week treatments of 
IMMG and placebo. Treatments were separated by a one-week washout period. The 
daily dose of IMMG was 1000 mg in week 1, 1500 mg in week 2 and 2000 mg in week 3. 
The primary outcome measure was the difference in change in Burke-Fahn-Marsden 
(BFM) scores after 3 weeks of treatment between both interventions. Secondary 
outcomes involved severity of dystonia, myoclonus, tremor, pain and functional activity. 
Data of 22 patients available for the per protocol analysis, which revealed no significant 
differences between IMMG and placebo treatment in any of the outcomes. In 
conclusion, there is no indication of efficacy of IMMG in a daily dose of 2000 mg as a 
muscle relaxant in CRPS-related dystonia.
Concluding remarks
The pathobiology of CRPS-related pain has been under debate for many years and 
several causes have been forwarded. For many years the link between nociceptive 
neurons and postganglionic sympathetic activity was believed to play a pivotal role in 
the development and maintenance of CRPS-related pain. In the last decade 
accumulating evidence indicates major involvement of mechanisms of endogenous pain 
modulation at different levels of the neuroaxis.6 These mechanisms comprise 1) long-
term potentiation and long-term depression of synaptic strength in the spinal dorsal 
horn, 2) deficient inhibition of spinal interneurons that utilize GABA, glycine or opioids,
and provide feed-forward and feed-back inhibition to the spinothalamic and spinobulbar 
projection neurons and 3) impaired function of the descending bulbospinal pathways 
that inhibit or facilitate peripheral nociceptive input in the spinal dorsal horn.7-9 The 
activity of these pain modulatory systems is altered in CRPS, giving rise to a state of 
central sensitization and reorganization of somatotopic maps within the somatosensory 
cortex. These findings are based on studies which used tactile stimuli to evaluate the 
involvement of endogenous pain modulation in CRPS.6,10 We examined the efficacy of 
ITB on ten different qualities of spontaneous pain in CRPS patients and found a 
172
significant improvement in severity of 4 pain qualities, which levelled off after 6 months 
of continuous ITB administration (Chapter 2). These results indicate that 1) GABA-B 
signalling pathways play a role in at least 4 distinctive pain qualities related to CRPS, 2) 
different processes may underpin the spectrum of pain components encountered in 
CRPS, and 3) continuous stimulation of GABA-B signalling pathways may induce 
desensitization. We also studied the efficacy of continuous ITG in CRPS patients and 
found no change in global pain sensation (Chapter 5). These results argue against a 
major involvement of spinal glycinergic signalling pathways in CRPS-related pain. 
However, the lack of efficacy of ITG may have resulted from an insufficient dose of ITG 
or compensatory increased reuptake of synaptic glycine into nerve terminals and 
adjacent glial cells.11 A contribution of the spinal glycinergic system in the regulation of 
CRPS-related pain can therefore not be ruled out. 
Silas Weir Mitchell thoroughly described the spectrum of pain experienced by his CRPS 
patients, but also recognized abnormal posturing as a distinctive feature in a subgroup 
of these patients.12 It remains unclear if the abnormal postures described by Mitchell 
reflect contractures or dystonia. More than a century later Marsden et al13 described 5 
patients who developed a movement disorder of the affected limb related to CRPS. Four 
of these patients suffered abnormal posturing described as sustained muscle spasms (3 
patients) and dystonic posturing (1 patient). This study provides no insights with respect 
to the mechanism underlying the abnormal postures. In 1985 en 1986 Schott reported 
on a total 14 patients afflicted with various involuntary movement disorders - including 
focal and segmental dystonia - that developed after a physical trauma.14,15 Although the 
presence of signs and symptoms of CRPS were not reported in any of the cases, Schott’s 
elaboration on the possible mechanisms involved in the development of movement 
disorders after a peripheral trauma is interesting. He suggested an interaction of the 
diencephalospinal dopaminergic motor system and central sensory mechanisms 
subserving pain to underlie these posttraumatic movement disorders.14 A few years 
later Jankovic and van der Linden proposed a cascade process triggered by a peripheral 
traumatic event starting with altered afferent input into the spinal cord or brain stem,  
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followed by reorganization of the local neuronal circuitry and finally enhancement of 
evoked and spontaneous motor output resulting in a hyperkinetic movement disorder.16
Using polyelectromyography they discovered synchronous bursts of activity in agonists 
and antagonists of the affected limb of patients with CRPS and dystonic posturing.16 This 
abnormal co-contraction of agonists and antagonists was, and still is, considered to be a 
fundamental characteristic of dystonia.17 In the following years several studies aimed to 
further clarify the pathophysiology of CRPS-related dystonia.18 The results of these 
studies point towards a major contribution of central processes, which largely 
correspond with mechanisms identified in other types of dystonia. For instance, the 
spontaneous spreading of dystonic posturing in many CRPS patients from one limb to 
the other19 is probably caused by maladaptive changes in the CNS and also found in 
other types of adult-onset dystonia.20 In the latter types of dystonia, the process of 
aging is believed to enhance abnormal cortical excitability and consequently facilitate 
spreading of symptoms.20 Neurophysiological and fMRI studies also indicate a major role 
of maladaptive neuroplasticity in the development and maintenance of CRPS-related 
dystonia.21,22 In primary dystonia deficient inhibition occurring at different levels of the 
neuraxis is also presumed to be a major pathophysiological feature.23,24 Three 
interrelated neurophysiological abnormalities have been identified in primary dystonia: 
1) impaired inhibition (including surround inhibition), 2) abnormal cortical plasticity 
(both in affected and unaffected body regions), and 3) sensory processing dysfunction.25
The efficacy of continuous ITB administration on dystonia severity in the majority of 
CPRS patients1 supports the role of GABA(B) receptor signalling pathways in the 
pathobiology of CRPS-related dystonia. Interestingly, a subset of patients with CRPS-
related dystonia did not improve on continuous ITB, regardless of the infusion rate of 
ITB (chapter 3), but some of these patients developed baclofen-induced chorea, which 
to a large extent coincided with body regions that were initially affected by dystonia
(chapter 4). Treatment with tiapride resolved the chorea, suggesting that striatal 
dopaminergic hyperactivity underlies baclofen-induced chorea. These findings argue 
against a major role of GABA(B) receptor signalling pathways in dystonia in these 
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patients, but make a compelling case that in subtypes of CRPS, a combination of 
changes in cerebral circuitry and exposure to ITB may contribute to increased striatal 
dopaminergic hyperactivity leading to the development of chorea.
Similar to GABA, glycine is a major central inhibitory neurotransmitter, especially at the 
level of the spinal cord. However, we found no effect of ITG on pain and dystonia in 
patients with CRPS (chapter 5). The involvement of glycinergic signalling pathways in 
pain and dystonia in CRPS, however, cannot be ruled out completely for reasons 
mentioned above. 
In spite of growing insights into the central mechanisms involved in CRPS, many aspects 
of processes underpinning the development and progression of CRPS-related pain and 
dystonia are still unclear. Several issues indicate that aside central mechanisms, 
peripheral mechanisms may also play a role in CRPS-related pain and dystonia. In other 
neuropathic pain syndromes, distinctive central and peripheral mechanisms have been 
identified to underlie the development of different pain qualities.26 In a recent study van 
Rooijen et al found muscle hyperalgesia to be the most prominent sensory abnormality 
in CRPS patients. Moreover, muscle hyperalgesia was most pronounced in CRPS patients 
who also suffered dystonia. The authors hypothesized that sensitization of neuronal 
networks involved in mediating muscle nociception may play an important role in CRPS-
related dystonia.27 The question remains, however, if the primary neuronal changes 
underpinning muscle hyperalgesia in these patients are mediated at a central or 
peripheral level. 
To identify metabolic profiles, which reflect systemic and central processes associated 
with the development of CRPS and CRPS-related dystonia, we examined urine (chapter 
6) and CSF (chapter 7) of CRPS patients using two different metabolomics approaches. 
The urinary metabolome was indicative of increased muscle proteolysis, a catabolic 
state which is associated with conditions such as chronic physical stress and starvation. 
Using 1H-NMR spectroscopy on CSF we aimed to gain more insight into central 
biochemical processes associated with CRPS-related dystonia, but interestingly found a 
metabolic profile which, similar to the urinary metabolome, corresponded largely with a 
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condition of muscle tissue catabolism. Such a catabolic state may impede the normal 
immune function and consequently play a role in the maintenance of inflammation, thus 
delaying the recovery of CRPS. 
Pathological changes in muscle tissue may also contribute to stiffness such that the 
range of motion around a joint is limited.28 Together with the limited efficacy and poor 
safety profile of intrathecal treatments investigated in CRPS patients, this feature 
stimulated research into muscle relaxants.  We considered magnesium sulphate a good
candidate drug, but in an explanatory study found no evidence of a muscle relaxant 
effect of magnesium sulphate in CRPS-related dystonia (chapter 8). 
Future perspectives
In this thesis we aimed to obtain better understanding of the pathophysiology 
underpinning dystonia in CRPS. Though our studies generated new insights on the 
central and peripheral processes underpinning this movement disorder, many new 
questions arose, which need to be addressed in future studies. 
First of all, molecular and neurophysiological aspects underpinning the different pain 
qualities found in CRPS patients need further exploration in order to develop more 
efficacious treatments. Current understanding of pathophysiological mechanisms of 
similar pain qualities found in other neuropathic pain syndromes may add to our 
knowledge on the pathophysiology of CRPS-related pain and provide a basis for future 
diagnostic and therapeutic CRPS studies.29
In order to gain better insight into the central pathobiology involved in CRPS-related 
dystonia, several techniques are currently available and potentially may provide new 
insights.  In vivo proton MR spectroscopy of the brain can be used for identification of 
different compound spectra - including excitatory and inhibitory neurotransmitters - in 
predefined regions of interest.30-32  Another technique involves pharmacologic magnetic 
resonance imaging, which uses receptor specific ligands to i) characterize brain circuitry 
specific to neurotransmitter systems; ii) measure parameters reflecting 
neurotransmitter release and binding associated with the pharmacokinetics and/or the 
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pharmacodynamics of drugs; and iii) measure up- and down-regulation of receptors in 
specific disease states.33
Knowledge on the pathobiology involved in CRPS-related dystonia is also a prerequisite 
for the development of more efficacious treatment. ITB may result in improvement of 
dystonia in CRPS patients but this treatment fails in 30% of cases and is associated with 
important adverse events.1 Though the results of ITB underscore the role of GABA-B 
receptor signalling pathways in dystonia of patients with CRPS, the large number of 
adverse events associated with intrathecal delivery in these patients raises the need for 
GABA-B receptor agonists with a better blood-brain barrier passage.      
We also recommend further exploration of neurophysiological aspects of CRPS-related 
dystonia. Transcranial magnetic stimulation (TMS) is a non-invasive technique, which 
allows the assessment of sensorimotor integration, cortical motor representation and 
excitability of the motor system, i.e. motor threshold, intracortical inhibition and 
facilitation. Several studies have employed TMS in CRPS patients and found abnormal 
cortical motor representation,34 bilateral motor cortex disinhibition,35 and normal 
sensorimotor interaction at a cortical level.36 Although motor signs were reported in 
many of the 47 patients described in these studies,34-36 dystonia was described in only 
one patient. Hence, it would be interesting to know whether the same TMS results are 
found in patients with CRPS-related dystonia. When comparing CRPS patients with and 
without dystonia, questions have to be answered such as: Are maladaptive changes in 
cortical sensorimotor areas more prominent in patients with dystonia? Confirmative 
answers will support the hypothesis of a strong contribution of central processes in 
CRPS-related dystonia, while negative results would favor a more important role of 
peripheral processes. Additionally, TMS studies may contribute to our understanding of 
differential mechanism involved in more typical mobile dystonia as compared to fixed 
dystonia in patients with CRPS.37   
Transcranial direct current stimulation modulates cortical excitability and may also 
provide a therapeutic alternative. Repetitive transcranial magnetic stimulation proved 
to be efficacious as an add-on to pharmacological therapy in patients with CRPS.38,39 The 
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therapeutic potential of TMS varies between movement disorders not related to CRPS, 
with no improvement in patients with writer's cramp40 and good outcome in patients 
with blepharospasm.41 Possibly, the area of stimulation is of importance as the motor 
cortex was stimulated in the writer’s cramp study and the anterior cingulate cortex was 
stimulated in the blepharospasm study.
The involvement of psychological factors in the onset and maintenance of CRPS-related 
dystonia is still under debate. However, CRPS patients do not exhibit particular 
psychological traits or a unique psychological profile before or around the period of 
disease onset, which would make them susceptible to develop and maintain abnormal 
postures.42 Furthermore, the efficacy of ITB in patients with CRPS-related dystonia was 
established in a single-blind placebo-run-in dose-escalation study1 and in several trials 
we found no detectable placebo response (chapters 3, 5 and 8). Hence we consider a 
psychogenic cause as a sole explanation for CRPS-related dystonia unlikely. Compelling 
evidence indicates that aberrant reorganisation of sensory and motor networks may 
occur in patients with CRPS.6,10,21 Such changes are considered to be responsible for
delayed recognition of hand laterality,43,44 impaired self-perception of the affected 
limb,45 distorted body image and body perception disturbances in CRPS.46 Planning and 
execution of movement depend on mapping of sensory input onto representations of 
intended movement.47 Functional changes of sensory and motor networks may also play 
a role in the development and maintenance of movement disorders in CRPS. 
Interestingly, abnormal processing in non-motor brain regions is already considered to 
play a major role in the development of primary dystonia.48 Possibly, these insights may 
contribute to a better understanding of currently so-called psychogenic or functional 
movement disorders. Although the aforementioned arguments support a somatic 
explanation as underlying cause of CRPS-related dystonia, the discussion in the 
literature is far from settled; the controversy as to whether the condition originates 
from a somatic or psychogenic cause (or both) is still ongoing. Many researchers hold 
the view that the CRPS-related dystonia – ‘fixed dystonia’ in particular - is a psychogenic 
movement disorder.49,50
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Future studies are also warranted to examine the role of peripheral processes, 
particularly muscle energy metabolism, in the development and maintenance of CRPS-
related dystonia.51 Especially studies using MR spectroscopy may provide useful data on 
the energy status of muscle tissue in CRPS patients with dystonia and together with 
neurophysiological studies may clarify the role of the contractile apparatus in the 
development of abnormal posturing (not related to contracture) in CRPS patients. Is 
abnormal posturing caused by abnormal co-contraction of agonists and antagonists, 
which we define as dystonia, or the result of deficient decoupling of myosin/actin 
filaments, e.g. because of low ATP production, or is there another underlying process? 
In a recent electromyographic study Bank et al demonstrated that abnormal posturing 
in chronic CRPS patients - at least in those patients with some active range of motion 
(AROM) - was not associated with sustained muscle contractions in the affected limb 
and the AROM was not restricted because of excessive agonist-antagonist co-
contraction.52
These findings as well as those of studies presented in this thesis, underline that in 
different CRPS patients or during different stages of the disease, different mechanisms 
may contribute to the development or maintenance of abnormal postures in these 
patients. We therefore suggest just using the term ‘abnormal posturing’ in CRPS 
patients, at least until the role of muscular mechanisms has been clarified. The lack of 
evidence of a muscle relaxant effect of magnesium sulphate, which we found in an 
explanatory study, does not invalidate this recommendation as only a small component 
of the contractile system is targeted by magnesium sulphate and pharmacokinetic 
limitations may be responsible for the lack of efficacy.
New studies are also warranted to answer questions such as: Are the findings in our 
mass-spectrometry studies, which hint at increased muscle protein breakdown, just the 
result of chronic immobilization or malnourishment secondary to the disease burden 
that CRPS patients experience, or are they closely related to intrinsic pathophysiological 
processes? Does muscle proteolysis manifest in the later stages of the disease or is it 
already present in the early phase? These questions need to be addressed in the near 
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future, not only as muscle protein breakdown negatively affects the human immune 
status but also because it may be reversed by adequate nutritional care and feeding.
It is most likely that different processes at the peripheral and central level influence 
each other. The interaction of these processes is probably responsible for the 
heterogeneous clinical spectrum of CRPS and the onset and progress CRPS symptoms. 
To gain more insight into this interplay of central and peripheral processes, we 
recommend future studies to evaluate for each subject both changes in central and 
peripheral processing. 
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Dit proefschrift beschrijft de resultaten van studies bij patiënten met complex regionaal 
pijnsyndroom (CRPS) die werden uitgevoerd binnen het programma van het landelijk 
consortium “Trauma RElated Neuronal Dysfunction” (TREND). De studies betreffen 
onderzoeken met intrathecale toediening van baclofen (Deel I) en glycine (Deel II), 
exploratieve evaluaties met behulp van massa-spectrometrie van urine en hersenvocht 
(Deel III) en een verklarende studie, waarin het spierverslappende effect van 
magnesiumsulfaat is onderzocht bij patiënten met dystonie gerelateerd aan CRPS (Deel 
IV).
Hoofdstuk 1
Hoofdstuk 1 geeft een overzicht van het uitgebreide scala aan klinische verschijnselen 
die bij CRPS wordt gezien. Er wordt een update gegeven over de veronderstelde 
moleculaire en neurofysiologische basis van CRPS, waaronder buitensporige 
ontstekingsreactie, vasomotorisch disfunctioneren en maladaptieve neuroplasticiteit. 
Vervolgens wordt in het kort een terugblik gegeven op de terminologie die door de 
jaren heen voor CRPS-gerelateerde dystonie is gebruikt en controversiële hypothesen 
over het onderliggende mechanisme van deze vorm van dystonie worden aangekaart.
Hoofdstuk 2
Het eerste deel van dit proefschrift is een vervolg op een studie, waarin de effectiviteit 
van intrathecaal baclofen (ITB) op CRPS-gerelateerde dystonie is onderzocht.1 Deze 
studie bestond uit een placebogecontroleerde screeningsfase met opklimmende dosis, 
gevolgd door een ‘open label’ studie voor de duur van één jaar. Tijdens de ‘open label’ 
fase kregen patiënten met CRPS-gerelateerde dystonie via een geleidelijke dosisopbouw 
ITB toegediend met behulp van een geïmplanteerde pomp. De ernst van de dystonie en 
de globale pijn werd beoordeeld vlak voordat ITB gestart werd en vervolgens om de 3 
maanden voor de duur van één jaar. ITB resulteerde in de loop van het jaar in 
significante verbetering van zowel de ernst van dystonie als van globale pijn, vooral 
tijdens de eerste 6 maanden. Interessant is, dat verbetering van pijn slechts ten dele 
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verklaard kon worden door vermindering van de dystonie, wat wijst op een direct 
antinociceptieve werking van baclofen.
Het doel van de studie beschreven in hoofdstuk 2 was om het gedifferentieerde effect 
van centraal gamma-aminoboterzuur B (GABA(B)) receptorstimulatie te analyseren op 
de tien pijnkwaliteiten van de neuropathische pijnschaal (NPS). Tweeënveertig CRPS-
patiënten met dystonie die ongeblindeerd in getitreerde doses ITB kregen, werden 
iedere 3 maanden geëvalueerd voor de duur van één jaar. De effectiviteit van langdurig 
toegediend ITB werd beoordeeld op de tien verschillende pijnkwaliteiten van de NPS, op 
globale ernst van dystonie en op veranderingen in gebruik van pijnmedicatie. Aan de 
hand van ‘linear mixed model’ analyse met correctie voor globale ernst van dystonie en 
gebruik van aanvullende analgetica, vonden we significante verbetering van globale 
intense pijn, scherpe pijn, zeurende pijn en diepe pijn gedurende de eerste 6 maanden. 
Na deze periode vlakten de scores af ondanks verdere verbetering van dystonie en 
aanhoudende verhoging van de ITB dosis. Onze conclusie is, dat GABA(B) 
receptorstimulatie via ITB gedifferentieerde antinociceptieve effecten genereert op 
specifieke pijnkwaliteiten bij CRPS-patiënten met dystonie.
Hoofdstuk 3
Van Rijn et al hadden in een enkelblinde placebo-inloop studie met opklimmende dosis 
een extern systeem gebruikt om ITB toe te dienen om zo patiënten met CRPS-
gerelateerde dystonie te selecteren voor implantatie van een pomp voor langdurige 
continue ITB-administratie.1 Tijdens de screeningsfase moesten patiënten op 2 
achtereenvolgende dagen van ITB-toediening ten opzichte van placebo tenminste 25% 
verbeteren in globale ernst van dystonie op een numerieke schaal die loopt van 0 tot 10, 
om door te kunnen gaan naar de fase van pompimplantatie.  Interessant genoeg bleken 
30% van de patiënten die een pomp geïmplanteerd kregen nooit deze verbetering te 
halen tijdens een jaar van continue ITB-toediening. Het viel ons op, dat deze afname in 
reactiviteit op ITB was geassocieerd met een afname in infusiesnelheid (IS) na 
omschakeling van toediening met een externe naar een geïmplanteerde pomp. 
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Hoofdstuk 3 beschrijft een dubbelblinde cross-over studie, waarin we het effect van 
variabele infusiesnelheden bij een constant gehouden dagdosis onderzochten op 
effectiviteit en veiligheid van ITB bij patiënten met CRPS-gerelateerde dystonie. 
Patiënten waren geschikt voor studiedeelname als zij geen gunstig effect van ITB 
ervaarden op dystonie bij een dosis van tenminste 600 μg/dag of omdat bijwerkingen 
dosisverhoging verhinderden. Patiënten werden gerandomiseerd naar een langzame 
(LIS) of een 4 keer snellere infusiesnelheid (SIS) voor de duur van 2 weken en 
continueerden vervolgens na 1 week ‘washout’ met de andere IS. Veranderingen in 
globale ernst van dystonie en pijn golden als uitkomstmaten. We vonden voor geen 
enkele uitkomstmaat significante verschillen tussen de SIS en de LIS-groep, behalve voor 
het aantal nadelige effecten die significant hoger was tijdens de SIS-behandeling. Deze 
nadelige effecten betroffen voornamelijk supraspinale symptomen. SIS kreeg de 
voorkeur van alle patiënten die waren geïncludeerd, omdat bijwerkingen verhoging van 
de ITB-dosis hadden verhinderd. Hoewel verhoging van de IS bij een constant gehouden 
dagdosis niet was geassocieerd met verbetering van dystonie of pijn bij de groep van 
patiënten als geheel, menen we dat verder onderzoek gerechtvaardigd is bij patiënten 
die dosisverhoging vanwege bijwerkingen niet tolereren. 
Hoofdstuk 4
Hoofdstuk 4 beschrijft de ontwikkeling van chorea na langdurige administratie van 
baclofen bij 4 patiënten met CRPS-gerelateerde dystonie. Wereldwijd wordt baclofen al 
meer dan 100 jaar gebruikt, aanvankelijk als behandeling tegen epilepsie en sinds de 
jaren 60 als eerste keuze middel bij de behandeling van spasticiteit.2 Voor zover ons 
bekend, is baclofen-geïnduceerde chorea (BIC) wereldwijd ooit eerder beschreven bij 
slechts 3 patiënten, wat een zeer beperkte fractie is van alle mensen die baclofen 
hebben gebruikt of nog steeds gebruiken.3-5 Het is daarom opvallend, dat wij binnen een 
beperkt aantal jaren 4 CRPS patiënten hebben geïdentificeerd, die BIC hebben 
ontwikkeld, wat een relatief groot aantal is van de totale populatie mensen die leidt aan 
dezelfde ziekte. Behandeling met tiapride zorgde voor verdwijnen van de BIC bij deze 
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mensen. Dit maakt aannemelijk, dat striatale dopaminerge hyperactiviteit ten grondslag 
ligt aan de BIC. Een interessante bevinding is, dat de verdeling van BIC in belangrijke 
mate correspondeerde met de distributie van dystonie, waarmee in ieder geval ten dele 
de theorie van centrale disinhibitie als onderliggend mechanisme van CRPS-gerelateerde 
dystonie wordt ondersteund.
Hoofdstuk 5
Glycinerge neurotransmissie speelt een belangrijke inhiberende rol bij de verwerking 
van sensibele en motorische informatie. Het doel van de studie beschreven in hoofdstuk 
5 was om de effectiviteit en veiligheid van intrathecaal glycine (ITG) bij patiënten met 
CRPS-gerelateerde bewegingsstoornissen en pijn te evalueren. Negentien patiënten 
werden geschikt bevonden om deel te nemen aan de studie en werden gerandomiseerd 
in een dubbelblinde placebogecontroleerde cross-over studie. Aan patiënten werd 4 
weken behandeling met ITG en 4 weken placebo toegewezen. Beide behandelingen 
werden gescheiden door een washout periode van 1 week. Veiligheid werd beoordeeld 
aan de hand van klinische evaluatie, bloedonderzoeken en electrocardiografie. 
Effectiviteitmaten bestonden uit pijn, bewegingsstoornissen, activiteit en een globale 
inschatting van het doorgemaakte effect door patiënt en arts.
We vonden voor geen enkele uitkomstmaat significante verschillen tussen ITG- en 
placebobehandeling. Onze conclusie is, dat ITG niet effectief is tegen pijn of dystonie bij 
CRPS, hoewel het aantal studiedeelnemers te klein was om definitieve conclusies te 
trekken ten aanzien van de mate van effectiviteit.
Hoofdstuk 6
CRPS wordt gekarakteriseerd door diverse combinaties van sensibele, autonome en 
motorische afwijkingen, welke een weergave vormen van betrokkenheid van meerdere 
biologische processen die ten grondslag liggen aan disproportionele ontstekingsreactie, 
vasomotorische dysfunctie en maladaptieve neuroplasticiteit. In de loop van de tijd kan 
het syndroom uitbreiden naar andere ledematen zonder voorafgaand nieuw trauma, 
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vooral bij jongere patiënten, wat een genetische predispositie zou kunnen 
veronderstellen. Mechanismen die in deze fase van het syndroom een rol spelen zijn 
grotendeels onbekend en als er al een bepaalde rol voor deze mechanismen wordt 
verondersteld, dan is dit zelden gebaseerd op zuivere biochemische data-extractie. Het 
metaboloom van urine geeft uitstekend inzicht in de actuele biochemische toestand van 
een organisme. In hoofdstuk 6 beschrijven we de exploratieve analyse van urine, 
uitgevoerd door middel van capillaire electroforese ‘time-of-flight’ massa-spectrometrie 
(CE-ToF-MS). Deze CE-ToF-MS methode genereert snelle en stabiele metabole profielen 
van urinemonsters. De gemiddelde ‘intraday’ en ‘interday’ CV’s waren respectievelijk 
<2% en <9% voor migratietijd en piekgebieden, waarmee het robuuste karakter van de 
techniek is aangetoond. Met behulp van multivariate chemometrische analyse konden 
urinemonsters van CRPS-patiënten en controles van elkaar worden onderscheiden en 
daarmee de verschillen in metabole profielen tussen CRPS-patiënten en controles 
worden uitgelicht. Verscheidene substraten, waaronder 3-methylhistidine, lagen ten 
grondslag aan de verschillen tussen de monsters van beide groepen mensen. 3-
Methylhistidine is het product van posttranslationele methylering van actine en myosine 
en wordt beschouwd als een tamelijk specifieke weergave van katabolisme van 
spierweefsel, een bevinding die is geassocieerd met condities zoals chronische fysieke 
stress, ondervoeding, schade aan spierweefsel, primaire spierziekten en maligniteit. We 
concluderen, dat onze resultaten verdere exploratie legitimeren naar factoren zoals 
fysieke spanningen en voedselconsumptie bij patiënten met chronisch CRPS.
Hoofdstuk 7
In tegenstelling tot urine vormt het metaboloom van hersenvocht voornamelijk een 
afspiegeling van de biochemische status van het centrale zenuwstelsel. Hoewel 
verondersteld wordt, dat centrale inhibitie een belangrijke rol speelt bij de ontwikkeling 
van CRPS-gerelateerde dystonie, is de onderliggende pathobiologie nog steeds niet 
opgehelderd. Hoofdstuk 7 beslaat een studie met een exploratieve basis, waarin gebruik 
gemaakt wordt van 1H-NMR spectroscopie met als doel om metabolieten in hersenvocht 
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aan te tonen die een reflectie vormen van de gezamenlijke pathobiologie van CRPS-
gerelateerde dystonie. Monsters van hersenvocht van 49 patiënten met CRPS-
gerelateerde dystonie en 56 controles werden geanalyseerd en de metabole profielen 
van beide groepen werden met elkaar vergeleken. Principale componentanalyse en 
partiële kleinste kwadraten discriminante analyse toonden significante separatie tussen 
patiënten en controles. Van de set van geïdentificeerde onderscheidende metabolieten 
waren de meest relevanten: verhoogde concentraties van 2-keto-isovaleraat, alanine, 
creatinine, glucose, glutamine, myo-inositol, lactaat, pyruvaat en tyrosine bij CRPS-
patiënten ten opzichte van controles en verlaagde concentratie van ureum bij patiënten 
met CRPS. Onze hypothese is, dat deze bevindingen voornamelijk een katabole conditie 
representeren die waarschijnlijk geassocieerd is met ontsteking. Onze bevindingen in 
hersenvocht leveren dus geen bewijs voor de betrokkenheid van een belangrijke 
primaire metabole ontregeling in het centrale zenuwstelsel, maar sluiten eerder aan op 
de bevindingen zoals beschreven in hoofdstuk 6.
Hoofdstuk 8
In voorgaande hoofdstukken beschreven we de resultaten van studies, waarin de 
effectiviteit van diverse centraal-opererende middelen bij patiënten met CRPS-
gerelateerde dystonie werd geëvalueerd. Het onbevredigende resultaat van deze 
middelen ondersteunde de focus op alternatieve aangrijpingspunten voor nieuwe 
interventies. Bij dystonie kunnen pathologische spierveranderingen optreden die 
bijdragen aan stijfheid van gewrichten en spieren. Magnesiumsulfaat (MG) zou als 
spierverslapper kunnen acteren door aan te grijpen op neuromusculaire structuren of 
structuren binnen de spier zelf. Hoofdstuk 8 beschrijft de resultaten van een verklarende 
studie, waarin we het spierverslappende effect en de veiligheid van intramusculair MG 
(IMMG) evalueerden bij CRPS-patiënten met dystonie. In een dubbelblinde 
gerandomiseerde placebogecontroleerde cross-over studie werd aan 30 patiënten een 
behandeling van 3 weken met IMMG en placebo toegewezen. Beide behandelingen 
werden gescheiden door een washout periode van een week. De dagdosis IMMG was 
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1000 mg in week 1, 1500 mg in week 2 en 2000 mg in week 3. De primaire uitkomstmaat 
was het verschil in verandering van de Burke-Fahn-Marsden (BFM) scores gedurende 3 
weken van behandeling tussen beide interventies. Secundaire uitkomstmaten betroffen 
ernst in dystonie, myoclonus, tremor, pijn en functionele activiteit. Data van 22 
patiënten waren beschikbaar voor analyse ‘per protocol’ en onthulden voor geen van de 
uitkomstmaten significante verschillen tussen IMMG- en placebobehandeling. De 
conclusie is, dat er geen aanwijzingen zijn voor een spierverslappend effect van IMMG 
bij een dagelijkse dosis oplopend tot 2000 mg op CRPS-gerelateerde dystonie.
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Concluderende opmerkingen
Over de pathobiologie van pijn gerelateerd aan CRPS wordt al vele jaren gediscussieerd 
en verscheidene oorzaken zijn al geopperd. Gedurende lange tijd werd aangenomen, 
dat de connectie tussen nociceptieve neuronen en postganglionaire sympathische 
activiteit essentieel was in de ontwikkeling en aanhouden van CRPS-gerelateerde pijn. In 
de laatste 10 jaar kwam er een opeenstapeling van bewijs voor betrokkenheid van 
mechanismen van endogene pijnmodulatie op verschillende niveaus van het centrale 
zenuwstelsel.6 Deze mechanismen omvatten 1) langdurige potentiatie en langdurige 
onderdrukking van synapssterkte in de achterhoorn van het ruggenmerg, 2) gestoorde 
inhibitie van spinale interneuronen die gebruik maken van GABA, glycine of opioïden en 
zorgen voor ‘feed-forward’ en ‘feed-back’ remming naar spinothalaam en spinobulbair 
projecterende neuronen en 3) gestoorde functie van afdalende bulbospinale banen die 
perifere nociceptieve input in de achterhoorn van het ruggenmerg inhiberen of 
stimuleren.7-9 De activiteit van deze pijnmodulerende systemen is veranderd bij CRPS 
resulterend in centrale sensitisatie en reorganisatie van de somatotopische atlas binnen 
de somatosensorische cortex. Deze bevindingen zijn gebaseerd op studies, waarin 
gebruik is gemaakt van tactiele stimuli om de betrokkenheid van endogene 
pijnmodulatie bij CRPS te evalueren.6,10 Wij onderzochten de effectiviteit van ITB op 10 
verschillende kwaliteiten van spontane pijn bij patiënten met CRPS en vonden een 
significante verbetering in ernst van 4 pijnkwaliteiten, die stagneerde na 6 maanden 
continue administratie van ITB (Hoofdstuk 2). Deze resultaten laten zien, dat 1) 
GABA(B)-erge zenuwbanen betrokken zijn bij tenminste 4 verschillende pijnkwaliteiten 
gerelateerd aan CRPS, 2) verschillende processen ten grondslag kunnen liggen aan het 
spectrum van pijncomponenten die worden gevonden bij CRPS en 3) continue stimulatie 
van GABA(B)-modulerende banen desensitisatie kan induceren. We bestudeerden ook 
de effectiviteit van continue ITB-toediening bij CRPS-patiënten en vonden geen 
verandering in globale pijnsensatie (Hoofdstuk 5). Deze resultaten pleiten tegen een 
grote rol voor spinale glycinerge modulerende banen bij CRPS-gerelateerde pijn. Echter 
de tekortkoming in effectiviteit van ITG zou te maken kunnen hebben met een 
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onvoldoende dosis ITG of compensatoir verhoogde heropname van glycine vanuit de 
synaps in zenuwuiteinden en aangelegen gliale cellen.11 Een bijdrage van het spinale 
glycinerge system aan de regulatie van CRPS-gerelateerde pijn kan daarom niet worden 
uitgesloten.
Silas Weir Mitchell gaf een zorgvuldige beschrijving van het scala aan pijnsoorten die 
door zijn patiënten met CRPS werd ervaren, maar herkende daarbij opvallende 
standsafwijkingen bij een deel van deze patiënten.12 Het blijft onduidelijk of de 
afwijkende standen die Mitchell beschreef een uiting waren van contracturen of 
dystonie. Meer dan 100 jaar later beschreven Marsden et al13 5 patiënten die een 
bewegingsstoornis ontwikkelden aan een ledemaat met verschijnselen van CRPS. Bij 4 
van deze patiënten werd de standsafwijking omschreven als aanhoudende 
spierspasmen (3 patiënten) en een dystone stand (1 patiënt). De studie leverde geen 
inzicht over het mechanisme die ten grondslag ligt aan de afwijkende standen. In 1985 
en 1986 beschreef Schott een totaal van 14 patiënten met verschillende ongewilde 
bewegingen, waaronder focale en segmentale dystonie die waren ontstaan in 
aansluiting op een fysiek trauma.14,15 Hoewel de aanwezigheid van CRPS-symptomen 
(anamnestisch en objectiveerbaar) bij geen enkele casus werd beschreven, is de 
uiteenzetting van Schott over de mechanismen die mogelijk betrokken zijn bij de 
ontwikkeling van de ongewilde bewegingen na een perifeer trauma interessant. Hij 
suggereerde, dat een interactie van het diencefalospinale dopaminerge motorsysteem 
en centrale sensibele mechanismen, gerelateerd aan pijn, ten grondslag ligt aan deze 
posttraumatische bewegingsstoornissen.14 Enkele jaren later lanceerden Jankovic en van 
der Linden de hypothese van een cascade van processen getriggered door een perifere 
traumatische gebeurtenis, beginnend met veranderde afferente input in ruggenmerg of 
hersenstam, gevolgd door reorganisatie het lokale neuronale circuit en uiteindelijk 
versterking van opgewekte of spontane motore output resulterend in een 
hyperkinetische bewegingsstoornis.16 Met behulp van polyelectromyografie ontdekten 
zij synchrone ontladingen van activiteit in agonist- en antagonistspieren van de 
aangedane ledemaat van patiënten met CRPS en dystone standsafwijkingen.16 Deze 
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abnormale co-contractie van agonisten en antagonisten werd, en wordt nog steeds, 
beschouwd als een fundamentele eigenschap van dystonie.17 In de hieropvolgende jaren 
was het doel in verschillende studies om de pathofysiologie van CRPS-gerelateerde 
dystonie verder op te helderen.18 De resultaten van deze studies wijzen op belangrijke 
betrokkenheid van centrale processen die grotendeels corresponderen met 
mechanismen die ook geïdentificeerd zijn bij andere typen dystonie. Bijvoorbeeld de 
spontane uitbreiding van dystone standen bij veel CRPS-patiënten van de ene 
extremiteit naar de andere19 wordt waarschijnlijk veroorzaakt door maladaptieve 
veranderingen in het centrale zenuwstelsel en ook gevonden bij andere typen dystonie
die op volwassen leeftijd ontstaan.20 Voor wat betreft de laatstgenoemde vormen van 
dystonie wordt verondersteld, dat het proces van veroudering abnormale corticale 
prikkelbaarheid versterkt en daarmee verspreiding van symptomen faciliteert.20
Neurofysiologische en fMRI-studies laten ook een belangrijke rol zien voor maladaptieve 
neuroplasticiteit bij de ontwikkeling en aanhouden van CRPS-gerelateerde dystonie.21,22
Bij primaire dystonie wordt er ook vanuit gegaan, dat deficiënte inhibitie binnen 
verschillende niveaus van het ruggenmerg een belangrijk pathofysiologisch fenomeen 
is.23,24 Drie aan elkaar gerelateerde neurofysiologische abnormaliteiten zijn 
geïdentificeerd bij primaire dystonie: 1) gestoorde inhibitie, waaronder uitgebreidere 
inhibitie in de omgeving of ‘surround inhibition’, 2) abnormale corticale plasticiteit , 
zowel betreffende aangedane als niet-aangedane lichaamsgebieden en 3) dysfunctie 
van sensibele signaalverwerking.25 De effectiviteit van continue ITB-toediening op de 
ernst van dystonie bij het merendeel van patiënten met CRPS1 ondersteunt de rol van 
GABA(B)-receptormodulerende banen binnen de pathobiologie van CRPS-gerelateerde 
dystonie. Het is interessant om te zien, dat een deel van patiënten met CRPS-
gerelateerde dystonie geen verbetering toonde op continue ITB-administratie, 
onafhankelijk van de infusiesnelheid (Hoofdstuk 3). Echter enkelen van deze patiënten 
ontwikkelden wel baclofen-geïnduceerde chorea, waarvan de verdeling in grote mate 
correspondeerde met lichaamsregio’s, waarin aanvankelijk dystonie was ontstaan 
(Hoofdstuk 4). Met behandeling met tiapride verdween de chorea. Hiermee kan 
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verondersteld worden, dat striatale dopaminerge hyperactiviteit ten grondslag ligt aan 
baclofen-geïnduceerde chorea. Deze bevindingen pleiten tegen belangrijke 
betrokkenheid van GABA(B)-receptormodulerende banen bij de totstandkoming van 
dystonie bij deze patiënten, maar maken het wel aannemelijk, dat bij bepaalde 
subtypen CRPS een combinatie van veranderingen in cerebrale circuits en blootstelling 
aan ITB zou kunnen bijdragen aan toegenomen striatale dopaminerge hyperactiviteit 
resulterend in de ontwikkeling van chorea.
Net als GABA is glycine een belangrijke centraal remmende neurotransmitter, 
voornamelijk op het niveau van ruggenmerg. Echter we vonden geen effect van ITG op 
pijn en dystonie bij patiënten met CRPS (Hoofdstuk 5). De betrokkenheid van glycinerge 
modulerende zenuwbanen bij CRPS-gerelateerde pijn en dystonie kan echter niet 
volledig worden uitgesloten op basis van argumenten die al eerder genoemd zijn.
Ondanks het groeiende inzicht in de centrale mechanismen die een rol spelen bij CRPS, 
blijven veel aspecten van processen die ten grondslag liggen aan de ontwikkeling en 
progressie van CRPS-gerelateerde pijn en dystonie nog steeds onduidelijk. Verschillende 
bevindingen wijzen erop, dat naast centrale mechanismen ook perifere mechanismen 
betrokken zijn bij pijn en dystonie gerelateerd aan CRPS. Bij andere neuropathische 
pijnsyndromen zijn al diverse centrale en perifere mechanismen onderliggend aan 
verschillende pijnkwaliteiten aangetoond.26 In een recente studie van van Rooijen et al
werd spierhyperalgesie als belangrijkste sensibele afwijking gevonden bij patiënten met 
CRPS. Bovendien bleek spierhyperalgesie het meest op de voorgrond te staan bij CRPS-
patiënten die ook leden aan dystonie. De auteurs stelden de hypothese, dat sensitisatie 
van neuronale netwerken betrokken bij de verwerking van spiernociceptie een 
voorname rol speelt bij CRPS-gerelateerde dystonie.27 De vraag blijft echter staan of de 
primaire neuronale veranderingen die spierhyperalgesie veroorzaken worden 
gemedieerd op een centraal of perifeer niveau.
Om metabole profielen in kaart te brengen die een weergave vormen van systemische 
en centrale processen, geassocieerd met ontwikkeling van CRPS en CRPS-gerelateerde 
dystonie, onderzochten we urine (Hoofdstuk 6) en hersenvocht (Hoofdstuk 7) van CRPS 
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patiënten aan de hand van 2 verschillende metabolomics-technieken. Het metaboloom 
van urine leverde aanwijzingen voor een toegenomen proteolyse in spierweefsel, een 
katabole toestand die wordt gezien bij condities als chronische fysieke stress en 
verhongering. Door middel van 1H-NMR spectroscopie onderzoek op hersenvocht 
beoogden we meer inzicht te krijgen in centrale biochemische processen die 
geassocieerd zijn met CRPS-gerelateerde dystonie, maar interessant genoeg vonden een 
metabool profiel die vergelijkbaar is met het eerder beschreven metaboloom in urine en 
grotendeels correspondeert met een toestand van spierkatabolisme. Een dergelijke 
katabole toestand kan de normale immuunfunctie negatief beïnvloeden en daarmee 
een belangrijke rol spelen bij het in standhouden van inflammatie, waarmee herstel van 
CRPS vertraagd wordt.
Pathologische veranderingen in spierweefsel kunnen ook een bijdrage leveren aan 
stijfheid van spieren, waardoor de bewegingsuitslag van een gewricht beperkt wordt.28
Samen met de beperkte effectiviteit en het povere veiligheidsprofiel van intrathecale 
behandelingen bij patiënten met CRPS vormde dit een basis om het effect van 
spierrelaxerende middelen te onderzoeken. We beschouwden magnesiumsulfaat een 
goede kandidaat, maar vonden in een verklarende studie geen bewijs voor een 
spierverslappend effect van magnesiumsulfaat op CRPS-gerelateerde dystonie.
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Toekomstperspectieven
In dit promotie-onderzoek hadden we als doel om de pathofysiologie die ten grondslag 
ligt aan dystonie bij CRPS op te helderen. Hoewel onze studies nieuwe inzichten hebben 
gegenereerd in de centrale en perifere processen die deze bewegingsstoornis 
veroorzaken, zijn er veel nieuwe vragen ontstaan die in toekomstige studies aandacht 
verdienen.
In de eerste plaats moleculaire en neurofysiologische aspecten die de oorsprong vormen 
van verschillende pijnkwaliteiten dienen verder onderzocht te worden om vervolgens 
meer effectieve behandelingen te kunnen ontwikkelen. De huidige kennis over 
pathofysiologische mechanismen van vergelijkbare pijnkwaliteiten bij andere 
neuropathische pijnsyndromen kan een bijdrage leveren in ons begrip over de 
pathofysiologie van CRPS-gerelateerde pijn en een basis vormen voor toekomstige 
diagnostische en therapeutische studies.29
Om meer inzicht te krijgen in de betrokkenheid van centrale pathobiologie bij CRPS-
gerelateerde dystonie, zijn er momenteel diverse potentiële technieken beschikbaar. In 
vivo proton MR-spectroscopie van de hersenen kan worden gebruikt om de
verschillende spectra van bestanddelen, zoals excitatoire en inhibitoire 
neurotransmitters, in vooraf bepaalde gebieden in kaart te brengen.30-32  Een andere 
techniek betreft farmacologische MRI die gebruik maakt van receptorspecifieke liganden 
om 1) cerebrale circuits die geassocieerd zijn met specifieke neurotransmittersystemen 
te karakteriseren, 2) parameters vast te leggen die een reflectie zijn van het vrijkomen 
en de binding van neurotransmitters en die geassocieerd zijn met farmacokinetiek en/of 
farmacodynamiek van medicijnen en 3) meting van up- en downregulatie van 
receptoren bij specifieke aandoeningen.33
Kennis over de pathobiologie van CRPS-gerelateerde dystonie is ook een vereiste om 
meer effectieve behandelingen te kunnen ontwikkelen. ITB kan verbetering geven van 
dystonie bij CRPS-patiënten, maar deze behandeling blijkt bij 30% van de patiënten niet 
te werken en geassocieerd te zijn met belangrijke nadelige effecten.1 Hoewel de 
resultaten van ITB de betrokkenheid van GABA-receptormodulatie bij CRPS-gerelateerde 
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dystonie onderstrepen, maakt het voorkomen van het grote aantal nadelige effecten 
door intrathecale behandeling bij deze patiënten de ontwikkeling van GABA(B)-
receptoragonisten met een betere bloed-hersenbarrière gewenst.
We bevelen ook verdere exploratie aan van neurofysiologische aspecten van CRPS-
gerelateerde dystonie. Transcraniële magnetische stimulatie (TMS) is een niet-invasieve 
techniek die beoordeling van sensorimotorische integratie, corticale motorrepresentatie 
en prikkelbaarheid van het motorsysteem, ook wel drempel naar motorische activiteit, 
intracorticale inhibitie en facilitatie mogelijk maakt. Verscheidene studies hebben TMS 
toegepast op CRPS-patiënten en vonden abnormale corticale motorrepresentatie,34
bilaterale motor cortex disinhibitie35 en normale sensorimotorische interactie op
corticaal niveau.36 Hoewel motorische verschijnselen zijn beschreven bij veel van de 47 
patiënten in deze studies,34-36 werd slechts bij 1 patiënt melding gemaakt van dystonie. 
Het zou derhalve interessant zijn om te weten of dezelfde TMS-resultaten ook worden 
gevonden bij patiënten met CRPS-gerelateerde dystonie. Als we CRPS-patiënten met en 
zonder dystonie met elkaar vergelijken, zullen vragen moeten worden beantwoord, 
zoals zijn maladaptieve veranderingen in corticale sensorimotorische gebieden meer 
prominent aanwezig bij patiënten met dystonie? Resultaten die dit bevestigen zullen de 
hypothese ondersteunen, dat er een sterke bijdrage is van centrale processen bij CRPS-
gerelateerde dystonie, terwijl negatieve resultaten daar en tegen eerder zouden wijzen 
op een belangrijke rol voor perifere processen. Daarbij kunnen TMS-studies helpen bij 
ons begrip over verschillende mechanismen die betrokken zijn bij de meer 
voorkomende mobiele dystonie in vergelijking tot de gefixeerde dystonie die wordt 
gezien bij patiënten met CRPS.37
Transcraniële directe stroomstimulatie moduleert corticale prikkelbaarheid en kan ook 
een therapeutisch alternatief vormen. Repetitieve transcraniële magnetische stimulatie 
is effectief gebleken als toevoeging aan farmacologische behandeling van patiënten met 
CRPS.38,39 De therapeutische potentie van TMS varieert tussen bewegingsstoornissen die 
niet zijn gerelateerd aan CRPS met geen verbetering bij patiënten met schrijverskramp40
en goed effect bij patiënten met blefarospasme.41 Mogelijk is het gebied, dat 
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gestimuleerd wordt hierin van belang, aangezien motorcortex werd gestimuleerd in de 
studie met schrijverskramp en de anterieure cortex cinguli in de blefarospasmestudie.
De invloed van psychologische factoren op aanvang en aanhouden van CRPS-
gerelateerde dystonie is nog steeds onderdeel van discussie. Echter patiënten met CRPS 
blijken geen specifieke psychologische kenmerken te hebben of een uniek psychologisch 
profiel voorafgaand of rond aanvang van de ziekte die hen kwetsbaarder zou maken om 
standsafwijkingen te ontwikkelen en onderhouden.42 Bovendien werd de effectiviteit 
van ITB bij patiënten met CRPS-gerelateerde dystonie aangetoond in een enkelblinde 
placebo-inloop dosisopbouw studie1 en in de diverse trials van ons promotie-onderzoek
vonden we geen aantoonbaar placeborespons (Hoofdstukken 3, 5 and 8). Derhalve 
beschouwen we een psychogene oorzaak als enige verklaring van CRPS-gerelateerde 
dystonie onwaarschijnlijk. Er is groeiend bewijs, dat bij patiënten met CRPS sprake is van 
aberrante reorganisatie van sensibele en motorische netwerken.6,10,21 Zulke 
veranderingen worden beschouwd de oorzaak te zijn voor vertraagde herkenning van 
handdominantie,43,44 gestoorde zelfperceptie van de aangedane ledemaat,45 een 
afwijkend lichaamsschema en abnormale lichaamsperceptie bij CRPS.46 Planning en 
uitvoering van beweging is afhankelijk van de afstemming van sensibele input op 
representaties van de intentionele beweging.47 Functionele veranderingen van sensibele 
en motorische netwerken kunnen ook een rol spelen in de ontwikkeling en handhaving 
van bewegingsstoornissen bij CRPS. Interessant om te vermelden is, dat abnormale 
verwerking in non-motore gebieden van de hersenen al een belangrijke rol wordt 
toebedeeld bij de ontwikkeling van primaire dystonie.48 Mogelijk leiden deze inzichten 
tot een beter begrip over de zogenaamde psychogene of functionele 
bewegingsstoornissen. Hoewel de eerdergenoemde argumenten een somatische 
verklaring als onderliggende oorzaak voor CRPS-gerelateerde dystonie ondersteunen, is 
de discussie in de literatuur nog ver van beëindigd. De controverse of een somatische of 
psychogene oorsprong (of beiden) ten grondslag ligt aan deze bewegingsstoornis is nog 
steeds actueel. Veel onderzoekers zijn van mening, dat CRPS-gerelateerde dystonie, met 
name gefixeerde dystonie, een psychogene bewegingsstoornis is.49,50
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Toekomstige studies zijn ook noodzakelijk om de rol van perifere processen, 
voornamelijk energiemetabolisme in spierweefsel te onderzoeken bij het tot stand 
komen en aanhouden van CPRS-gerelateerde dystonie.51 Vooral studies die gebruik 
maken van MR-spectroscopie kunnen nuttige informatie leveren over de energiestatus 
van spierweefsel bij CRPS-patiënten met dystonie en samen met neurofysiologische 
studies opheldering geven over de rol van het contractiele apparaat bij de 
totstandkoming van abnormale houdingen (niet gerelateerd aan contractuur) bij 
patiënten met CRPS. Worden deze standsafwijkingen veroorzaakt door abnormale co-
contractie van agonisten en antagonisten die we definiëren als dystonie of zijn deze het 
resultaat van deficiënte koppeling van myosine/actinefilamenten, bijvoorbeeld door een 
lage ATP-productie, of is er een ander onderliggend proces? In een recente 
electromyografische studie demonstreerden Bank et al, dat abnormale standen bij 
chronische CRPS-patiënten, in ieder geval bij patiënten die enige actieve 
bewegingsuitslag hadden, niet geassocieerd waren met aanhoudende spiercontracties 
in de aangedane extremiteit en dat de actieve bewegingsuitslag niet gelimiteerd was 
vanwege excessieve agonist-antagonist spiercontractie.52
Deze bevindingen, samen met de studies die in dit proefschrift gepresenteerd staan, 
onderstrepen, dat bij verschillende CRPS-patiënten of in verschillende stadia van de 
ziekte verschillende pathofysiologische mechanismen ten grondslag liggen aan de 
ontwikkeling en handhaving van standsafwijking bij deze patiënten. We stellen daarom 
voor om ons te beperken tot het gebruik van de term “abnormale houding” bij 
patiënten met CRPS, in ieder geval tot de rol van processen in spierweefsel is 
opgehelderd. Het gebrek aan bewijs van een spierverslappend effect van 
magnesiumsulfaat die we vonden in een verklarende studie doet geen afbreuk aan deze 
aanbeveling, aangezien magnesiumsulfaat zich slechts richt op een klein onderdeel van 
het contraciele apparaat en farmacokinetische beperkingen verantwoordelijk kunnen 
zijn voor het ontbreken van effectiviteit.
Nieuwe studies zijn ook noodzakelijk om vragen te beantwoorden als: zijn de 
bevindingen in onze massa-spectrometriestudies die wijzen op een verhoogde 
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eiwitafbraak in spierweefsel alleen maar het gevolg van chronische immobilisatie of 
ondervoeding secundair aan de ziektelast die CRPS-patiënten ervaren of zijn deze nauw 
verwant aan intrinsieke pathofysiologische processen? treedt spierproteolyse pas in 
latere stadia van de ziekte op of is hier al sprake van in een vroege fase? Deze vragen 
moeten in de nabije toekomst worden aangekaart, niet alleen omdat afbraak van 
spiereiwitten het immuunsysteem negatief beïnvloeden, maar ook omdat het wellicht 
gecorrigeerd zou kunnen worden met een adequaat voedingsbeleid.
Het is zeer waarschijnlijk, dat verschillende processen op perifeer en centraal niveau 
elkaar beïnvloeden. De interactie van deze processen is waarschijnlijk verantwoordelijk 
voor het heterogene klinische spectrum van CRPS en de aanvang en progressie van CRPS 
-symptomen. Om meer inzicht te krijgen in dit samenspel van centrale en perifere 
processen adviseren we in toekomstige studies voor ieder individu zowel verandering in 
centrale als perifere procesverwerking te evalueren.
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